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ABSTRACT 
 
Colorectal cancer is the second most common cause of cancer death in the Western world but 
the factors that determine disease progression remain poorly understood. At the outset of this 
thesis it was recognised that tumour growth and metastases were determined by complex 
interactions between tumour and host. It was evident that a systemic inflammatory response 
was associated with poor prognosis in colorectal cancer while a strong local immune cell 
response conferred a favourable outcome.  
 
This thesis investigated this topic by examining the factors responsible for activating, 
maintaining and regulating these inflammatory responses and drew the following 
conclusions: 
 
Chapter 3 concluded that abnormal patient physiology, in particular the presence of anaemia 
and cardiac disease, was strongly associated with a systemic inflammatory response in 
patients with colorectal cancer. Targeting specific physiological parameters may therefore be 
a novel way to improve a patients‟ inflammatory status.  Chapter 5 used CT image analysis to 
confirm a strong relationship between systemic inflammation and reduced skeletal muscle 
mass in patients with colorectal cancer. This offered insight into the underlying basis of 
cancer-related weight loss and suggested attenuation of the host inflammatory response may 
be a therapeutic target in cancer cachexia. Chapter 6 built on these results with a detailed 
examination of the relative importance of pre-, intra- and post-operative factors in patients 
undergoing surgery for colorectal cancer. Rather than being the cause of disease recurrence, 
surgical complications appeared to be a consequence of pre-existing physiological 
disturbance and systemic inflammation, supporting a concept whereby pre-operative status is 
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of paramount importance to long-term cancer outcomes.  Chapter 7 investigated possible 
links between the local and systemic inflammatory responses. The pathological feature of 
tumour necrosis was confirmed as both an independent prognostic indicator in colorectal 
cancer and the first documented link between local and systemic inflammation. A model was 
proposed whereby failure of local anti-tumour control leads to rapid growth, tissue hypoxia 
and cellular necrosis, triggering the host to initiate a systemic inflammatory response. The 
local inflammatory response in colorectal cancer was then considered. Chapter 8 confirmed 
that, while a strong local response was primarily the result of lymphocyte infiltration, the 
examination of individual cell types did not add prognostic value compared to an overall 
grade of peritumoural inflammation. Chapter 9 built on this knowledge to examine the 
clinical utility of the local inflammatory response in colorectal cancer. It was clear that the 
density of cellular infiltrate was more important than the type or location of individual 
immune cells. After comparing a number of methodologies, an overall grade of peritumoural 
inflammation, using the Klintrup-Makinen (K-M) criteria, was established as the preferred 
technique for assessing the local inflammatory response in colorectal cancer.  
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1.0                   INTRODUCTION 
1.1  EPIDEMIOLOGY OF COLORECTAL CANCER 
1.1.1  Disease burden worldwide 
Colorectal cancer is the third most common cancer in the world with a prevalence of over 3 
million people in 2006 (Kamangar, Dores et al. 2006). Worldwide, the annual incidence is 
estimated at over 1.2 million with the highest rates seen in Australasia, Western Europe and 
North America.  The African nations have the lowest incidence although countries with a 
rapid „westernisation‟ of diet and lifestyle, such as Japan, have seen a substantial increase in 
the number of new cases of colorectal cancer.  Worldwide, the disease accounts for more than 
600,000 deaths each year, making it the fourth commonest cause of cancer death (Parkin, 
Pisani et al. 1999). 
1.1.2  Disease burden in the United Kingdom 
In the United Kingdom (UK), colorectal cancer is the third most common cancer in men and 
the second most common cancer in women.  The incidence rates in the UK are estimated to 
be the 14
th
 (males) and 12
th
 (females) highest in the European Union.  Each year over 40,000 
new cases of colorectal cancer are diagnosed in the UK and the disease accounts for over 
16,000 deaths (CRUK).  A north-south divide in the incidence of colorectal cancer currently 
exists, especially for men, with higher rates seen in Scotland and the North of England 
compared to London and the South East.  Overall, the incidence of the disease has increased 
since the 1970‟s. For men, age-standardised incidence rates increased by 27% between 1975-
1977 and 2007-2009 but for women the rise has been much smaller at around 8% (CRUK). 
24 
 
Despite the increased number of new cases diagnosed each year, mortality from colorectal 
cancer has fallen across all age groups since the 1970‟s.  Mortality rates decreased steadily 
from the early 1970‟s to the early 1990‟s and have decreased more rapidly since then.  The 
largest improvements have been seen in younger patients with mortality rates dropping by 
over 50% in 45-59 year olds between 1971 and 2008.   
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1.2.  COLORECTAL CARCINOGENESIS  
Colorectal cancer is a heterogenous disease which can arise from different pathological 
precursors. There are at least three major molecular pathways through which colorectal 
mucosa can undergo malignant transformation; (1) the chromosomal instability (CIN) 
pathway, (2) the microsatellite instability (MSI) pathway and (3) the CpG island methylator 
phenotype (CIMP+) pathway. Each of these pathways are characterised by distinct molecular 
signatures and involve different mechanisms of carcinogenesis (Worthley, Whitehall et al. 
2007).  
1.2.1  Chromosomal instability  
In the late 1980‟s Vogelstein and colleagues proposed a model for colorectal carcinogenesis 
whereby a series of genetic alterations leads to the transformation of benign colorectal 
adenoma to adenocarcinoma (the adenoma-carcinoma sequence) (Vogelstein, Fearon et al. 
1988).  This transition from normal epithelium to malignant tumour is associated with a 
number of specific molecular events including alterations in chromosome number 
(aneuploidy), activation of oncogenes and mutation of p53.  Among the earliest events in this 
pathway are deletions of the adenomatous polyposis coli (APC) gene.  This initial defect 
occurs in over 60% of colorectal neoplasms although the order and timing of subsequent 
molecular events is inconsistent. Mutations in oncogenes such as K-ras result in further 
growth and progression of the adenoma with the final transition to adenocarcinoma mediated 
through the inactivation or mutation of p53.  It is now accepted that this original model may 
be too simplistic and recent evidence suggests carcinogenesis to be an extremely complex 
process involving cumulative mutations in a growing number of oncogenes and tumour 
suppressor genes (Staton, Chetwood et al. 2007).  It is hypothesised that the character of 
26 
 
individual mutations may influence the type of pathological change and rate of tumour 
growth seen in sporadic colorectal cancers. Figure 1.1 summarises the order of the adenoma 
to carcinoma sequence along with the key genetic mutations.  
 
 
 
Figure 1.1. The adenoma-carcinoma sequence in sporadic colorectal cancer. The order in 
which key genes may be affected are shown above the stage during which they are thought to 
occur. Functional pathways affected are at the bottom of the diagram. Adapted from 
Fearnhead et al.  
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1.2.2  Microsatellite instability  
Microsatellites are repetitive sequences of DNA distributed throughout the human genome. 
Microsatellite instability (MSI) is a form of genomic instability associated with defective 
DNA mismatch repairs (MMR) and results from failings within the MMR system to repair 
errors that occur during DNA replication.  This results in the accumulations of base pair 
mismatches and alterations in the length of the microsatellite sequences, ultimately leading to 
protein truncations. These genetic defects were first discovered in the 1990‟s and are broadly 
linked to the pathogenesis of cancer.  MSI is observed in the majority of Hereditary Non-
polyposis Colon Cancer (HNPCC) tumours (discussed below) but is also found in a smaller 
proportion of sporadic colorectal cancers (Aaltonen, Peltomaki et al. 1993; Ionov, Peinado et 
al. 1993; Thibodeau, French et al. 1998).  
Since its discovery, numerous studies began to describe the presence of MSI in different 
tumour types. However, initial variability in study methodology saw different panels of 
molecular markers used to define the phenomenon until an international consensus on the 
definition of MSI was finally reached in 1998 (Boland, Thibodeau et al. 1998).  To grade 
microsatellite instability, five standard markers known collectively known as the Bethesda 
panel are now assessed (D2S123, D5S346, D17S250, BAT-25 and BAT-26). Tumours are 
described as having high frequency microsatellite instability (MSI-H) if two or more loci are 
unstable and low frequency microsatellite instability (MSI-L) if one is unstable.  Overall, it is 
estimated that MSI is present in approximately 15% of colorectal tumours. Tumours without 
evidence of MMR defects can be referred to as microsatellite stable (MSS) tumours (Poynter, 
Siegmund et al. 2008).  
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Colorectal cancers associated with MSI tend to show a stable karyotype without the 
chromosomal instability seen in sporadic tumours. More than 30 different genetic mutations 
have been identified in MMR deficient tumours with the proteins they encode involved in a 
variety of cellular functions; DNA repair (MRE11A), growth factor receptors (IGF receptor 
II) and pro-apoptotic factors (BAX).  Other notable differences in MSI tumours are a lower 
prevalence of KRAS mutations and more mutations in the phophatidylinositol 3-kinase 
(PI3K) pathways, a known driver of tumourigenesis (Vivanco and Sawyers 2002).  
From a clinical perspective MSI tumours tend to be right-sided and are often diagnosed at an 
earlier stage. In addition, the tumours are often poorly differentiated, have a strong infiltration 
of inflammatory cells and tend to have less tumour necrosis (Greenson, Bonner et al. 2003). 
The clinical implications of determining the MSI status of colorectal cancer are described in 
more detail below.  
1.2.3  Hypermethylation 
In addition to chromosomal and microsatellite instability, a third carcinogenic pathway, 
known as hypermethylation, has recently been described.  The precursor lesions for the 
development of carcinomas via this route are not adenomas but serrated polyps and include 
hyperplastic aberrant crypt foci, serrated adenomas and hyperplastic polyps. These tumours 
are thought to develop along a pathway where hypermethylation rather than genetic mutation 
is responsible for the inactivation of tumour suppressor gene function (Esteller, Fraga et al. 
2002; Ferracin, Gafa et al. 2008). A subset of colorectal tumours have been shown to exhibit 
such hypermethylation at specific gene reporters and are referred to as CpG island methylator 
phenotype (CIMP+) (Issa 2004).  Akin to cancers resulting from microsatellite instability, 
CIMP+ tumours also display certain clinicopathological features, including proximal tumour 
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location, poor differentiation and a high frequency of BRAF mutations (van Rijnsoever, 
Grieu et al. 2002; Weisenberger, Siegmund et al. 2006). Furthermore, CIMP+ colorectal 
cancers often lack the alteration of p53 or APC seen in tumours resulting from chromosomal 
instability. Work is ongoing in an attempt to standardise the classification of CIMP+ 
colorectal cancer.  
30 
 
1.3  AETIOLOGY OF COLORCETAL CANCER  
The aetiology of colorectal cancer is still poorly understood.  The majority of colorectal 
tumours (>90%) are termed „sporadic‟ and are thought to result from complex interactions 
between host and environmental factors. In a small number of cases, the pathogenesis of 
colorectal cancer can be attributed to specific aetiological factors such as inflammatory bowel 
disease or inherited genetic mutations (Figure 1.2) (Ponz de Leon, Benatti et al. 2004). The 
aetiology of sporadic and non-sporadic colorectal cancer is described below.  
 
 
Figure 1.2. Frequency of the main known causes of colorectal cancer. Cancers with „no 
apparent cause‟ are often referred to as sporadic. Adapted from Ponz de Leon 2004. 
HNPCC: hereditary non-polyposis colorectal cancer, IBD: inflammatory bowel disease, FAP: 
familial adenomatous polyposis, AIDS:  acquired immunodeficiency syndrome 
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1.3.1  SPORADIC COLORECTAL CANCER  
A large number of factors have been implicated in the development of sporadic colorectal 
cancer but few have been confirmed as causative (Table 1.1).  Epidemiological studies have 
consistently reported associations between colorectal cancer and certain ill-defined risk 
factors, such as diet and Western lifestyle. Over the years the role of these host and 
environmental factors has been extensively investigated but no clear conclusions have yet 
been drawn. Many studies have relied on epidemiological data and there are often conflicting 
reports. The factors described below are those that have been commonly associated with an 
increased risk of colorectal cancer.  
1.3.1.1  Age  
Age is the single biggest risk factor for sporadic colorectal cancer. The incidence of the 
disease increases with age and over 85% of cases are diagnosed in patients aged 60 years or 
older (CRUK).  The reasons for this association with age are likely to be a result of increased 
exposure to the environmental risk factors described below, in particular an increased time 
for chromosomal mutations to develop.  There is now evidence that age-related degradation 
of telomeres, molecular „caps‟ which act to protect chomosomes‟ structural integrity during 
cell division, may be one mechanism through which cancer risk increases with time 
(Hoeijmakers 2007).  However, shortening of telomeres does not occur at a uniform rate, 
leading some to suggest that biological age is more important to the development of 
colorectal cancer than chronological age (Mayor 2009).  It is of interest that the relationship 
between CRC and age appears to be restricted to sporadic cancers. The incidence of HNPCC 
tumours, for example, occurs during the 5
th
 decade of life before reducing again (Umar, 
Risinger et al. 2004).  
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Table 1.1. Environmental and host factors associated with the development of sporadic 
colorectal cancer.  
 
 
1.3.1.2  Western Lifestyle  
The highest rates of colorectal cancer are found in Western countries and up to 15-fold 
differences in age-standardised incidence rates are observed between different geographical 
locations across the world (Muir and Parkin 1985). Studies on migrant populations have 
demonstrated that the incidence rates of the host country are adopted within a generation 
(Haenszel and Kurihara 1968; Potter, Slattery et al. 1993). This has led to a widely held belief 
that a Western lifestyle is responsible for the development of CRC in many cases. Many 
Environmental factors 
Western lifestyle - diet 
 - smoking 
 - alcohol 
 - sedentary lifestyle 
Diet - red meat 
 - fibre 
 - carotenoids, vitamins and anti-oxidants 
Drugs - Aspirin (reduced risk) 
 - NSAID’s (reduced risk) 
 - Statins (reduced risk) 
 - HRT (reduced risk) 
Host factors 
Host physiology - age 
 - comorbidity 
 - cardiovascular disease 
 - obesity and body habitus 
Inflammatory response - systemic  
 - local  
 
 
NSAID: non-steroidal anti-inflammatory drugs 
HRT: hormone replacement therapy 
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studies have attempted to focus on specific components of a Western lifestyle although 
multiple interactions between individual factors mean an integrated picture is still lacking 
(Slattery, Edwards et al. 1999).  
1.3.1.3  Dietary fibre 
The role of diet as a risk factor for colorectal cancer has been extensively investigated over 
the years. As early as the 1970‟s a link with dietary fibre was suggested after incidence rates 
of CRC were noted to be significantly lower in populations with a high fibre intake (Burkitt 
1971). The suggested mechanism was one by which high dietary fibre would mean ingested 
food moved more rapidly through the gastrointestinal tract; giving less time for carcinogens 
to be in contact with the mucosa thereby reducing the likelihood of carcinogenesis. This 
hypothesis has since been tested by several large prospective studies with somewhat 
conflicting results. A study by Fuchs and colleagues examining the diets of almost 90,000 
women over a 16 year period found no association between dietary fibre intake and the risk 
of colorectal cancer (Fuchs, Giovannucci et al. 1999). However, these results were challenged 
by the European Prospective Investigation into Cancer and Nutrition (EPIC) study, an 
investigation of over 500,000 individuals, which reported that doubling the intake of dietary 
fibre could reduce the risk of colorectal cancer by 40% (Bingham, Day et al. 2003).  Finally, 
a pooled analysis of over 13 prospective studies (>700,000 men and women) concluded that, 
after accounting for other dietary risk factors, high fibre intake was not associated with a 
reduced risk of colorectal cancer (Park, Hunter et al. 2005).  Currently, it is therefore unclear 
whether dietary fibre is an independent risk factor for the development of colorectal cancer.  
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1.3.1.4  Red meat consumption 
Over the past 30 years epidemiological studies have consistently observed that countries with 
a high intake of red meat and animal fat have a higher incidence of colorectal cancer 
(Armstrong and Doll 1975; Graham and Mettlin 1979). These early studies generated the 
hypothesis that meat consumption was associated with the development of gastrointestinal 
malignancy in general and colorectal cancer in particular. However, despite over 50 studies 
investigating this hypothesis, the relationships between red meat consumption and colorectal 
cancer are equivocal. In the majority of studies the impact of meat consumption is relatively 
weak (RR<1.5) and there is no clear dose-response relationship (Sandhu, White et al. 2001). 
Despite this, the World Cancer Research Fund (WCRF) in conjunction with the American 
Institute for Cancer Research (AICR) released a consensus statement in 2007 describing red 
meat as a convincing cause of colorectal cancer and suggested individuals should limit their 
intake to 500g per week (AICR 2007). In contrast to the wealth of epidemiological evidence, 
studies evaluating the mechanisms by which red meat may be linked to tumour development 
have been sparse.  Some studies have suggested that cooking meat at high temperature may 
release carcinogenic hydrocarbons while others have postulated that haem iron (Cross, 
Pollock et al. 2003) or the N-nitroso compounds found in processed meats are to blame 
(Santarelli, Pierre et al. 2008). Overall, current evidence does not support a clear association 
between red meat intake and the development of colorectal cancer. 
1.3.1.5  Exercise and sedentary lifestyle 
The role of exercise in reducing the risk of colorectal cancer is now well established (AICR 
2007). The majority of studies have reported individuals with high levels of daily activity to 
have a significantly lower risk than those with sedentary lifestyles (White, Jacobs et al. 1996; 
Samad, Taylor et al. 2005). In 2009, a meta-analysis concluded that regular exercise reduced 
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the risk of colon cancer by almost 25% in both men and women (Wolin, Lee et al. 2007).  
The optimum type, intensity and duration of exercise remains unclear but it is apparent that 
any regular exercise bestows significant benefits in terms of cancer reduction.  Furthermore, 
this effect appears to be independent of potentially confounding variables such as 
cardiovascular health, diet and obesity (Colditz, Cannuscio et al. 1997). Suggested 
mechanisms to explain the effect of exercise include lowering levels of prostaglandins, 
decreasing gut transit time and improving immune function (Samad, Taylor et al. 2005). 
1.3.1.6  Coronary artery disease 
Coronary artery disease has been shown to have similar risk factors as colorectal cancer 
(Neugut, Jacobson et al. 1995). It has been demonstrated that obesity, sedentary lifestyle 
(Giovannucci, Ascherio et al. 1995), diabetes (Larsson, Giovannucci et al. 2005), a high fat 
diet (Stemmermann, Nomura et al. 1984) and smoking (Le Marchand, Wilkens et al. 1997) 
are associated with both disease processes, leading some to propose that cardiovascular 
disease itself may be implicated in the aetiology of CRC. This is further supported by autopsy 
studies which have reported that atherosclerosis and colorectal adenomatous polyps tend to 
occur in the same individuals (Correa, Strong et al. 1982; Stemmermann, Heilbrun et al. 
1986). Kune and co-workers, however, found no association between coronary artery disease 
and the presence of colorectal cancer in a case matched study of over 1400 individuals (Kune, 
Kune et al. 1988). 
1.3.1.7  Obesity and insulin resistance 
Obesity is now well established as a risk factor for colorectal cancer. In 2007, a meta-analysis 
from Moghaddam and colleagues estimated that individuals with a Body Mass Index (BMI) 
≥30kg/m2 had a 20% greater risk of developing CRC compared to normal weight controls 
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(Moghaddam, Woodward et al. 2007). There appeared to be a dose-response relationship 
with central obesity in particular, and every 2cm increment in waist circumference increased 
the risk of CRC by 4%.  This association with central obesity, a surrogate marker for levels of 
metabolically-active visceral fat, may give insight into the mechanisms through which excess 
weight can increase cancer risk. There are now a growing number of reports that suggest 
insulin resistance plays a key role in this association (McKeown-Eyssen 1994; Giovannucci 
1995). Not only have studies shown close relationships between glucose levels, diabetes and 
malignancy (Larsson, Giovannucci et al. 2005), experimental work has also demonstrated 
that insulin and insulin-like growth factor (IGF-1) can stimulate the proliferation of both 
normal colonic mucosal cells and carcinoma cell lines (La Vecchia, Negri et al. 1997; 
Limburg, Anderson et al. 2005).     
1.3.1.8  Smoking 
Cigarette smoking is associated with an increased risk of a number of malignancies including 
lung, stomach, kidney, bladder and pancreas. There is now consistent evidence that cigarette 
smoking also causes colorectal cancer. Almost all studies that have investigated the impact of 
smoking on precursor lesions have concluded that cigarette smoking increases the likelihood 
of colorectal adenoma formation albeit only after decades of exposure (Giovannucci and 
Martinez 1996).  Dose-response relationships with CRC have also been reported when 
studies have assessed smoking duration, cigarette pack years and smoking intensity (Wu, 
Paganini-Hill et al. 1987; Le Marchand, Wilkens et al. 1997; Slattery, Potter et al. 1997). The 
relative importance of intensity and duration of tobacco use are unresolved but it is clear that 
long term heavy smokers are at highest risk. Indeed, some reports estimate that up to 20% of 
colorectal cancers in the United States are directly attributable to cigarette smoking 
(Heineman, Zahm et al. 1994).  
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1.3.1.9  Alcohol  
Alcohol has been implicated in the aetiology of colorectal cancer. The EPIC trail investigated 
the impact of alcohol consumption on a cohort of almost half a million subjects over a 6 year 
period and concluded that both lifetime and baseline alcohol intake increased the risk of 
colon and rectal cancer (Ferrari, Jenab et al. 2007).  Furthermore, a pooled analysis of 
fourteen separate studies suggested that a high alcohol intake, defined as more than 
100g/week, was associated with a 19% increase in the risk of colon cancer in men and 
women (Moskal, Norat et al. 2007). The mechanisms through which alcohol leads to tumour 
development have yet to be elucidated but may include a direct carcinogenic effect of 
acetaldehyde, the primary metabolite of alcohol and a compound known to alter DNA.  
1.3.1.10 Hormone replacement therapy  
In 1999 a large meta-analysis reported that the risk of colorectal cancer was significantly 
lower in postmenopausal women who had taken Hormone Replacement Therapy (HRT) 
compared to those who had never received such treatment (Grodstein, Newcomb et al. 1999). 
In addition to this epidemiological evidence, there are several biological reasons why 
endogenous hormones may be protective. Oestrogens decrease the production of bile acids 
which have been implicated in initiating and promoting malignant change of colonic 
epithelium (McMichael and Potter 1980). The presence of oestrogen also decreases serum 
levels of insulin-like grown factor-1 (IGF-1), an important mitogen required for cellular 
proliferation and subsequent malignant transformation (Campagnoli, Biglia et al. 1993).  
1.3.1.11 Non-steroidal anti-inflammatory drugs 
There is good evidence that patients taking non-steroidal anti-inflammatory drugs (NSAIDs) 
reduce their risk of developing colorectal cancer. In 2003, a randomised controlled trial of 
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over 1000 patients concluded that daily aspirin reduced the risk of colorectal adenoma 
formation in patients with a history of polyps (Baron, Cole et al. 2003). These findings are 
supported by epidemiological data which suggests that NSAIDs not only reduce the incidence 
of adenomas (Arber 2000) but also reduce the risk of progression to adenocarcinoma (Peleg, 
Maibach et al. 1994). Despite this evidence, the cardiovascular and gastrointestinal side 
effects of these drugs have meant that trials investigating them as colorectal cancer 
chemoprevention have failed to recommend their routine use (Baron, Sandler et al. 2006; 
Bertagnolli, Eagle et al. 2006). The precise mechanisms which explain the anti-carcinogenic 
effect of NSAIDs have yet to be clarified although it is recognised that this class of drugs 
reduces the synthesis of prostaglandins through inhibition of cyclooxygenase (COX) 
enzymes. One hypothesis is that they exert their beneficial effect by direct inhibition of COX-
2, the COX isoform implicated in carcinogenesis (Wu, Gu et al. 2003). An alternative 
explanation is that NSAIDs work by modulating the local and systemic inflammatory 
responses, recognised to be associated with the development and progression of colorectal 
cancer (see below) (McMillan, Canna et al. 2003; Erlinger, Platz et al. 2004).  
1.3.1.12 Statins 
Statins are a class of drug which inhibit HMG-CoA reductase, an enzyme important in the 
synthesis of cholesterol, and were originally designed as lipid-lowering agents. However, 
HMG-CoA is over-expressed in colorectal cancer cell lines (Hentosh, Yuh et al. 2001) and 
statins were shown to induce apoptosis of tumour cells in vitro (Rao, Newmark et al. 2002). 
With this hypothesis in mind, Poynter and colleagues analysed the drug histories of almost 
4000 patients and reported that statin use was associated with a significant reduction in the 
relative risk of developing colorectal cancer (Poynter, Gruber et al. 2005). A subsequent 
meta-analysis of 18 studies, involving over 1.5 million patients, concluded that statins may be 
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associated with a reduction in the risk of colorectal cancer although the relationship was not 
as strong as first reported (Bonovas, Filioussi et al. 2007). More recently, studies have 
suggested that the impact of statins on tumour development may be mediated by their anti-
inflammatory properties. The inhibition of HMG-CoA prevents the synthesis of mevalonic 
acid a downstream pre-requisite for a number of molecular processes including inflammation, 
cellular proliferation and angiogenesis (Zhu, Daghini et al. 2008). There is also evidence that 
statins may act to prevent distant metastases through the sensitization of colorectal tumours to 
chemotherapeutic agents (Siddiqui, Nazario et al. 2009).  
 
1.3.1.13 Systemic inflammatory response 
A number of studies have suggested that the risk of CRC is higher in individuals with 
evidence of a pre-existing systemic inflammatory response. (Tsilidis, Branchini et al. 2008). 
In a prospective study of over 22,000 patients, Erlinger and co-workers discovered that 
plasma C-reactive protein (CRP) levels were consistently elevated among people who 
subsequently developed colon cancer (Erlinger, Platz et al. 2004). The authors suggested that 
inflammation may therefore play a role in carcinogenesis but pointed out that systemic 
inflammation was also associated with other potential risk factors such as obesity, smoking 
and coronary artery disease. Such associations have been confirmed by other studies (Ross 
1999; Visser, Bouter et al. 1999; Freeman, Norrie et al. 2002) and raise the possibility that 
systemic inflammation may simply represent a surrogate marker for a variety of different 
CRC risk factors (Figure 1.3). However, regardless of whether a systemic inflammatory 
response represents a final common pathway or is considered an independent risk factor, it is 
clear that inflammation and carcinogenesis are intimately related.  In experimental models, 
pro-inflammatory cytokines have been shown to damage DNA, promote cellular proliferation 
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and inhibit apoptosis (Jaiswal, LaRusso et al. 2000; Meira, Bugni et al. 2008; Davies, Powell 
et al. 2009). It remains to be established whether inflammation is a cause or a consequence of 
cancer development, but their intimate relationship has led to inflammation recently being 
proposed as an inherent hallmark of cancer (Colotta, Allavena et al. 2009)  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3. Systemic inflammation as a risk factor for colorectal cancer. The solid arrows 
represent an association through established colorectal cancer risk factors while the dashed 
arrows represent a possible independent association. 
Systemic inflammation 
Smoking CAD Diabetes Obesity 
Colorectal cancer 
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1.3.2  NON-SPORADIC COLORECTAL CANCER 
In a small number of cases the aetiological factors implicated in the development of 
colorectal cancer are more clearly defined. This category, termed „non-sporadic‟ colorectal 
cancer includes hereditary forms of the disease as well as specific disease processes 
associated with the development of colorectal malignancy.  
1.3.2.1  Inflammatory bowel disease  
Patients with inflammatory bowel disease, namely Crohn‟s disease (CD) or ulcerative colitis 
(UC), have an increased risk of developing colorectal cancer. A meta-analysis of over 60,000 
patients concluded that the risk of CRC in patients with CD was 2.59, although this risk 
increased in patients with severe or long-standing colitis (Canavan, Abrams et al. 2006). The 
risk of CRC in patients with UC is related to the duration of symptoms and is estimated at 2% 
after 10 years, 8% after 20 years and 18% after 30 years (Eaden, Abrams et al. 2001).  The 
predisposition to cancer in patients with inflammatory bowel disease does not appear to have 
a specific genetic basis but instead is assumed to be the result of chronic inflammation 
(Triantafillidis, Nasioulas et al. 2009).  The hypothesis of inflammation as the precursor of 
tumour development is supported by epidemiological data including evidence that cancer risk 
increases with both the severity (Gupta, Harpaz et al. 2007) and duration of colitis (Lakatos 
and Lakatos 2008).  It should be emphasised that the same carcinogenic pathways, namely 
chromosomal instability and microsatellite instability, lead to the development of both 
sporadic and colitis-associated colorectal cancer. The complex relationships between 
inflammation and cancer development are described in more detail below but it is thought 
that the inflammatory process can interact directly with genes involved in the carcinogenic 
pathways, including p53 and DNA MMR genes (Itzkowitz and Yio 2004).    
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1.3.2.2  Hereditary Non-Polyposis Colon Cancer  
Hereditary Non-Polyposis Colon Cancer (HNPCC) is an autosomal dominant disease which 
predisposes carriers to the development of several different tumour types but primarily to 
those of the colorectum (Umar, Risinger et al. 2004).  It is the most common cause of so-
called „familial CRC‟ and was recognised as distinct from Familial Adenomatous Polyposis 
(FAP) in the 1960‟s by Henry Lynch; for this reason the disease is sometimes referred to as 
Lynch syndrome (Lynch, Shaw et al. 1966).  HNPCC has an incidence of approximately 
1:1000 in the general population and bestows an estimated 80% lifetime risk of colorectal 
cancer on carriers (Lynch and de la Chapelle 1999).  In addition, such individuals have an 
increased risk of endometrial, stomach, ovarian, biliary and urothelial tumours.  Patients with 
HNPCC differ from those with sporadic CRC in a number of ways; they are often diagnosed 
at an earlier age, the tumours are often right-sided, they have an increased risk of 
synchronous or metachronous tumours and their disease often carries a better prognosis 
(Vasen, Mecklin et al. 1991). 
The key to understanding these differences is the recognition that HNPCC cancers arise 
through a different molecular pathway than sporadic tumours.  As opposed to the 
chromosomal mutations seen in sporadic CRC, HNPCC cancers are the result of 
microsatellite instabilities and are therefore associated with certain molecular and 
pathological characteristics (see „microsatellite instability‟ below). At a molecular level, 
HNPCC is caused by germline mutations in any of 5 DNA MMR genes – MSH2, MLH1, 
MSH6, PMS2 or PMS1 (Kolodner, Tytell et al. 1999). The resultant microsatellite instability 
(MSI) is often used as a surrogate marker for HNPCC although it should be emphasised that 
the disease can occasionally occur without mismatch-repair mutations; conversely a 
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proportion of sporadic colorectal cancers will have MMR deficiency, preventing MSI status 
being used as the sole diagnostic criteria for HNPCC.  
The diagnosis of HNPCC is therefore based on a set of international guidelines, known 
collectively as the „Amsterdam‟ and „Bethesda‟ guidelines (Table1.2).  In essence, the 
condition is usually diagnosed with a detailed family history followed by genetic testing of 
potentially susceptible individuals. The Amsterdam criteria were originally developed in the 
early 1990‟s to determine whether a family should be classified as having HNPCC and were 
subsequently revised in 1998 (Amsterdam II criteria) (Vasen, Watson et al. 1999).  The 
Bethesda guidelines were developed with the purpose of deciding whether to genetically test 
individuals with cancer in their family who do not satisfy the Amsterdam criteria; these 
guidelines were also subsequently revised in 2003 (Umar, Boland et al. 2004).  
1.3.2.3  Familial Adenomatous Polyposis  
Familial Adenomatous Polyposis (FAP) is an autosomal dominant disease characterized by 
the development of hundreds of adenomas in the colon and rectum during the second decade 
of life.  The disease is rare, with an estimated incidence of 1:8000 and accounts for <1% of 
all cases of colorectal cancer (Fearnhead, Wilding et al. 2002).  The condition results from a 
mutation in the adenomatous polyposis (APC) gene, a tumour suppressor gene located on 
chromosome 5, leading to chromosomal instability and the development of CRC along the 
CIN pathway (Groden, Thliveris et al. 1991). Almost all patients with FAP will go on to 
develop CRC if they are not diagnosed and treated at an early age. Disease registries now 
mean it is unusual for people with FAP mutations to remain undiagnosed and most undergo 
regular surveillance and, ultimately, prophylactic colectomy.  Despite this, the association 
with extracolonic malignancies including pancreatic mucinous adenocarcinoma, 
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hepatoblastoma and desmoid tumours means that a significant number of patients with FAP 
still die from malignant disease (Belchetz, Berk et al. 1996).  
 
Table 1.2. International criteria used in establishing a diagnosis of HNPCC.  
 
Amsterdam II criteria (1998) 
Three or more relatives with an HNPCC associated cancer plus all of the following: 
- one affected individual should be a first degree relative of the other two 
- two or more successive generations should be affected 
- cancer in one or more affected relative should be diagnosed before the age of 50 years 
- FAP should be excluded in cases of colorectal cancer 
- tumours should be verified by pathological examination 
 
Revised Bethesda guidelines (2003) 
Just one of the following criteria need to be met: 
- diagnosed with colorectal cancer before the age of 50 
- synchronous or metachronous HNPCC associated cancer, regardless of age 
- colorectal cancer with MSI-H morphology, diagnosed before the age of 60 
- colorectal cancer with one or more first degree relative with an HNPCC associated tumour, diagnosed 
before the age of 50 
- colorectal cancer with two or more relatives with an HNPCC associated tumour, regardless of age 
 
Hereditary non-polyposis colorectal cancer 
FAP: Familial adenomatous polyposis 
MSI-H: high levels of microsatellite instability 
 
 
1.3.2.4  Hamartomatous Polyposis Syndromes 
A number of different syndromes have been described whereby patients have a propensity to 
develop multiple hamartomatous polyps in the gastrointestinal tract. The majority of these 
syndromes are inherited in an autosomal dominant fashion and include Juvenile Polyposis 
syndrome (JPS), Peutz-Jeghers syndrome (PJS), hereditary mixed polyposis syndrome 
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(HMPS) and the PTEN hamartoma tumour syndromes (Calva and Howe 2008).  Although the 
clinical features of these syndromes are variable, all give patients an increased risk of 
developing colorectal cancer. It is estimated that JPS carries a 38% risk of colorectal cancer 
(Howe, Mitros et al. 1998) while a diagnosis of PJS bestows an 84 fold relative risk of 
developing colon cancer when compared to the general population (Giardiello, Welsh et al. 
1987). The progression of hamartomatous polyps to cancer is poorly understood but probably 
represents a different mechanism to that observed in the adenoma to carcinoma sequence 
described above.  The histological changes are thought mainly to affect the lamina propria, a 
process described as „landscaping‟ which leads to the development of epithelial cancers.  In 
addition to an increased risk of colorectal cancer, patients with multiple hamartomas‟ are 
prone to malignancies of the stomach, pancreas and small bowel (Kinzler and Vogelstein 
1998).  
1.3.3  Summary – Aetiology of colorectal cancer 
The development of colorectal cancer occurs following complex interactions between host 
and environmental factors.  In a small number of cases, specific genetic mutations mean the 
disease is inevitable but in the majority of people the development of colorectal cancer is 
difficult to predict.  Environmental factors such as a Western diet rich in red meat and low in 
fibre may predispose an individual but tumour development does not always occur. 
Individual susceptibility appears largely to depend on host factors such as age, an absence of 
comorbidity or pre-existing systemic inflammation.  It is of particular interest that 
inflammation has been associated with many other individual risk factors for colorectal 
cancer and raises the possibility that a final common pathway is responsible for both tumour 
development and the generation of a systemic inflammatory response.  
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1.4  MANAGEMENT PRINCIPLES IN COLORECTAL CANCER  
1.4.1  Presentation 
The presentation of colorectal cancer is dependent on the site of tumour and extent of disease. 
Many patients with early cancers have no symptoms and a diagnosis is only made via 
population screening. Common symptoms associated with colorectal cancer include 
abdominal pain, rectal bleeding, altered bowel habit and involuntary weight loss (Thompson, 
Perera et al. 2007). The likelihood of individual symptoms varies by tumour location. 
Proximal cancers for example, rarely cause gross rectal bleeding because the blood tends to 
mix with the stool and degrade during colonic transit. This occult blood loss means such 
patients often present with iron deficiency anaemia (Harewood and Ahlquist 2000). In 
contrast, distal rectal tumours may present with fresh rectal bleeding, pelvic pain or tenesmus 
(Cappell 2005).  In a few cases, patients without recent symptoms present as an emergency 
with intestinal obstruction, fistulation or perforation (Bass, Fleming et al. 2009). 
1.4.2  Diagnosis 
The diagnostic work up for colorectal cancer depends on the mode of presentation. If a 
patient presents as an emergency with symptoms and signs of peritonitis, a diagnosis of 
colorectal cancer may only be made incidentally during operative intervention. However, in 
the elective setting, a histological diagnosis should be made and the disease fully staged 
before treatment is commenced (ACPGBI). The investigations used in the diagnosis of 
colorectal cancer are detailed below.  
1.4.3  Diagnostic modalities 
Colonoscopy is the gold standard investigation of the colon and rectum allowing direct 
visualisation of the mucosal surface and offering the capacity to obtain tissue for histological 
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diagnosis. Colonoscopy is highly sensitive at detecting both malignant tumours and benign 
adenomas (Rex 1995). Colonoscopy has a number of disadvantages including the impact on 
healthcare resources, its invasive nature and a small but significant risk of serious 
complications (Scholefield 2000). Flexible sigmoidoscopy, examining only the distal colon, 
is an alternative to colonoscopy and is effective in diagnosing the majority of colorectal 
tumours (Thompson, Flashman et al. 2008). To examine the right colon, however, this test 
must be augmented with additional investigations, such as barium enema.  
Double contrast barium enema is a radiological technique offering the capacity to image the 
entire colon. The presence of alternative colonic pathology such as diverticular disease, 
however, can make interpretation difficult and often necessitates the need for direct 
endoscopic visualisation. A review of over 2000 consecutive cases estimated that barium 
enema had a sensitivity of 83% for the detection of colorectal cancer compared to 95% for 
colonoscopy. In addition, barium enema was less adept in the identification of early stage 
tumours (Rex, Rahmani et al. 1997).  
CT colonography is a minimally invasive technique increasingly used as an alternative to 
colonoscopy for examining the lower gastrointestinal tract. Individual protocols vary but the 
technique involves the administration of bowel preparation followed by high resolution CT 
scanning. The sensitivity of CT colonography for the detection of colorectal cancer was 
estimated by one systematic review as 93%, a figure comparable to conventional 
colonoscopy (Halligan, Altman et al. 2005). This modality has the added benefit of offering 
simultaneous staging information (Chung, Huh et al. 2005). 
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1.4.4  Staging of colorectal cancer 
The staging of colorectal cancer quantifies the extent of disease and provides a framework for 
selecting the appropriate treatment. A number of staging systems exist but across the world 
the most common is the Tumour, Node Metastases (TNM) system produced by the American 
Joint Committee on Cancer (AJCC). Using this system, the stage of colorectal cancer has 
three components, the primary tumour (T), the regional lymph nodes (N) and the presence of 
metastatic disease (M), which are combined to form stage groupings. Current practice in the 
UK dictates that colorectal cancers are staged according to the 5
th
 edition of the AJCC/TNM 
classification (Fleming ID 1997). An alternative staging system for colorectal cancer also 
exists in the UK, commonly referred to as Dukes staging.  The original system, proposed by 
Cuthbert Dukes in the 1930‟s (Dukes 1937) for the classification of rectal cancer, has been 
modified on several occasions and now encompasses both colon and rectal cancer and 
includes a “D” stage for the presence of distant metastases  (Table 1.3). 
Final staging of colorectal cancer relies on the pathological assessment of the resected tumour 
and can only be completed after surgery.  Pre-treatment staging, used to select the most 
appropriate management strategy relies on a combination of physical examination, 
visualisation of the colon and radiological imaging of the chest, abdomen and pelvis. In 
patients with newly diagnosed colorectal cancer, abdominal, pelvic and chest CT is used to 
define the extent of local tumour extension and establish the presence or absence of regional 
lymphatic spread and distant metastases. It is preferable to obtain these scans prior to, rather 
than after operation, as the results may influence surgical planning. If a patient requires an 
emergency operation for complications associated with a recently diagnosed colorectal 
cancer, staging may be completed in the post-operative period.  
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In patients with colon cancer, additional staging modalities such as contrast-enhanced 
magnetic resonance imaging (MRI) and Positron Emission Tomography (PET) are not 
routinely used but may be employed if there is diagnostic uncertainty regarding the presence 
of metastatic disease.  
In patients with rectal cancer, current Royal College of Radiology guidelines state that pre-
operative staging should include pelvic MRI to assess the circumferential resection margin 
and exclude disease outwith the mesorectum. Endoanal and endorectal ultrasound may also 
be employed to assess the depth of invasion through the bowel wall and involvement of 
mesorectal lymph nodes. Accurate staging of the rectum is important for decision-making 
regarding the provision of neo-adjuvant treatment in rectal cancer (Brown 2005).  
 
Table 1.3. Comparison of colorectal cancer staging systems currently used in the UK. 
Staging systems 
TNM Stage T N M Dukes 
Stage 0 Tis N0 M0 - 
Stage I T1 N0 M0 A 
Stage II T2 N0 M0 A 
Stage IIA T3 N0 M0 B 
Stage IIB T4 N0 M0 B 
Stage IIIA T 1-2 N1 M0 C 
Stage IIIB T 3-4 N1 M0 C 
Stage IIIC Any T N2 M0 C 
Stage IV Any T Any N M1 D 
 
TNM: AJCC Tumour, Node and Metastases staging system 
Dukes: Modified Dukes classification of colorectal cancer 
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1.4.5  Management principles in colon cancer 
Approximately 80% of colon cancers are localised to the bowel wall and can be surgically 
resected. These operations are undertaken with curative intent and involve complete removal 
of the tumour, the vascular pedicle and the lymphatic drainage of the affected colonic 
segment. In most cases intestinal continuity can be restored with a primary anastomosis but in 
the presence of unfavourable circumstances a diverting stoma may be employed. 
Laparoscopic-assisted colectomy is an acceptable alternative to open surgery and follows the 
same oncological principles. There is some evidence that recovery may be quicker with 
laparoscopic surgery while morbidity, mortality and oncological outcomes appear 
comparable (Delaney, Chang et al. 2008).  
1.4.6  Polyp cancers 
Benign polyps or those with carcinoma in situ can be managed with endoscopy resection 
(polypectomy). If invasive cancer is discovered in a polyp then management decisions are 
centred on the choice between endoscopic polypectomy versus formal surgical resection of 
the affected colonic segment. Endoscopic resection is an acceptable strategy for early stage 
polyp cancers with no adverse pathological features. However, in the presence of 
unfavourable characteristics including poorly differentiated histology, lymphovascular 
invasion, tumour cells at the stalk margin or cancer in a sessile polyp, radical surgical 
resection is indicated (Coutsoftides, Sivak et al. 1978; Kikuchi, Takano et al. 1995).   
1.4.7  Management principles in rectal cancer 
Surgical resection is also the cornerstone of potentially curative treatment for rectal cancer. 
The choice of operation is dependent on the size, stage and position of the tumour. Small 
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tumours that are confined to the mucosa may be effectively managed by local excision using 
techniques such as transanal endoscopic microsurgery (TEMS) (Langer, Liersch et al. 2003; 
Lee, Lee et al. 2003) while larger tumours require more radical resection. Invasive rectal 
cancers are ideally removed using a sphincter-sparing procedure provided the distal margin of 
resection is histologically clear of tumour. Tumours of the upper and middle third of rectum 
are usually managed with a low anterior resection while those in the distal rectum may be 
amenable to ultra low anterior resection with colonic pouch. For low-lying rectal tumours 
with confirmed sphincter invasion or in whom a clear distal resection margin cannot be 
guaranteed, the operation of choice is an abdomino-perineal resection (APR).  Recently, a 
more radical approach to low rectal tumours using an extralevator or „cylindrical‟ APR has 
been reported to be oncologically superior with lower rates of positive circumferential 
resection margins (CRM) (Holm, Ljung et al. 2007). In order to achieve the greatest 
likelihood of complete tumour clearance in rectal cancer surgery, it is important that any 
potentially curative operation for invasive disease includes total mesorectal excision (TME) 
(Heald, Husband et al. 1982; Law and Chu 2004).  
1.4.8  Neo-adjuvant treatment in rectal cancer 
Management of cancer in the low rectum presents clinicians with the dual challenge of 
preserving anal sphincter function while removing local tumour. In many cases an APR 
offers the greatest chance of curative surgery but leaves patients with a permanent colostomy. 
For patients with large or low-lying tumours initially precluding sphincter-sparing surgery, 
neo-adjuvant treatment may enhance the prospects of resection with curative intent but its 
provision is unlikely to avoid the need for APR.  The indications for neo-adjuvant 
chemoradiotherapy include T3/4 tumours, positive mesorectal nodes on preoperative imaging 
and tumours threatening or involving the mesorectal fascia (Sauer, Becker et al. 2004; Rodel, 
52 
 
Martus et al. 2005). The optimal regime for neo-adjuvant chemoradiotherapy in rectal cancer 
has yet to be established and is the subject of ongoing clinical trials.  
1.4.9  Adjuvant chemotherapy  
In patients with colon cancer who have undergone potentially curative surgery, disease 
recurrence is presumed to be the result of clinically occult metastases that are present at the 
time of resection. The goal of adjuvant chemotherapy is to eliminate these tumour cells and 
thereby increase the likelihood of cure. A 5 year survival advantage after adjuvant 
chemotherapy has been clearly demonstrated in stage III (node-positive) colon cancer but its 
benefit in node-negative disease has yet to be confirmed (Wolmark, Fisher et al. 1988; 
Moertel, Fleming et al. 1995; Wolmark, Wieand et al. 2000).  Current recommendations are 
that only patients with Stage II colon cancer who have high risk pathological features should 
be considered for adjuvant chemotherapy (ACPGBI ; Benson, Schrag et al. 2004). The status 
of the inflammatory response is not currently a criteria for the consideration of adjuvant 
chemotherapy in patients with colorectal cancer.  
Adjuvant chemotherapy is usually started within 6 to 8 weeks or when patients have 
recovered from surgery. Although there is no agreement as to the optimum timing of 
chemotherapy, there is consensus that excessive treatment delays can have a negative impact 
on survival (Dahl, Fluge et al. 2009). 
The choice of chemotherapy regime for patients who have undergone potentially curative 
colorectal cancer resection is not well established but effectiveness, drug toxicity and patient 
fitness are taken into account. Combination therapy where oxaliplatin, cetuximab or 
bevacizumab are given along with 5-Fluorouracil (5-FU) are reported to offer superior 
disease free survival compared to 5-FU alone (Andre, Boni et al. 2004; Gill, Loprinzi et al. 
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2004). Alternative oral agents such as capecitabine can be considered for patients unable to 
tolerate intravenous regimes (Twelves, Wong et al. 2005).  
There is uncertainty as to whether adjuvant chemotherapy offers a survival advantage to 
patients with rectal cancer who have previously undergone preoperative treatment. One 
school of thought suggests that those with a good tumour response do not require further 
treatment postoperatively (Fietkau, Barten et al. 2006) while others argue that this 
demonstrates a tumour cell sensitivity to chemotherapy that should be utilised (Bosset, 
Collette et al. 2006).  
1.4.10  Metastatic disease 
Approximately 20% of patients with colorectal cancer have evidence of metastatic disease at 
the time of diagnosis. In selected patients with limited metastases, surgical resection still 
provides a potentially curative option. Long term survival can be achieved with aggressive 
surgical treatment of both the primary tumour and secondary deposits. Such a strategy is 
usually combined with chemotherapy although the optimal timing of surgery in relation to 
oncological treatment has yet to be determined. In patients who present with colorectal cancer 
and synchronous resectable hepatic metastases, the management options include 
simultaneous colonic and liver resection (Tanaka, Shimada et al. 2004; de Santibanes, 
Fernandez et al. 2010) or a staged approach (Jamison, Donohue et al. 1997; Choti, Sitzmann 
et al. 2002).  
1.4.11  Colorectal cancer screening programme 
Colorectal cancer has a number of features that make it an attractive candidate for population 
screening. These include the fact that most cases develop slowly over a number of years and 
the disease is more effectively treated when diagnosed at an earlier stage. In addition, there is 
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a safe screening test which is acceptable to the majority of the population. Most importantly, 
trials in North America and Europe reported that the incidence and mortality of colorectal 
cancer was reduced in screened populations (Selby, Friedman et al. 1992; Hardcastle, 
Chamberlain et al. 1996; Scholefield, Moss et al. 2002).  In 2006 the NHS Bowel Cancer 
Screening Programme commenced by inviting all men and women aged 60 to 69 (50 – 74 in 
Scotland) to submit a faecal occult blood (FOB) test every 2 years. Local screening centres 
have been established to provide endoscopy for people who have an abnormal test result. In 
the UK, the expectation of the colorectal cancer screening programme is that more tumours 
will be detected at an earlier stage and the incidence of advanced disease will reduce (Kaye 
and Shulman 1992). This so-called „stage shift‟ means the ability of clinicians to risk stratify 
and treat patients with node-negative disease will become increasingly important (see below).  
55 
 
1.5  PROGNOSTIC FACTORS IN COLORECTAL CANCER  
The prognosis of colorectal cancer is often summarised according to tumour stage at 
diagnosis.  Five year survival rates in the United Kingdom vary from over 90% for patients 
with tumours confined to the mucosa to less than 10% for those with metastatic disease 
(CRUK).  However, it is now recognised that the prognosis of patients with colorectal cancer 
is not governed exclusively by pathological stage. Rather, disease progression appears to be 
determined by complex interactions between both tumour and host characteristics. Tumour 
factors include specific pathological features, molecular markers or genetic mutations. Host 
factors include age, physiological function, local immune cell response and the presence of a 
systemic inflammatory response.  
1.5.1  TUMOUR FACTORS AND COLORECTAL CANCER PROGNOSIS 
A large number of tumour characteristics have been described as having prognostic value in 
colorectal cancer. These range from gross pathological features such as evidence of lymph 
node involvement right through to the presence or absence of specific molecular markers or 
genetic mutations. The following summarises those tumour factors reported to influence 
disease progression and survival in colorectal cancer.  
1.5.1.1  Pathological stage 
The pathological stage of the tumour is widely regarded as the single biggest determinant of 
outcome in colorectal cancer. The staging systems most commonly employed in the UK are 
the Dukes and TNM classifications.  
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Dukes system 
As described above, Dukes‟ original classification of rectal cancer has undergone a series of 
modifications in an attempt to improve prognostic stratification and encompass both colon 
and rectal tumours. This system stratifies tumours according to the depth of invasion into the 
bowel wall and the presence or absence of lymph node or distant metastases. Dukes A 
describes a cancer confined to the colorectal mucosa or submucosa, Dukes B1 extends to the 
muscularis propria while Dukes B2 penetrates the muscularis propria. By definition, tumours 
termed Dukes C have evidence of lymph node involvement with C1 tumours confined to the 
bowel wall and C2 tumours penetrating through the bowel wall. More recently, an additional 
stage, termed Dukes D, was added to describe the presence of distant metastases. The Dukes 
system is adept at giving a gross description of the extent of the primary tumour and is still 
used by some clinicians in the UK as a prognostic indicator. The 5 year survival rates of 
patients with colorectal cancer, stratified by Dukes stage are summarised in Table 1.4.  
TNM system 
Although the Dukes system is still used by some, confusion over modifications and 
terminology (Mainprize, Mortensen et al. 2002) mean that the system has been superseded by 
the Tumour Node Metastases (TNM) system. This system was developed and is maintained 
by the American Joint Committee on Cancer (AJCC) and the International Union Against 
Cancer (UICC) and is based on the extent of the primary tumour (T), the extent of regional 
lymph node involvement (N) and the presence or absence of distant metastases (M). The 
rationale behind this standardised system is to indicate prognosis, plan and assess the 
response to treatment and compare data objectively between centres. The TNM system is 
regularly updated and is currently on its 7
th
 edition. Despite this, in the UK the Royal College 
of Pathologists (RCPath) still currently recommends the 5
th
 edition as the optimal staging 
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system for colorectal cancer (Table 1.5). The reasons behind this decision include disputes 
over evidence underlying recent amendments as well as the difficulties in standardising long 
term clinical trials using a continuingly evolving system (Quirke, Williams et al. 2007).  For 
example, a given stage may have quite different prognosis depending on which staging 
edition is used, an effect that has been termed „stage migration‟.  
Although both the Dukes and TNM system provide useful prognostic information they have a 
number of potential problems. To allocate an accurate stage, both systems are reliant on the 
quality of surgical excision and the subsequent pathological assessment of the specimen 
(Johnson, Porter et al. 2006). For example, an adequate assessment of nodal status requires 
the surgeon to harvest a minimum number of lymph nodes and the pathologist to accurately 
identify and stage each individual node.  Low lymph node counts can under-stage a tumour 
and have been suggested as an independent risk factor for disease recurrence (Chang, 
Rodriguez-Bigas et al. 2007). Lymph node number has therefore become a surrogate marker 
for quality of surgical resection and pathological assessment and current guidelines 
recommend that a minimum of 12 nodes are required to allow accurate staging (RCPath). 
The other primary problem with the Dukes and TNM systems is that survival rates vary 
considerably within and across each prognostic category.  Indeed, it is now accepted that 
patients with node-negative disease (Stage II) who have certain high risk pathological 
features such as venous invasion have a worse survival than some patients with lymph node 
metastases (Stage III) (Petersen, Baxter et al. 2002; Morris, Maughan et al. 2007).  
In summary, the pathological stage of the tumour provides important prognostic information 
in colorectal cancer and is the standard against which all other prognostic factors are 
measured. The TNM system is employed throughout the world but despite continuous 
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modifications, cannot yet accurately identify all patients who will ultimately succumb to their 
disease.  
 
Table 1.4. Five year survival rates of patients with colorectal cancer, stratified by TNM and 
Dukes stage at diagnosis. Adapted from the CRUK cancer statistics website.  
 
 
TNM stage Dukes stage % of all cases 5 year survival 
Stage I A 8.7% 93.2% 
Stage IIA B 
24.2% 77.0% 
Stage IIB B 
Stage IIIA C 
23.6% 47.7% Stage IIIB C 
Stage IIIC C 
Stage IV D 9.2% 6.6% 
Unknown Unknown 34.3% N/A* 
*Not applicable.  
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Table 1.5. AJCC/TNM (5
th
 edition) system for the classification of colorectal cancer.  
 
 
 
pT    Primary tumour 
pTx  Primary tumour cannot be assessed 
pT0   No evidence of primary tumour 
pT1   Tumour invades submucosa 
pT2   Tumour invades muscularis propria 
pT3   Tumour invades through muscularis propria  
pT4   Tumour directly invades other organs (pT4a) or visceral peritoneum (pT4b)  
 
pN     Regional lymph nodes 
pNX   Regional lymph nodes cannot be assessed 
pN0   No regional lymph node metastases 
pN1   Metastases in 1-3 regional lymph nodes 
pN2   Metastases in 4 or more regional lymph nodes 
 
pM     Distant metastases 
pMX   Distant metastases cannot be assessed 
pM0   No distant metastases  
pM1   Distant metastases 
 
 
1.5.1.2  High risk pathological characteristics 
In addition to conventional pathological stage, as described by the Dukes or TNM system, a 
number of other pathological characteristics have been reported to affect prognosis. These 
high risk tumour features, which can occur alone or in combination, are described below.  
Tumour grade 
Tumour grade describes how well the tumour is differentiated and is reported subjectively by 
the pathologist examining the specimen. Colorectal tumours are generally categorized as low 
grade (well or moderately differentiated) or high grade (poorly differentiated). A number of 
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studies have suggested that tumour grade is a prognostic factor in colorectal cancer. For 
example, in a study of over 100,000 patients O‟Connell and colleagues reported reduced 
survival in patients with high grade tumours compared to low grade tumours in stage II – IV 
colon cancer (O'Connell, Maggard et al. 2004). Similar results have been reported in rectal 
cancer with poorly differentiated tumours displaying an increased risk of local recurrence and 
reduced 5 year survival (McDermott, Hughes et al. 1984). However, there remains concern 
that the histological grading of tumours in this way is subject to significant inter-observer 
variability (Thomas, Dixon et al. 1983). In conclusion, there is evidence that tumour grade 
influences survival in colorectal cancer although its effect appears to be small and is not 
likely to apply to stage I disease.  
Venous invasion 
The microscopic diagnosis of venous invasion is made when tumour cells are identified 
within a endothelium lines space surrounded by a rim of smooth muscle and/or containing red 
blood cells (Sternberg, Amar et al. 2002). Venous invasion is an established predictor of poor 
prognosis in colorectal cancer and its presence is associated with an increased incidence of 
disease recurrence and reduced survival (Krasna, Flancbaum et al. 1988; Minsky, Mies et al. 
1988; Ouchi, Sugawara et al. 1996; Stewart, Morris et al. 2007). The reported incidence of 
venous invasion within colorectal tumours varies widely between studies from as low as 10% 
to as high as 89% (Dirschmid, Lang et al. 1996; Sternberg, Amar et al. 2002).  Venous 
emboli are more prevalent in advanced disease and can occur in any part of the tumour so 
may be missed during routine pathological sectioning. However, the most decisive factor 
influencing the variance in reporting rates between different laboratories is likely to be the 
pathological technique employed. While some centres rely on haematoxylin and eosin (H&E) 
staining alone (Horn, Dahl et al. 1990), others employ sensitive immunohistochemistry 
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techniques to stain elastin fibres (elastase), greatly aiding the identification of venous emboli 
(Minsky, Mies et al. 1988; Dirschmid, Lang et al. 1996). In conclusion, there is strong 
evidence that venous invasion is an important prognostic factor in colorectal cancer but its 
clinical application is hampered by variations in reporting rates and techniques of assessment.  
Perineural invasion 
Perineural invasion (PNI) is a pathological process whereby tumour cells invade nervous 
tissues and spread along nerve sheaths (Batsakis 1985). It is recognised to represent an 
aggressive tumour phenotype in other solid organ cancers (Soo, Carter et al. 1986; de la 
Taille, Katz et al. 1999) and its presence in colorectal tumours is reported to be a poor 
prognostic sign. Several reports now indicate that PNI is a high risk feature in colorectal 
cancer and is associated with local recurrence and reduced survival (Krasna, Flancbaum et al. 
1988; Ross, Rusnak et al. 1999; Liebig, Ayala et al. 2009). The evidence appears to be 
particularly strong for rectal cancer, perhaps reflecting the dense network of autonomic 
nerves in the pelvis. Despite this evidence, the RCPath do not currently recommend the 
assessment of PNI as core data in the reporting of colorectal tumour pathology. It is likely 
therefore that the incidence of PNI is under-estimated.  Indeed, a retrospective examination of 
269 colorectal cancer cases by Leibig and co-workers identified evidence of PNI in 22% of 
tumours compared to an incidence of just 0.5% on the original reports (Liebig, Ayala et al. 
2009). In conclusion, PNI should be considered a high risk pathological feature in colorectal 
cancer but its prognostic utility is limited until its presence is routinely reported.  
Peritoneal involvement 
Serosal or peritoneal involvement is said to be present if tumour cells are visible either on the 
peritoneal surface or free in the peritoneal cavity. It is regarded as a poor prognostic sign in 
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both colon and rectal cancer and is associated with disease recurrence and metastatic spread 
(Shepherd, Baxter et al. 1997; Stewart, Morris et al. 2007). The identification of peritoneal 
involvement is reliant on accurate pathological assessment and there is some evidence that 
rates may be under-reported in many centres (Stewart, Morris et al. 2007). 
Tumour perforation 
Tumour perforation is defined as a visible defect through the tumour such that the bowel 
lumen is in communication with the external surface of the resected specimen. It is widely 
recognised as a high risk pathological characteristic and has been associated with increased 
risk of disease recurrence and reduced survival, independent of tumour stage, in patient with 
colorectal cancer (Petersen, Baxter et al. 2002; Benson, Schrag et al. 2004). 
Margin involvement 
Tumour cells present at or within 1mm of the surgical margin indicate inadequate tumour 
excision and are an exceedingly poor prognostic indicator. Studies have consistently 
demonstrated that involvement of the circumferential resection margin (CRM) is one of the 
strongest predictors of disease recurrence after rectal cancer resection (Adam, Mohamdee et 
al. 1994; Birbeck, Macklin et al. 2002). It is intuitive that residual tumour in situ results in a 
poor outcome and many clinicians therefore consider margin involvement as a marker of 
surgical quality rather than a true histological characteristic.  
1.5.1.3  Petersen Index 
Petersen and co-workers set out to identify objective and easily determined pathological 
features that could help identify which patients with Dukes B colon cancer may benefit from 
chemotherapy.  After a meticulous pathological review of 268 consecutive cases the authors 
concluded that four factors – venous invasion, peritoneal involvement, tumour perforation 
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and margin involvement – were independent prognostic markers on multivariate analysis 
(Petersen, Baxter et al. 2002). Combining these factors into a cumulative scoring system 
stratified patients effectively into low risk (score 0 – 2) or high risk (score 3 – 5) categories. 
The prognostic value of the Petersen Index (PI) was subsequently confirmed in a large 
validation cohort of patients with Dukes B disease (Morris, Maughan et al. 2007). 
1.5.1.4  Lymph node ratio 
The lymph node ratio (LNR), calculated by dividing the number of lymph nodes with 
confirmed metastatic disease by the total number of lymph nodes sampled, has received 
attention as a possible prognostic indicator in colorectal cancer. A study of over 26,000 
patients by De Ridder and colleagues suggested that the LNR could be used effectively to 
stratify patients with node positive colon cancer into two distinct prognostic groups (De 
Ridder, Vinh-Hung et al. 2006). These results are supported by other work which suggests 
that the LNR provides superior prognostic information compared to N stage alone (Le Voyer, 
Sigurdson et al. 2003; Berger, Sigurdson et al. 2005). The rationale behind the prognostic 
utility of the LNR is that patients with inadequate lymph node resection are at risk of being 
under-staged and receiving less adjuvant treatment. Using the ratio of metastatic to examined 
nodes reduces the likelihood of disease misclassification and under-treatment. Despite 
evidence that the LNR may provide additional prognostic information to TNM stage, there is 
little agreement as to which thresholds to use. The study by De Ridder outlined above used a 
LNR cut-off of 0.4 to split patients into two groups while other studies have used different 
thresholds (Peschaud, Benoist et al. 2008) or have stratified patients into three prognostic 
groups (Rosenberg, Friederichs et al. 2008). In conclusion, the LNR clearly has no role to 
play in predicting disease outcomes in patients with node negative disease.  It may represent 
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an additional prognostic marker for patients with positive lymph nodes although agreement 
has yet to be reached regarding the optimum thresholds.  
1.5.1.5  Microsatellite instability 
A large number of studies have now investigated the prognostic implications of determining 
the miscrosatellite instability (MSI) status of colorectal tumours. As described previously, 
MSI tumours tend to be located in the right colon and are often poorly differentiated with 
higher numbers of inflammatory cells present in the tumour microenvironment (Greenson, 
Bonner et al. 2003). In general, MSI tumours have a favourable prognosis, respond well to 5-
FU chemotherapy (Ribic, Sargent et al. 2003) and have a lower metastatic potential than 
sporadic MSS cancers.  In 2005, a meta-analysis of 32 studies by Popat and colleagues 
confirmed that patients with MSI tumours had a survival advantage over those with MSS 
tumours, particularly for those with node-negative disease (Popat, Hubner et al. 2005).  
Despite these findings, MSI testing has yet to be incorporated into routine clinical practice.  
1.5.1.6  Molecular markers 
A large number of molecular markers have been proposed as prognostic indicators in 
colorectal cancer. The majority of these molecules are confined to experimental studies and 
only a small number, such as carcinoembryonic antigen and K-ras, are ever used in clinical 
practice.  The following provides a summary of the prognostic value of the most common 
molecular markers used in colorectal cancer.    
Carcinoembryonic antigen 
Carcinoembryonic antigen (CEA) was first described in 1965 by Gold and Freedman as a 
molecule found only in foetal colon and colonic adenocarcinoma (Gold and Freedman 1965) 
although it has subsequently been discovered in very low concentrations in other tissues 
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(Boucher, Cournoyer et al. 1989). CEA is a glycoprotein with considerable heterogeneity 
whose primary function is thought to involve binding to bacteria within the gut, either as a 
means of facilitating bacterial colonization or to prevent infection (Duffy 2001). The 
discovery that CEA could be detected in the serum of patients with colorectal cancer but not 
in healthy controls prompted its promotion as a marker for colorectal cancer (Thomson, 
Krupey et al. 1969) and it is still one of the most widely used tumour markers in the world.  
CEA has been proposed for roles in both the diagnosis and prognosis of colorectal cancer but 
recently its clinical utility has been questioned. The low positive predictive value of CEA in 
unselected patient populations mean it is unsuitable for use as a screening tool (Fletcher 
1986) and an unacceptable sensitivity and specificity profile mean its use in the diagnosis of 
colorectal cancer is similarly limited (Begent 1984). In terms of the prognostic value of CEA 
in patients with known colorectal cancer, the evidence has been conflicting. A number of 
studies have shown that patients with high preoperative concentration of CEA have a worse 
outcome than those with low levels (Grem 1997). However, the value of the molecule over 
and above conventional pathological staging has yet to be proven and studies have failed to 
agree as to whether CEA is useful in stratifying patients with node-negative disease (Moertel, 
O'Fallon et al. 1986; Harrison, Guillem et al. 1997). Currently, CEA is most often measured 
postoperatively as a means of detecting disease recurrence or monitoring response to 
treatment (Graham, Wang et al. 1998). In conclusion, the available evidence suggests that 
CEA has no role in the diagnosis or preoperative prognostic stratification of patients with 
colorectal cancer. It may have a role in the surveillance of patients postoperatively but no 
large randomised trial has yet addressed the effect of CEA testing on quality of life, cost of 
care or overall survival (Duffy 2001). 
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Carbohydrate antigen 19-9 
Carbohydrate (CA) 19-9, an adhesion molecule detectable in serum, is raised in a variety of 
gastrointestinal malignancies including pancreatic and colorectal cancer (Koprowski, Herlyn 
et al. 1981). A small number of studies have suggested that pre-operative levels of Ca19-9 
provide stage independent prognostic information in patients with colorectal cancer (Filella, 
Molina et al. 1992; Reiter, Stieber et al. 2000). However, conflicting evidence suggests that 
serum level do not accurately predict disease recurrence (Morita, Nomura et al. 2004) and the 
routine use of Ca 19-9 is not currently recommended for the diagnosis or prognostic 
stratification of colorectal cancer (Locker, Hamilton et al. 2006).  
Proliferation indices 
Cellular proliferation can be measured using a number of techniques from complex reverse 
transcriptase polymerase chain reaction (PCR) assays to simple immunohistochemical 
staining for Ki-67. Data relating to the prognostic value of Ki-67 in colorectal cancer has 
been inconsistent and often underpowered (Chen, Henk et al. 1997; Garrity, Burgart et al. 
2004; Zlobec, Baker et al. 2008). For example, Allegra and colleagues initially examined Ki-
67 in 703 patients with colorectal cancer and observed a positive prognostic effect using an 
arbitrary cutoff of 40% (Allegra, Paik et al. 2003). However, the same team could not 
replicate these results on a different cohort derived from five different clinical trials (Allegra, 
Parr et al. 2002).  Cellular proliferation as measured by Ki-67 cannot yet be considered a 
useful prognostic marker in colorectal cancer. Standardisation of methodology and 
identification of optimum thresholds may increase the clinical utility of proliferation indices.   
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Angiogenesis 
New blood vessels are essential to the growth of any solid organ tumour (Folkman, Cole et al. 
1966). In colorectal cancer the process of angiogenesis is thought to increase the metastatic 
potential of tumours and as such its occurrence was proposed to have potential prognostic 
utility.  Indeed, an early study by Frank et al reported that increased microvessel density 
(MVD), a surrogate marker of neovascularisation, was associated with decreased survival in 
patients with Dukes B colon cancer (Frank, Saclarides et al. 1995). Subsequent studies have 
examined angiogenesis by measuring growth factors associated with the process, such as 
vascular endothelial growth factor (VEGF) (Bhatavdekar, Patel et al. 2001). A subsequent 
meta-analysis (45 studies examining MVD; 27 studies examining VEGF) concluded that 
angiogenesis was associated with reduced recurrence free survival in patients with colorectal 
cancer (Des Guetz, Uzzan et al. 2006). However, the authors commented that the 
methodology varied considerably between studies. In conclusion, there is evidence that 
angiogenesis is a poor prognostic indicator in colorectal tumours but its assessment requires 
standardisation if it is to be useful in clinical practice.  
1.5.1.7  Oncogenes and tumour suppressor genes 
Mutations in p53, a tumour suppressor gene located on chromosome 17p, are common in 
colorectal tumours with a prevalence estimated at 40 – 50% (Scott, Sagar et al. 1991). The 
prognostic value of detecting such p53 mutations has yet to be determined and much of the 
evidence to date is conflicting. Several studies have suggested that tumours with p53 
mutations carry a poorer prognosis (Yamaguchi, Kurosaka et al. 1992; Hamelin, Laurent-
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Puig et al. 1994; Houbiers, van der Burg et al. 1995). However, other authors report no 
correlation between p53 expression and survival (Scott, Sagar et al. 1991; Bell, Scott et al. 
1993; Kressner, Lindmark et al. 1996).  A recent review of the literature identified 35 studies 
which reported p53 mutations to be associated with poor outcome and 24 studies in which no 
correlation with survival was observed (Mutch 2007). These aberrant results may be due to 
variability of the detection and retrieval systems used to quantify p53 (Wynford-Thomas 
1992). 
K-ras is one of the most commonly mutated oncogenes in colorectal cancer and is associated 
with cellular proliferation and early tumourogenesis (Forrester, Almoguera et al. 1987). To 
date, no consistent results have been observed regarding the prognostic significance of K-ras 
mutations. Some studies have proposed that K-ras mutations are associated with reduced 
overall survival in patients with colorectal cancer (Bazan, Migliavacca et al. 2002; Conlin, 
Smith et al. 2005) while others have found no such correlation (Pricolo, Finkelstein et al. 
1996; Andersen, Lovig et al. 1997).  
In conclusion, the prognostic value of genetic mutations in colorectal cancer has yet to be 
confirmed. Much of the evidence is conflicting and results are blighted by study 
heterogeneity and methodological variability.  Unless a consensus regarding techniques and 
thresholds can be reached genetic profiling cannot be considered a useful prognostic for 
colorectal cancer.  
1.5.1.8  Tumour necrosis 
Tumour necrosis is a common histological feature of many solid organ tumour types and has 
been proposed as a marker of poor prognosis in renal (Frank, Blute et al. 2002), breast 
(Fisher, Palekar et al. 1978) and lung cancer (Swinson, Jones et al. 2002).  The presence of 
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necrosis has associated with unfavourable host characteristics including increasing age, 
elevated white cell count and anaemia (Edwards, Swinson et al. 2003; Sengupta, Lohse et al. 
2005) and one hypothesis is that necrosis may impact survival by influencing the host 
inflammatory response. Summary data describing the prognostic value of tumour necrosis in 
solid organ tumours is given in Table 1.6.  
Five studies, comprising data on a total of 1,051 patients, have reported the prognostic value 
of tumour necrosis in colorectal malignancy (Table 1.7).  All studies used a similar semi-
quantitative assessment of necrosis with the most common method a four group extent-based 
classification. The largest study to date was conducted by Pollheimer and colleagues who 
reported necrosis to be an independent predictor of cancer specific survival in a cohort of 381 
patients with TNM Stage I – IV disease (Pollheimer, Kornprat et al. 2010).  These results 
supported an earlier study by Gao and coworkers who reported necrosis to reduce overall 
survival, independent of pathological stage, in 300 patients with colorectal cancer (Gao, 
Arbman et al. 2005). Two of the studies related specifically to node negative disease.  An 
early study by Svennevig et al (Svennevig, Lunde et al. 1984) reported no relationship 
between necrosis and survival in 100 patients with Dukes B cancer while a subsequent study 
reported tumour necrosis and perineural invasion as the only independent predictors of 
survival in 117 patients with Dukes B disease (Mulcahy, Toner et al. 1997). The relationship 
between tumour necrosis and disease recurrence was examined by Knutsen and colleagues in 
a study of 153 patients with rectal cancer. The authors reported a higher rate of recurrence in 
patients with extensive necrosis but also observed an association with preoperative 
radiotherapy which may partly explain why necrosis did not have independent prognostic 
value (Knutsen, Adell et al. 2006).     
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In terms of pathological associations, the majority of studies reported a relationship between 
tumour necrosis and aggressive characteristics including large size, high grade, poor 
differentiation and venous invasion (Mulcahy, Toner et al. 1997; Gao, Arbman et al. 2005; 
Pollheimer, Kornprat et al. 2010). 
With regard to relationships with the host inflammatory response, reports have been 
conflicting.  One study linked tumour necrosis with the local inflammatory response as 
assessed by cyclooxygenase-2 (COX-2) expression (Knutsen, Adell et al. 2006) while 
another study reported that tumours with a strong inflammatory cell infiltrate had less 
necrosis (Gao, Arbman et al. 2005). Meanwhile, other studies have reported no relationships 
between necrosis and either a general inflammatory reaction or lymphocytic infiltration 
(Svennevig, Lunde et al. 1984; Pollheimer, Kornprat et al. 2010).   
In conclusion, there is evidence that tumour necrosis is associated with outcome in a range of 
solid organ tumour types. A limited number of studies suggest an association between tumour 
necrosis and poor prognosis in patients with colorectal cancer. More research is needed to 
establish whether necrosis exerts a prognostic effect independently of other high risk 
pathological features.  To date, evidence regarding the interaction between tumour necrosis 
and the host inflammatory response has been contradictory.  
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Table 1.6. Summary characteristics of studies reporting the prognostic value of tumour necrosis in solid organ tumour types. 
 
Tumour type No. of studies Total no. of patients Relationship with outcome  Associations 
Renal 23 15,852 Predicted poor prognosis (n=19) 
No relationship with outcome (n=4) 
Increasing tumour grade/stage 
Poor performance status, High WCC/ESR 
Ki-67 expression 
Breast 13 9,277 Predicted poor prognosis (n=9) 
No relationship with outcome (n=4) 
Increasing tumour size/grade 
Increasing age 
High microvessel density, High macrophage 
count, Angiogenesis 
Lung 7 1218 Predicted poor prognosis (n=6) 
No relationship with outcome (n=1) 
Increasing tumour stage 
High platelet count, Anaemia 
P53 expression, High VEGF expression 
Sarcoma 4 1208 Predicted poor prognosis (n=4) Not related to tumour size/grade 
Thyroid 2 241 Predicted poor prognosis (n=2) Not reported 
Pancreas 1 348 Predicted poor prognosis (n=1) Increasing tumour size/grade 
Venous invasion 
Hypoxic foci 
Hepatocellular 1 33 No relationship with outcome (n=1) Not reported 
WCC: white cell count 
ESR: erthythrocyte sedimentation rate 
VEGF: vascular endothelial growth factor 
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Table 1.7. Studies reporting the prognostic value of tumour necrosis in colorectal cancer. 
 
Year Author 
Sample 
Size 
Population Studied Necrosis Method 
Relationship with 
Outcome 
Associations 
1984 Svennevig  100 Dukes B colorectal 
cancer 
Semi-quantitative 
(weak/moderate/extensive) 
Not significant Not related to 
inflammatory cell 
infiltrate 
1997 Mulcahy  117 Dukes B colorectal 
cancer 
Semi-quantitative 
(minimum/extensive) 
Reduced overall survival 
(multivariate analysis) 
Increasing tumour size 
2005 Gao  300 Dukes A – D 
colorectal cancer 
Semi-quantitative 
(absent/<10%/10-
30%/>30%) 
Reduced overall survival 
(multivariate analysis) 
Increasing tumour 
stage, 
Poor differentiation 
2006 Knutsen  153 Dukes A – D rectal 
cancer 
Semi-quantitative 
(<5%/>5%) 
Higher rate of recurrence  
(univariate analysis) 
Preoperative 
radiotherapy, 
Higher COX-2 
expression 
2010 Pollheimer  381 TNM Stage I – IV 
colorectal cancer 
Semi-quantitative 
(absent/<10%/10-
30%/>30%) 
Reduced cancer specific 
survival (multivariate 
analysis) 
Increasing tumour 
size/grade/stage, 
Venous invasion, 
Not related to 
lymphocytic infiltrate 
 
TNM: AJCC Tumour, Node, Metastases staging system 
COX: Cyclooxygenase 
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1.5.1.9  Summary – Tumour factors and colorectal cancer prognosis 
The prognosis of colorectal cancer is based primarily on pathological stage as described by 
the Dukes or TNM staging systems.  A number of additional pathological characteristics, 
including tumour grade, venous invasion, peritoneal involvement, tumour perforation and 
margin involvement, have the capacity to stratify patients with node negative disease and 
may be useful in the allocation of adjuvant treatment.  Despite the obvious benefits of 
identifying these high risk characteristics, their assessment is variable and depends almost 
exclusively on accurate pathological processing and reporting.  
A host of other molecular and genetic markers have been proposed to have predictive value 
in colorectal cancer but so far none have been incorporated into routine clinical practice. The 
reasons for this include a failure to provide prognostic information independent of stage, a 
lack of standardized methodology, disagreement regarding optimum cutoffs and conflicting 
results between centres. This is exemplified by that fact that none of the markers described 
above is recommended for routine use by the American Society of Clinical Oncologists 
(ASCO), the American Joint Committee on Cancer (AJCC) or the Royal College of 
Pathologists (RCPath) in the United Kingdom. 
 
 
74 
 
1.5.2  HOST FACTORS AND COLORECTAL CANCER PROGNOSIS 
It is now recognised that disease progression in colorectal cancer is influenced by complex 
interactions between both tumour- and host-related factors. The tumour characteristics 
described above, while providing a degree of prognostic information, cannot fully explain the 
survival differences observed in patients with cancers of the same pathological stage. It is 
increasingly apparent that host factors, defined as patient characteristics that promote or 
inhibit tumour growth, are equally important determinants of outcome. These patient factors 
include inherent characteristics such as chronological age as well as potentially modifiable 
traits such as physiological function and the host inflammatory response. The latter has 
received particular attention in relation to cancer outcomes and may represent the intrinsic 
ability of a person to generate an anti-tumour response.  
1.5.2.1  Inflammation and cancer 
Links between inflammation and cancer were described as far back as the 19
th
 century and 
epidemiological evidence now confirms that inflammatory diseases increase the risk of 
developing many different types of cancer (Balkwill and Mantovani 2001). It is also well 
recognised that anti-inflammatory drugs reduce the risk of developing certain cancers (Thun, 
Namboodiri et al. 1993; Baron, Cole et al. 2003) and targeting inflammatory mediators 
decreases the incidence and spread of a number of different malignant tumours (Burton and 
Libutti 2009). These links between inflammation and cancer are further strengthened by the 
fact that immune cells and inflammatory mediators are often observed in tumour tissue and 
the cellular processes usually associated with chronic inflammation are also active in the 
tumour microenvironment (Mantovani, Allavena et al. 2008).  Inflammation is now 
recognised as a key component of the biological capabilities that are acquired during the 
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development of human tumours (Colotta, Allavena et al. 2009).  These capabilities, described 
as the „hallmarks‟ of cancer, enable tumour cells to survive, proliferate and disseminate. The 
relationships between inflammation and the Hallmarks of Cancer are represented in Figure 
1.3.  
1.5.2.2  The host immune response  
The human immune system comprises a number of interdependent organs, cells and 
processes that collectively protect the body from foreign pathogens.  Broadly categorised into 
innate (non-specific) and adaptive (acquired) immunity, the system functions to recognise 
and destroy antigens associated with bacterial, viral or fungal infections. The immune system 
can also recognise cancer-specific antigens, allowing the identification and destruction of 
tumour cells in a process known as immunosurveillance (see below). Paradoxically, some 
cellular processes associated with inflammation can promote tumour progression (Vakkila 
and Lotze 2004) and it is therefore the balance of pro- and anti-tumour factors that many 
believe to be of primary importance in determining cancer outcomes (Zlobec and Lugli 
2009). 
Innate immunity 
The innate immune system, comprising phagocytic cells (neutrophils and macrophages), 
degranulating cells (basophils, eosinophils and mast cells) and natural killer (NK) cells as 
well as humoral (complement) components, provides a crucial first line of defence against 
common microorganisms. Bacteria that successfully penetrate the epithelial surfaces of the 
body are met by macrophages, bound by cell surface receptors and engulfed in a process 
known as phagocytosis.  This is followed by the release of biologically active molecules, 
known as chemokines and cytokines, which generate an inflammatory response.  Although 
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most infectious agents and/or tissue damage initially induce this non-specific response, the 
innate system may subsequently activate an adaptive immune response (Janeway and 
Medzhitov 2002; Medzhitov 2007).   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4. The relationships between inflammation and the Hallmarks of Cancer. Adapted 
from Hanahan et al.  
 
Angiogenesis 
Resisting cell death 
Invasion and metastases 
Evading suppression 
Proliferative signalling 
Replicative immortality 
Tumour 
cell 
Tumour-promoting 
inflammation 
Genomic instability and 
mutation 
Enabling characteristics 
77 
 
Adaptive immunity 
The adaptive immune system is composed primarily of lymphocytes and serves to aid in the 
recognition of „non-self‟, eliminate specific pathogens and produce an immunological 
memory of previously encountered antigens. Activation of adaptive immunity is usually 
triggered by the presentation of antigens by specialised cells associated with the innate 
immune system known as antigen-presentation cells (APC). Adaptive immunity can be 
divided into humoral and cell-mediated immunity although many of the processes and cell 
types are inter-dependent. B cells are the major cell types in humoral immunity and produce 
antibodies, known as immunoglobulins, which recognise and bind to specific antigens, 
making them easy targets for phagocytes and triggering the complement cascade (Janeway 
2001). T lymphocytes, identified by the presence of specific T-cell receptors (TCR), are 
responsible for coordinating cell-mediated immunity and can be categorised into a number of 
subsets; helper T cells (CD4
+
), cytotoxic T cells (CD8
+
), memory T cells (CD45R0
+
) and 
regulatory T cells (FOXP3
+
).  Each subset plays a specific role in the identification and 
destruction of antigens. CD8+ T cells are the effector cells of adaptive immunity, inducing 
cell death through the release of cytotoxins such as peforin, granzyme B and granulysin 
(Janeway 2001). 
1.5.2.3  Cancer immunoediting 
As described above, cancer immunosurveillance is the process whereby tumour-specific 
antigens provoke an effective immunological reaction in the host thereby preventing the 
development of otherwise inevitable malignancy (Burnet 1957). The concept is not new but 
advances in genetic understanding have now validated the hypothesis and expanded it to 
include contributions from both the innate and adaptive immune systems (Dunn, Old et al. 
2004). However, there is growing recognition that the relationship between cancer and the 
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immune response is yet more complex still and may involve the promotion as well as 
prevention of tumourogenesis (Shankaran, Ikeda et al. 2001; Schreiber and Podack 2009). A 
broader concept has therefore been developed, termed „cancer immunoediting‟, which 
describes a dynamic process composed of three phases: elimination, equilibrium and escape.  
Elimination represents the original idea of cancer immunosurveillance, equilibrium is the 
period of latency after incomplete tumour destruction and escape refers to the final growth 
and dissemination of cancer cells (Dunn, Old et al. 2004).  The immune response in cancer is 
thus now recognised as a complex relationship between pro- and anti-tumour factors with the 
potential to impact outcome in either a positive or negative manner. The host response can be 
broadly categorised into the systemic inflammatory response (describing a prolonged and 
inappropriate activation of the acute phase response) and the local inflammatory response 
(describing the infiltration of immune cells in the tumour microenvironment). These 
responses and their relationships with the prognosis of patients with colorectal cancer are 
described below.  
1.5.2.4  The tumour microenvironment 
The tumour microenvironment can be defined as the tissue medium in which tumour cells 
grow and develop. It is a complex and unique environment comprised of the invasive margin, 
proliferating tumour cells, tumour stroma, blood vessels, tissue cells and inflammatory cells 
(Figure 1.4). The tumour microenvironment represents a dynamic interface between tumour 
and host and it is postulated that the molecular events which occur here dictate whether a 
tumour progresses or is successfully eliminated by the host (Whiteside 2008). As described 
above, the host does not allow tumour development to progress unchecked but instead 
attempts to mount an effective immune response. This local inflammatory response can be 
considered an attempt to destroy tumour cells but it is often attenuated. The methods through 
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which tumour cells evade host immunity are referred to as „escape mechanisms‟ and are 
thought to include direct interference with immune cell signalling capabilities, an 
accumulation of T regulatory cells which can suppress T cell function and downregulation of 
HLA expression on tumour cells resulting in inadequate recognition by the hosts immune 
cells (Ferrone and Whiteside 2007). 
 
The changes that occur in the tumour microenvironment over time are similar to those seen in 
chronic inflammation and, once established, become dominated by pro-tumour processes. 
One of the earliest events is tissue hypoxia resulting in relative cellular ischaemia (Denko, 
Fontana et al. 2003). This favours the influx of macrophages which become activated and 
propagate hypoxia through the generation of reactive oxygen species (ROS). Mediated 
through NF-kB, a protein complex that controls the transcription of DNA, a number of 
signalling events then take place in both cancer cells and surrounding inflammatory cells 
(Karin and Greten 2005; Lluis, Buricchi et al. 2007). Pro-inflammatory cytokines, including 
TNF-α, are produced which alter the microenvironment to benefit the tumour.  This cascade 
of cytokines influences a variety of key events including angiogenesis, cellular proliferation 
and matrix re-modelling, ultimately resulting in tumour growth and progression (Balkwill and 
Coussens 2004). It is evident that infiltrating immune cells are one of the most important 
components of the tumour microenvironment. Indeed, the nature, function, density and 
localization of immune cells within the tumour microenvironment have all been reported to 
influence tumour progression and clinical outcome in human colorectal cancer (Galon, Costes 
et al. 2006). The function and prognostic value of individual immune cell types are 
considered below.  
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Figure 1.5. How components of the tumour microenvironment influence tumour growth and 
metastases. Adapted from Leyva-Illades et al.  
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1.5.2.5  The local inflammatory response 
A strong inflammatory response at a local level has been consistently associated with 
improved clinical outcomes in patients with colorectal cancer. As far back as the 1970‟s it 
was observed that tumours with a high concentration of inflammatory cells often carried a 
favourable prognosis (House and Watt 1979) and a strong local response was hypothesised to 
represent effective anti-tumour immunity. This idea has now been supported by a wealth of 
studies which have examined the prognostic implications of inflammatory cell infiltration in 
the tumour microenvironment (Table 1.8). While it is generally accepted that a local 
inflammatory response is beneficial to patients with colorectal cancer the relative importance 
of type, density and location of individual immune cells has yet to be established. Similarly, 
the factors responsible for inhibiting or promoting an in-situ immune response are unclear 
and there is no agreement as to how the local inflammatory response should be defined.  
Measuring the local inflammatory response 
Over the past 40 years, a large number of studies, often using different methodologies, have 
examined the prognostic implications of the local inflammatory response in colorectal cancer. 
These studies have explored inflammatory cells in different areas of the tumour 
microenvironment, including the invasive margin (peritumoural), tumour stroma and cancer 
cell nests. The latter components may be combined into an area termed „intratumoural‟ 
(Figure 1.5). Different methods for defining the local inflammatory response along with their 
prognostic value in colorectal cancer are summarised below. 
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Table 1.8. Summary of studies reporting the associations of the local inflammatory response 
with survival in patients with colorectal cancer. Adapted from Roxburgh et al . 
 
 
Measure of the local inflammatory response 
Total number of 
studies 
% of studies reporting an 
association with survival 
Generalised inflammatory cell infiltrate 39 92% 
T lymphocytes   
   CD3+ expression 12 83% 
   CD4+ expression 5 20% 
   CD8+ expression 25 80% 
   CD45R0+ expression 8 100% 
   FOXP3+ expression 7 43% 
B lymphocytes 1 0% 
Natural Killer (NK) cells 4 75% 
Tumour associated macrophages (TAM’s) 13 69% 
Neutrophils 4 75% 
Mast cells 7 86% 
Dendritic cells 6 67% 
Eosinophils 6 83% 
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Generalised inflammatory cell infiltrate 
In the 1980‟s, Jass and colleagues suggested that local infiltration of immune cells had 
independent prognostic value in patients with rectal cancer. Using a semi-quantitative 
assessment of lymphocytic infiltrate, they reported five year survival rates of 92% for those 
with a pronounced lymphocyte response compared to 36% for those with a weak response 
(Jass 1986; Jass, Love et al. 1987). This was followed in the 1990‟s with a series of studies 
describing the association of lymphoid aggregates around the tumour, termed the Crohn‟s-
Like reaction (CLR), with improved outcomes in patients with colorectal cancer (Graham and 
Appelman 1990; Harrison, Dean et al. 1995; Adams and Morris 1997). Since this time, 
further methods for the assessment of a generalised inflammatory cell reaction have been 
undertaken by several groups including Nagtegaal and co-workers (Nagtegaal, Marijnen et al. 
2001) and Ogino and co-workers (Ogino, Nosho et al. 2009) who both reported associations 
with survival.  A particularly simple technique for assessing local inflammation has recently 
been proposed by Klintrup and Makinen. Using a semi-quantitative assessment of 
peritumoural inflammatory infiltrate on haematoxylin and eosin (H&E) stained sections, the 
authors reported high-grade inflammation at the invasive margin to be an important 
prognostic indicator in patients with node negative colorectal cancer (Klintrup, Makinen et al. 
2005). These findings were subsequently validated in an external cohort of patients with 
node-negative disease (Roxburgh, Salmond et al. 2009). Overall, there is consistent evidence 
that a generalised increase in inflammatory cell infiltrate is associated with improved 
prognosis in patients with colorectal cancer.  
Tumour infiltrating lymphocytes 
Cells associated with the adaptive immune system have been extensively studied in colorectal 
cancer. The majority of studies have reported that high numbers of tumour infiltrating 
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lymphocytes (TILs) are associated with a favourable prognosis but there is debate about 
which T cell subtypes are most important. The prognostic value of sub-populations of T 
lymphocytes in colorectal cancer is discussed below.  
 
 
 
 
Figure 1.6. Schematic representation of different components within the tumour 
microenvironment.  
 
 
 
 
 
 
 
85 
 
CD3+ cells 
TILs are predominantly T cells characterized by the presence of the cluster of differentiation 
3 (CD3) surface protein. CD3+ antibody is thus used as a marker of global T cell infiltration 
and has been studied by a number of groups in relation to colorectal cancer outcome. 
Nagtegaal and colleagues were one of the first to report that CD3+ infiltration was associated 
with early tumour stage in patients with rectal cancer. Of particular interest was their finding 
that tumours with low levels of TILs were more likely to have evidence of distant metastases 
(Nagtegaal, Marijnen et al. 2001). After similar results were reported by other authors 
(Guidoboni, Gafa et al. 2001; Baeten, Castermans et al. 2006), attention was focused on 
which areas of the tumour were most important. Galon and co-workers reported that CD3+ 
infiltration at both the invasive margin and central tumour was associated with reduced 
recurrence and longer survival in 415 patients with colorectal cancer (Galon, Costes et al. 
2006). Furthermore, the authors suggested that an „immune score‟ based on the relative 
densities of CD3+ and CD45RO+ (memory T cells) was a more accurate predictor of survival 
than tumour stage. One potential confounding factor in the assessment of TIL‟s as prognostic 
markers is their association with microsatellite status.  It is recognised that lymphocyte 
infiltration is marked in tumours with high frequency microsatellite instability (MSI-H) and 
this may explain the better clinical outcomes seen in these patients (Kumar, Chang et al. 
2009). However, a number of studies have now reported that while lymphocyte infiltration is 
higher in MSI-H tumours, the survival relationships of CD3+ are independent of 
microsatellite status (Guidoboni, Gafa et al. 2001; Laghi, Bianchi et al. 2009; Sinicrope, Rego 
et al. 2009).  
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CD8+ cells 
The effector cells of the cell mediated immune response, CD8+ cells are often referred to as 
cytotoxic T lymphocytes (CTLs). Antigens are presented to CD8+ cells in a complex with 
human leukocyte antigen (HLA) class 1 proteins. Upon encounter with this antigen/HLA 
complex, CD8+ cells expand and differentiate into CTLs with the capacity to directly destroy 
tumour cells. This destructive capacity is mediated by the release of perforins which disrupt 
the cell membrane allowing enzymatic proteases (such as granzyme B) to enter and induce 
apoptosis of the target cell (Loose and Van de Wiele 2009). The prognostic value of CD8+ 
cells in colorectal cancer has been studied over a number of years. One of the first to report 
the value of this T cell subtype was Naito et al who demonstrated that a dense CD8+ 
infiltration was associated with improved survival in 139 patients with colorectal cancer 
(Naito, Saito et al. 1998). Looking specifically at the location of lymphocytes in the tumour 
microenvironment, the group concluded that cytoxic T cells in the cancer cell nests were 
most closely associated with outcome. Galon and co-workers subsequently investigated the 
capacity of the adaptive immune response to control tumour behaviour. They demonstrated 
that an increased intratumoural expression of CD8+ was significantly associated with the 
absence of early metastatic events and with a decreased rate of disease recurrence in 415 
patients with colorectal cancer (Galon, Costes et al. 2006). These findings have been 
corroborated by a host of other studies and it is now evident that CD8 infiltration in both the 
invasive margin and central tumour is a marker of good prognosis in colorectal cancer 
(Guidoboni, Gafa et al. 2001; Nagtegaal, Marijnen et al. 2001; Menon, Janssen-van Rhijn et 
al. 2004; Baker, Zlobec et al. 2007). Akin to CD3+ infiltration, there has been debate as to 
whether CD8+ cells are simply a surrogate marker for MSI status. However, there is reliable 
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evidence that the beneficial effect of CD8+ infiltration is observed in both MSS and MSI 
colorectal tumours with (Prall, Duhrkop et al. 2004).  
Memory T cells 
Memory T cells are a subset of T lymphocytes that have previously encountered and 
responded to an antigen. At a second encounter with the same antigen, these cells can 
reproduce quickly to mount a faster and stronger immune cell reaction. Memory CD8+ cells 
are sensitive to such re-stimulation and can become cytotoxic again in a short space of time. 
Similarly, memory CD4+ cells have comparable characteristics to CD4+ cells but require 
additional re-stimulation before acting on target cells. The expression of cell surface 
molecules changes with the loss of L seletin and an alteration of the CD45 isoform from 
CD45RA+ to CD45RO+. These cells can then be described as „activated‟ memory T cells 
and have the capacity to become armed effector cells on re-exposure to antigen. There is now 
some evidence that high densities of CD45RO+ cells are beneficial to the host anti-tumour 
immune response. Indeed, a study conducted by Pages and colleagues reported that high 
numbers of activated memory T cells in colorectal tumours were associated with fewer 
indicators of metastatic potential, including less venous and lymphatic invasion (Pages, 
Berger et al. 2005). Galon and co-workers followed this up with a detailed investigation of 
the prognostic values of different immune cells in a cohort of over 400 patients with 
colorectal cancer, concluding that CD45RO+ and CD3+ cells at the invasive margin and 
central tumour were strong and stage-independent indicators of good prognosis (Galon, 
Costes et al. 2006). 
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T regulatory cells 
T regulatory cells (Tregs) are a heterogenous group of T lymphocytes which play a unique 
role in the modulation and control of cell mediated immunity. Originally identified as a 
subset of CD4+ CD25+ cells, they were thought to act primarily as immunosuppressants. In 
experimental models, Tregs were shown to reduce the activity of cytotoxic T cells (Chen, 
Pittet et al. 2005) and their presence was associated with adverse outcomes in breast and 
ovarian cancer (Curiel, Coukos et al. 2004; Bates, Fox et al. 2006). These findings appeared 
to support a hypothesis whereby Tregs acted to dampen down any effective host immune 
response but their role in cancer immunotherapy has recently been re-examined (Zou 2006; 
Curiel 2007). The transcription forkhead box P3 (FOXP3+) has been identified as a more 
sensitive marker of Tregs (Sinicrope, Rego et al. 2009) and there is now some evidence that 
their presence in colorectal tumours may be beneficial. Despite a small-scale study reporting 
that FOXP3+ expression was not related to survival (Loddenkemper, Schernus et al. 2006), 
Salama et al recently reported that a high density of intratumoural FOXP3+ cells was 
associated with improved survival in 967 patients with colorectal cancer (Salama, Phillips et 
al. 2009). These seemingly contradictory reports regarding the prognostic value of Tregs in 
different cancer types may be explained by a number of parameters. First, the precise role of 
Tregs may differ according to tumour stage. Second, because it is supposed that the 
deleterious effect of Tregs is mediated by their inhibition of effector T cells, it may be that 
studies which have reported Treg numbers without knowledge of CD8+ density have drawn 
inaccurate conclusions. Finally, it is recognised that tumour cells and T cells, with or without 
suppressive functions, may transiently express FOXP3+ (Badoual, Hans et al. 2009). In 
summary, Tregs may play a role in determining outcome in colorectal cancer but their 
prognostic value is not well established.  
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B Lymphocytes 
In contrast to the wealth of studies which have examined T cells, few have investigated the 
prognostic effect of B lymphocytes in human colorectal cancer. A small study by Baeten and 
co-workers reported that patients with high intratumoural CD20
+
 counts showed a trend 
towards improved survival although this did not reach statistical significance (Baeten, 
Castermans et al. 2006). One reason for this may be that although the CD20 protein is found 
on the majority of B cells it is not expressed on plasma cells, the effector cell responsible for 
antibody production.   
Natural Killer cells 
Natural Killer (NK) cells are part of the innate immune system and, unlike T lymphocytes, 
have the capacity to eliminate tumour cells that do not express the HLA complex. NK cells 
can interact with macrophages to incite phagocytosis but also have direct cytotoxic 
capabilities, particularly in the cytokine-rich tumour environment (Loose and Van de Wiele 
2009).  Several studies have reported that a strong infiltration of intratumoural NK cells is 
associated with improved survival and reduced recurrence in patients with colorectal cancer 
(Nagtegaal, Marijnen et al. 2001; Menon, Janssen-van Rhijn et al. 2004; Atreya and Neurath 
2008).   
Macrophages 
Macrophages are a prevalent inflammatory cell and play an indispensible role in both innate 
and cell mediated immunity. Macrophages can be activated by a variety of stimuli to 
differentiate into two functionally different phenotypes. Classically activated macrophages 
(M1) express a series of pro-inflammatory mediators such as IL-2, IL-23 and TNF-α. In 
contrast, alternatively activated macrophages (M2) express a wide array of anti-inflammatory 
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molecules (Mantovani, Sozzani et al. 2002). The prognostic role of tumour-associated 
macrophages (TAMs) in colorectal cancer has thus far been controversial, perhaps reflecting 
the different roles of these distinct phenotypes. While TAMs have been associated with 
proliferation, angiogenesis and tumour growth in a variety of cancers (Siveen and Kuttan 
2009; Solinas, Germano et al. 2009), several studies have reported that high numbers of 
TAMs are associated with improved prognosis in colorectal cancer (Oberg, Samii et al. 2002; 
Forssell, Oberg et al. 2007). One hypothesis is that M1 TAMs are predominant in colorectal 
tissue, promoting an anti-tumour immune response (Dumont, Berton et al. 2008)[Dumont 
2008]. However, reports have not been consistent and several authors have reported no 
correlation between TAM infiltration and survival (Baeten, Castermans et al. 2006; 
Nagorsen, Voigt et al. 2007). The role of TAMs in tumour progression thus appears complex 
and variable depending on the phenotype involved.  
Neutrophils 
Neutrophils and polymorphonuclear cells (PMC) are intimately associated with the innate 
immune system and are some of the first inflammatory cells to respond to tissue damage. 
Their prognostic value in colorectal cancer has been poorly studied, although there is limited 
evidence that high numbers of neutrophils are associated with increased survival (Klintrup, 
Makinen et al. 2005; Baeten, Castermans et al. 2006) and reduced recurrence (Nagtegaal, 
Marijnen et al. 2001). These studies have observed that while neutrophils are present at the 
invasive margin, they appear to provide less rigorous prognostic information than other 
inflammatory cell types.  
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Mast cells 
Mast cells play a key role in the inflammatory response and, when activated, degranulate to 
release inflammatory mediators including histamine, prostaglandins and leukotrienes. In 
1999, a study of nearly 600 patients with colorectal cancer reported that high mast cell 
numbers were associated with improved survival, independent of tumour stage (Nielsen, 
Hansen et al. 1999). Subsequent studies have reported that mast cell infiltration in either the 
central tumour or invasive margin is a marker of good prognosis (Nagtegaal, Marijnen et al. 
2001; Acikalin, Oner et al. 2005; Tan, Fan et al. 2005).  
Eosinophils 
A small number of studies have examined the relationships between eosinophil infiltration 
and colorectal cancer survival. These studies have used quantitative and semi-quantitative 
techniques to examine eosinophils in both the tumour centre and the invasive margin. Despite 
study heterogeneity, there is consistent evidence that a strong infiltration of eosinophils is 
beneficial (Fisher, Paik et al. 1989; Nielsen, Hansen et al. 1999; Klintrup, Makinen et al. 
2005) with the largest study to date suggesting the survival relationships are independent of 
tumour stage (Nagtegaal, Marijnen et al. 2001).  
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1.5.2.6  The systemic inflammatory response  
Inflammation is the natural reaction to tissue injury caused by mechanical, chemical or 
microbial stimuli. The systemic inflammatory response is usually a rapid and non-specific 
response involving a number of key events: vasodilation, increased vascular permeability, 
cellular activation and coagulation. The complement, kinin and coagulation cascades are 
triggered, phagocytes activated and, in some cases, an adaptive immune cell response is 
mounted. The normal physiological response to inflammation is one of stress and consists of 
alterations in cardiovascular function (increased heart rate and blood pressure) and 
neuroendocrine control (release of catecholamines, cortisol, antidiuretic hormone, growth 
hormone, insulin and glucagon). Cytokines, the principle molecules responsible for the 
initiation and maintenance of inflammation, are released and include interleukins (IL-1 and 
IL-6), tumour necrosis factor (TNF) and interferons (Heinrich, Castell et al. 1990). The 
cellular effectors of the inflammatory response, polymorphonucleocytes (PMNs), 
macrophages and endothelial cells, then come into play and their activation results in the 
synthesis and secretion of secondary inflammatory mediators such as prostaglandins, 
leukotrienes, proteases and free radicals. Finally, activation of the coagulation cascade and 
local thrombosis develops as the injured tissues attempt to wall off damaged areas and 
prevent blood loss (Davies and Hagen 1997). 
Inflammation is thus a normal and usually beneficial physiological response to injury. 
Problems for the host can arise however if the normal tight controls of the inflammatory 
response are lost. Loss of these controls results in an exaggerated inflammatory response, 
clinically identified as systemic inflammatory response syndrome (SIRS) (Figure 1.6). SIRS 
is often seen as the result of an amplified response to infection (sepsis) but can be triggered 
by a host of alternative stimuli such as drugs, trauma or malignancy. With a failure of normal 
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homeostasis there is a flood of inflammatory mediators and the predominant effects of 
cytokines start to become destructive rather than protective. The uncontrolled vasodilation, 
fluid shifts, thrombosis and anaerobic metabolism ultimately result in end-organ damage 
(Bone, Grodzin et al. 1997).  
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Figure 1.7. Steps involved in the development of a systemic inflammatory response 
syndrome (SIRS). 
 
  
Stage 1 
 Cytokines are produced in response to an insult. 
 Inflammation ensues and tissue repair is promoted.  
 This acute phase response is well controlled. 
Stage 2 
 Further cytokines are released to enhance the local response. 
 Macrophages and platelets are recruited. 
 A controlled acute phase response is achieved.  
Stage 3 
 Homeostasis fails and a significant systemic reaction occurs (SIRS) 
 Excess systemic cytokines are chronically released. 
 Uncontrolled acute phase response ensues.  
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Systemic inflammation in the context of malignancy  
In recent years it has become clear that the response of the body to cancer is not a unique 
process but shares many parallels with inflammation and the physiological responses to tissue 
damage described above (Mantovani, Allavena et al. 2008). The presence of a systemic 
inflammatory response is a common finding in patients with cancer and malignant tumours 
have even been described as „wounds that do not heal‟ (Dvorak 1986). The reasons that 
cancers induce an inflammatory response are likely to be complex although it is recognised 
that some tumours directly produce and secrete growth factors and proinflammatory 
cytokines (Burke, Relf et al. 1996).  Tumour-associated leukocytes and platelets represent 
alternative inflammatory stimuli while other cytokines and chemokines are inducible by 
hypoxia, a major physiological difference between tumours and normal tissue (Koong, Denko 
et al. 2000).  
The inflammatory cytokines associated with malignancy may influence the growth, mutation, 
proliferation and survival of both tumour and surrounding stromal cells. These far reaching 
effects are mediated through a number of mechanisms including DNA damage, the 
inactivation of p53, autocrine growth factor functions, angiogenesis and metastatic invasion 
(Germano, Allavena et al. 2008). Indeed, chemokines may induce cellular proliferation, 
migration and adhesion (Tricot 2000) and direct evidence for their role in the secondary 
localisation of cancer has been obtained in mouse models (Wang, Chertov et al. 1998). 
 Regardless of the initial catalyst, the presence of a systemic inflammatory response in 
patients with cancer is almost universally considered an indicator of poor prognosis. There is 
evidence that systemic inflammation is associated with the cachexia and functional decline of 
patients with advanced disease (McMillan, Preston et al. 1994) and measures of the systemic 
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inflammatory response have been reported as prognostic markers in a variety of tumour types 
including lung (Forrest, McMillan et al. 2004), breast (Al Murri, Bartlett et al. 2006) and 
pancreatic cancer (Glen, Jamieson et al. 2006). The prognostic value of the systemic 
inflammatory response in colorectal cancer is discussed in below.  
Measuring the systemic inflammatory response 
The systemic inflammatory response can be measured using a variety of biochemical or 
haematological markers. One option for detecting the presence of inflammation is to measure 
the serum concentrations of acute phase proteins; a class of proteins synthesised in the liver 
whose concentrations change in the presence of inflammation. Positive acute phase proteins 
including C-reactive protein (CRP), complement and ferritin increase during an inflammatory 
response while negative acute phase proteins such as albumin and transferrin decrease 
(Gruys, Toussaint et al. 2005). CRP in particular is now recognised as a sensitive biomarker 
of inflammation and demonstrates marked and measurable changes in serum concentration 
(Hogarth, Gallimore et al. 1997).  Measuring the numbers of inflammatory cells present in 
the bloodstream represents an alternative technique for quantifying the presence of an 
inflammatory response in patients. Total white cell count (WCC), neutrophils, lymphocytes 
and platelets can all be detected using standard laboratory techniques. In an effort to 
standardise the measurement of the systemic inflammatory response in patients with cancer, a 
number of simple „inflammatory scores‟ have been described whose values have been shown 
to correlate directly with clinical outcomes. The modified Glasgow Prognostic Score (mGPS) 
combines circulating CRP and albumin concentrations (McMillan, Crozier et al. 2007) while 
the neutrophil lymphocyte ratio (NLR) measures the relative values of neutrophil and 
lymphocyte counts (Walsh, Cook et al. 2005). Alternative inflammatory scores include total 
while cell count (Shankar, Wang et al. 2006) and the platelet to lymphocyte ratio (PLR) 
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(Smith, Ghaneh et al. 2008).  The thresholds and allocated values used in these scoring 
systems are shown in Table 1.9. 
 
 
Table 1.9. Scoring systems used to describe and measure the systemic inflammatory 
response. 
 
Scoring system Score 
 
White cell count (WCC) 
 
WCC <8.5 (109/l) 0 
WCC 8.5 - 11.0 (109/l) 1 
WCC >11 (109/l) 2 
 
Neutrophil:Lymphocyte Ratio (NLR) 
NLR <5:1 0 
NLR ≥5:1 1 
 
Platelet:Lymphocyte Ratio (PLR) 
 
PLR < 150:1 0 
PLR 150-300:1 1 
PLR >300:1 2 
 
The modified Glasgow Prognostic Score (mGPS) 
 
C-reactive protein ≤10 mg/l and albumin ≥35 g/l 0 
C-reactive protein ≤10 mg/l and albumin <35 g/l 0 
C-reactive protein >10 mg/l 1 
C-reactive protein >10 mg/l and albumin <35 g/l 2 
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Prognostic value of the systemic inflammatory response in colorectal cancer 
It is now clear that inflammation plays a critical role in the pathogenesis, control and eventual 
metastasis of cancers.  Although particular aspects of the host immune response may protect 
against disease progression (see below), there is evidence that an ongoing systemic 
inflammatory response is consistently associated with poor outcomes in patients with cancer. 
These relationships were first described in the early 1980‟s when concentrations of acute 
phase proteins were observed to be elevated in patients with a variety of malignancies, 
especially in those with evidence of metastatic spread (Weinstein, Skinner et al. 1984). 
Following these initial observations, the prognostic value of the systemic inflammatory 
response has been reported in a wide variety of tumour types (McMillan, Elahi et al. 2001; 
Jamieson, Glen et al. 2005; Hara, Matsuzaki et al. 2007).  These relationships have been 
particularly well described in gastrointestinal tumours and there is now evidence that a 
systemic inflammatory response is associated with impaired response to chemotherapy, early 
disease recurrence and reduced long term survival in colon and rectal cancer (Goransson, 
Jonsson et al. 1996; Longo, Virgo et al. 2000; Canna, McMillan et al. 2004; Miki, Konishi et 
al. 2004; Ishizuka, Nagata et al. 2007; Sharma, Zucknick et al. 2008). Inflammation-based 
prognostic scores, in particular the mGPS, thus hold the promise of identifying patients at 
increased risk of disease progression as well as providing well-defined therapeutic targets for 
future clinical trials.   
  
99 
 
1.5.2.7  Summary – Host factors and colorectal cancer prognosis 
There is consistent evidence that host factors are important determinants of prognosis in 
patients with colorectal cancer. In particular, the host inflammatory response appears to play 
a critical role in the development, control and progression of colorectal cancer. Although the 
relationships between host and tumour are complex, encompassing an array of pro- and anti-
tumour responses, certain consistencies in observations are now emerging. It is apparent that 
a prolonged and inappropriate activation of the systemic inflammatory response is associated 
with poor outcomes in many solid organ tumour types, including colorectal cancer. Equally 
apparent are the observations that a strong and coordinated inflammatory response at a local 
level is beneficial to survival. The cell mediated immune response in particular appears to 
play a prominent role in protecting against tumour growth and dissemination in colorectal 
cancer. Overall, emergent evidence suggests that the host inflammatory response in colorectal 
cancer is an equally, if not more, important determinant of outcome than pathological tumour 
stage.  
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2.0  SUMMARY AND AIMS 
2.1  Summary 
Colorectal cancer is the second most common cause of cancer death in the Western world. 
Advances in molecular biology have increased our understanding of the genetic pathways 
involved in colorectal carcinogenesis but the factors which determine disease progression are 
still unclear. Pathological stage remains the mainstay of colorectal cancer prognosis and 
decisions regarding the provision of adjuvant chemotherapy are still based on the presence or 
absence of tumour characteristics first described over 80 years ago.  The need for improved 
prognostic stratification is evidenced by the disparate outcomes observed between tumours of 
the same AJCC/TNM stage and by the fact that, even in patients undergoing surgery with 
curative intent, only half will survive to five years.  
It is now recognised that tumour growth, recurrence and metastases in colorectal cancer are 
determined by complex interactions between tumour- and host-related characteristics. A 
broad concept, deemed „immunoediting‟, now exists to describe the process whereby the host 
immune system may act to either suppress or facilitate tumour progression. With this model 
in mind, there is consistent evidence that activation of the systemic inflammatory response is 
associated with poor prognosis in colorectal cancer while an effective local immune cell 
response confers a favourable outcome. Despite this knowledge, the factors responsible for 
regulating the systemic and local inflammatory responses in patients with colorectal cancer 
have yet to be determined.  
The underlying basis of the systemic inflammatory response in patients with colorectal cancer 
is unclear. Previous reports have linked systemic inflammation with increasing burden of 
comorbidity in patients with benign disease (Sin and Man 2003) but it is uncertain whether 
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these associations are dependent on particular aspects of host physiology.  In addition, there 
is evidence that inflammation and cancer cachexia are closely related (Argiles, Busquets et al. 
2005) and it may be that an activation of the systemic inflammatory response is indicative of, 
or indeed responsible for, the changes in body composition seen in cancer patients.  Finally, 
septic complications in the postoperative period, associated with early disease recurrence in 
colorectal cancer (McArdle, McMillan et al. 2005), are recognised to induce a profound 
inflammatory response (Moyes, Leitch et al. 2009). No study to date has investigated the 
inter-relationships between systemic inflammation, postoperative complications and disease 
recurrence in a single cohort of patients with colorectal cancer.   
Links between the systemic inflammatory response and the local infiltration of immune cells 
in patients with colorectal cancer are similarly unclear. Although previous work has 
suggested that there is no direct relationship, certain aspects of tumour pathology, such as T 
stage, have been associated with both systemic and local inflammation. Tumour necrosis, a 
pathological characteristic extensively studied in breast and renal cancer, has recently been 
linked to certain aspects of inflammation but has been poorly studied in colorectal cancer. No 
study to date has examined the relationships between tumour necrosis and measures of the 
systemic and local inflammatory responses in patients with colorectal cancer.  
It is now recognised that a strong infiltration of immune cells in and around colorectal 
tumours is a favourable prognostic sign. Previous work has demonstrated that a strong 
peritumoural inflammatory response is a stage-independent prognostic factor but the 
prevalence of individual immune cells and the relative importance of cellular subtypes within 
this reaction are unknown.  
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In patients with colorectal cancer the presence of high numbers of tumour infiltrating 
lymphocytes (TILs) is generally perceived as beneficial but here again there remains a 
number of outstanding questions. Akin to the systemic response, the factors responsible for 
initiating and/or maintaining a local inflammatory response are unknown. Many previous 
studies have investigated lymphocyte subtypes in isolation or have failed to describe their 
localization within the tumour microenvironment.  Fewer still have analysed the relationships 
between individual immune cells and patient-related characteristics. Finally, although a large 
number of studies have examined the prognostic impact of immune cells in colorectal 
tumours, there is considerable disparity in the methodologies and definitions used. No study 
has yet compared the prognostic utility of different methods of assessing the local 
inflammatory response in patients with colorectal cancer.  
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2.2  Aims 
To investigate the areas of uncertainty detailed above, in patients undergoing potentially 
curative resection of colorectal cancer, studies were carried out: 
1. To examine the relationships between patient physiology, the systemic inflammatory 
response and survival. 
2. To compare the performance of surgical scoring systems in high risk patient 
subgroups, including those with systemic inflammation. 
3. To examine the relationships between parameters of body composition and the 
systemic inflammatory response. 
4. To investigate the impact of preoperative risk factors, tumour pathology and 
postoperative complications on disease recurrence and survival in patients wtih 
colorectal cancer. 
5. To investigate the prognostic value of tumour necrosis in colorectal cancer and to 
examine its relationships with the systemic and local inflammatory responses.  
6. To examine the relationships between an overall measure of peritumoural 
inflammation, the prevalence of individual immune cells and survival in patients with 
colorectal cancer. 
7. To investigate the clinical utility of the local inflammatory response in primary 
operable colorectal cancer.  
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3.0 THE RELATIONSHIPS BETWEEN PATIENT PHYSIOLOGY, THE 
SYSTEMIC INFLAMMATORY RESPONSE AND SURVIVAL IN PATIENTS WITH 
PRIMARY OPERABLE COLORECTAL CANCER.  
3.1 Introduction 
Following potentially curative surgery for colorectal cancer, the prognostic stratification and 
provision of adjuvant therapy is usually guided by tumour pathology (Figueredo, Coombes et 
al. 2008). It is increasingly recognised, however, that pathological stage is not the sole 
determinant of outcome and host-related factors, in particular the systemic inflammatory 
response, also appear to be important.  There is now a considerable body of evidence that 
markers of systemic inflammation such as the modified Glasgow Prognostic Score can 
predict survival in patients with primary operable colorectal cancer (Roxburgh and McMillan 
2010).  This effect seems to be independent of TNM stage or other high-risk pathological 
features (Ishizuka, Nagata et al. 2007; Koike, Miki et al. 2008).  
The basis of the relationship between systemic inflammation and cancer survival is not clear. 
It has yet to be established which host characteristics, if any, an elevated inflammatory 
response may represent.  It is of interest that a systemic inflammatory response has been 
reported to predict cardiac events (Lloyd-Jones and Levy 2003) and is associated with 
patient-related factors such as obesity (Ridker, Buring et al. 2003), diabetes (Dehghan, 
Kardys et al. 2007) and smoking (Frohlich, Sund et al. 2003).  One hypothesis, therefore, is 
that systemic inflammation may reflect altered patient physiology.  Indeed, several studies 
have reported that abnormal physiology scores are associated with reduced long term survival 
in patients with colorectal cancer (Brosens, Oomen et al. 2006; Jenkins, O'Neill et al. 2007). 
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The aim of the present study was to examine the relationship between patient physiology, the 
systemic inflammatory response and survival in patients undergoing potentially curative 
resection of colorectal cancer. 
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3.2 Materials and Methods 
Patients with histologically proven colorectal cancer who, on the basis of laparotomy findings 
and pre-operative staging CT scan, were considered to have undergone potentially curative 
resection for colorectal cancer (Stage I – III) between January 1997 and December 2006 in a 
single surgical unit at Glasgow Royal Infirmary were included in the study.  This cohort was 
identified from a prospectively maintained database and included both elective (> 24 hours 
from admission) and emergency (< 24 hours from admission) operations. The identification 
of patients for the study was made primarily through the multi-disciplinary team (MDT) 
gastrointestinal cancer meetings and it is possible that some emergency cases were not 
included. Patients with conditions known to acutely or chronically evoke a systemic 
inflammatory response were excluded.  These included (i) pre-operative chemo-radiotherapy, 
(ii) clinical evidence of infection and (iii) chronic active inflammatory disease such as active 
rheumatoid arthritis.  Patients who died within 30 days of surgery were excluded from the 
survival analysis.  The tumours were staged according to conventional AJCC/TNM 
classification (5
th
 Edition) (Fleming ID 1997).  
Prospectively collected data included patient demographics, pathological characteristics of 
the tumour, haemotology and biochemistry results.  The medical notes were then retrieved 
and data extracted on patient physiological status.  The case notes included surgical pre-
operative assessment including details of known comorbidity, smoking status, anaesthetic 
assessment of cardiovascular function and ECG interpretation, nursing notes and drug 
prescription charts. Patient physiology was assessed by scoring patients according to the 
Physiological and Operative Severity Score for the enumeration of Mortality and Morbidity 
(POSSUM) criteria (Copeland, Jones et al. 1991).  The original POSSUM model was chosen 
as a basis for assessing physiological function for two reasons; (1) the same physiological 
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variables are also used in the P-POSSUM model which has proved accurate in predicting 
post-operative mortality following colorectal cancer resection (Poon, Chan et al. 2005; Slim, 
Panis et al. 2006; Ugolini, Rosati et al. 2009) and (2) the original POSSUM model is the only 
model developed to predict both morbidity and mortality after surgical resection. Age was 
excluded from the physiological component of POSSUM and analysed as an independent 
variable, in line with previous work (Tekkis, Prytherch et al. 2004). The remaining eleven 
physiological parameters (cardiac disease, respiratory disease, ECG changes, pulse, blood 
pressure, haemoglobin, white cell count, sodium, potassium, urea and Glasgow Coma Scale) 
were used to construct a POSSUM physiology score (Table 3.1).  Patients were then assigned 
to one of four groups (score 11 – 14, 15 – 20, 21 – 30, > 30) as previously described (Tekkis, 
Prytherch et al. 2004).  
Deprivation was defined using the Carstairs Deprivation Index (Morris and Carstairs 1991).  
This is composed of four indicators of deprivation (car ownership, overcrowded housing, 
Registrar General social class and male unemployment) and has been validated for use within 
central Scotland (Hole and McArdle 2002).  Deprivation scores were based on the postcode 
of the patients‟ residence at the time of surgery. 
The development and rationale behind the Glasgow Prognostic Score has been described 
previously (McMillan 2008).  Briefly, patients with both an elevated C-reactive protein 
(>10mg/l) and hypoalbuminaemia (<35g/l) were allocated a score of „2‟.  Patients in whom 
neither of these abnormalities was present were allocated a score of „0‟.  In line with the 
recent modification of the Glasgow Prognostic Score, patients with an elevated C-reactive 
protein alone were assigned a score of „1‟ while those with hypoalbuminaemia alone were 
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assigned a score of „0‟. All measurements of C-reactive protein and albumin were taken 
within a 24 hour period prior to surgery.  
Patients received regular follow-up (3 months, 6 months and then annually to five years) with 
CT scanning each year and regular colonoscopic surveillance until 5 years post surgery.  
Information on date and cause of death was cross-checked with that received by the cancer 
registration system and the Registrar General (Scotland). Overall survival analysis evaluated 
deaths from any cause in the follow up period. Cancer specific survival evaluated deaths only 
as a direct result of colorectal cancer. Cancer specific survival was measured from the date of 
surgery to the date of death from colorectal cancer, with patients who died of other causes 
censored in the analysis. The study was approved by the West of Scotland Research Ethics 
Committee (WoSREC), Glasgow. 
Statistics  
Grouping of all variables was carried out using standard or previously published thresholds.  
Deaths up to September 2009 were included in the survival analysis.  Univariate survival 
analysis was carried out with Kaplan-Meier curves and long rank testing. Multivariate 
survival analysis, using the Cox model and a stepwise backward procedure, was carried out 
for all variables showing a significant association on univariate analysis.  Hazard ratios (HR) 
and 95% confidence intervals (C.I.) were calculated. A p-value of less than 0.05 was 
considered statistically significant. Inter-relationships between variables were assessed using 
contingency table analysis with the chi-square test for trend as appropriate.  Analysis was 
performed using SPSS
®
 version 19.0 (IBM SPSS, Illinois, USA).  
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3.3 Results 
Baseline clinico-pathological characteristics for the 320 included patients are shown in Table 
3.2.  All elective operations were carried out by one of four colorectal surgeons while 
emergency operations were carried out by on-call general surgeons. All operations were open 
and details of operative technique were at the discretion of the operating surgeon. The 
majority of patients were aged 65 years or older (65%), lived in deprived areas (65%) and 
were current or previous smokers (58%).  There was a significant association between 
smoking history (current or ex) and increasing deprivation (p=0.04).  The majority of patients 
underwent elective operations (96%), had colonic tumours (62%), had well to moderately 
differentiated tumours (89%) and had node negative disease (60%).  The distribution of 
patients by systemic inflammatory response (mGPS) and POSSUM physiology score is 
summarised in Table 3.2.  
The minimum follow up was 32 months; the median follow up of the survivors was 74 
months.  During this period 83 patients died of colorectal cancer and there were 53 non-
cancer related deaths.  The relationships between clinico-pathological characteristics and 
survival are shown in Table 3.2.  On univariate analysis, age (p=0.001), smoking history 
(p=0.037), presentation (p<0.001), TNM stage (p<0.001), mGPS (p<0.001) and POSSUM 
physiology score (p<0.001) were significantly associated with cancer specific survival.  Age 
(p<0.001), smoking history (p=0.004), presentation (p=0.001), TNM stage (p=0.004), mGPS 
(p<0.001) and POSSUM physiology score (p<0.001) were significantly associated with 
overall survival.  The Kaplan Meier survival curves demonstrating the relationships between 
POSSUM physiology score and both cancer specific (p<0.001; log-rank test) and overall 
survival (p<0.001; log-rank test) are shown in Figures 3.1 and 3.2 respectively. 
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Multivariate survival analysis was then carried out. Using cox regression analysis, age (HR 
1.46, p<0.01), emergency presentation (HR 2.08, p=0.08), TNM stage (HR 2.39, p<0.001), 
mGPS (HR 1.78, p<0.001), and POSSUM physiology score (HR 1.38, p=0.02) were 
independently associated with cancer specific survival. Age (HR 1.64, p<0.001), smoking 
history (HR 1.52, p=0.02), TNM stage (HR 1.64, p<0.001), mGPS (HR 1.60, p<0.001), and 
POSSUM physiology score (HR 1.27, p=0.03) were independently associated with overall 
survival (Table 3.3). 
In the group of patients with Stage III disease, we noted a significant association between 
POSSUM physiology score and the likelihood of adjuvant therapy being administered (X 
2
 = 
9.94, df = 3, p = 0.019). Of the 129 patients with Stage III disease, 46 patients (36%) received 
adjuvant therapy and 83 patients (64%) did not. In patients with physiology score 11 – 14, 21 
patients (51%) received adjuvant therapy; physiology score 15 – 20, 19 patients (35%) 
received adjuvant therapy; physiology score 21 – 30, 6 patients (21%) received adjuvant 
therapy; physiology score > 30, no patient received adjuvant therapy. However, there was no 
significant association between the systemic inflammatory response and the likelihood of 
adjuvant therapy being administered in patients with Stage III. 
The relationships between POSSUM physiology score and clinico-pathological 
characteristics are shown in Table 3.4.  There was a significant relationship between 
POSSUM physiology score and mGPS (p=0.006). A higher POSSUM physiology score was 
also significantly associated with increasing age (p<0.001), tumours of colonic origin 
(p<0.001) and advanced TNM stage (p<0.05).  POSSUM physiology score was significantly 
related to all its component variables except potassium level (p=0.11) and Glasgow Coma 
Scale, the latter of which was uniformly normal.  The individual physiological variables that 
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contributed most to elevated POSSUM physiology score were low haemoglobin level 
(202/320), abnormal systolic blood pressure (192/320) and impaired cardiac function 
(166/320). Those that contributed least were sodium level (25/320), potassium level (21/320) 
and GCS (0/320).  (Table 3.4).   
The relationships between POSSUM physiology score and mGPS were then examined in 
more detail by calculating the mean score for each of the physiological variables. This 
demonstrated significant associations between mGPS and the individual physiological 
variables of abnormal pulse rate (p=0.008), raised white cell count (p=0.05), low sodium 
(p<0.001), raised potassium (p=0.01) and low haemoglobin (<0.001) (Figure 3.3).  
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3.4 Discussion 
The results of the present study show that pre-operative measures of impaired patient 
physiology, such as elevated POSSUM physiology scores, are significantly associated with 
poorer cancer specific and overall survival in patients undergoing potentially curative 
resection of colorectal cancer.  However, when considered with age, TNM stage, smoking 
status and the systemic inflammatory response (mGPS), the POSSUM physiology score was 
reduced in statistical significance.  Although the POSSUM physiology score was strongly 
associated with mGPS, multivariate survival analysis demonstrates that both were 
independent predictors, suggesting that poor patient physiology alone cannot fully explain the 
relationship between systemic inflammation and reduced survival.   
The results of the present study are consistent with previous work.  Jenkins and co-workers 
(2007) reported that, using the same thresholds, there was a significant association between 
an elevated POSSUM physiology score and poorer cancer specific survival in 432 patients 
with colorectal cancer (Jenkins, O'Neill et al. 2007).  Brosens and colleagues (2006) also 
reported that, in 542 colorectal cancer patients, there was an association between POSSUM 
physiology score and overall survival using „low‟ and „high‟ risk groups based on the median 
physiology score (Brosens, Oomen et al. 2006).   
Given that the POSSUM score was developed to predict post-operative mortality and 
morbidity, the basis of this relationship with long term survival is not clear.  One explanation 
is that poor patient physiology is associated with an increased likelihood of post-operative 
complications such as an anastomotic leak; recognised to be associated with early recurrence 
and cancer death, independent of tumour stage (McArdle, McMillan et al. 2005; Jung, Yu et 
al. 2008; Marra, Steffen et al. 2009).  Another possible explanation, examined in the present 
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study, is that a pre-operative systemic inflammatory response reflects, in part, abnormal 
patient physiology.  It is of interest therefore that Moyes and coworkers recently reported 
that, in 455 patients undergoing colorectal cancer surgery, the pre-operative mGPS was 
independently associated with an increased risk of developing post-operative infectious 
complications (Moyes, Leitch et al. 2009).  It remains to be determined whether infectious 
complications are the basis of the relationships between patient physiology, systemic 
inflammation and cancer specific survival. Of interest, we noted that patients with deranged 
physiology were significantly less likely to receive adjuvant therapy for Stage III tumours. 
However, when patients with node-negative disease were considered separately, patient 
physiology was again found to predict cancer specific survival, suggesting the survival 
benefit of good physiology is independent of the influence of chemotherapy.  
In the present study the individual physiological components associated with the mGPS were 
an elevated pulse rate, low haemoglobin and high WCC, as well as the biochemical 
abnormalities of low sodium and raised potassium.  It may be that poor cardiac function in 
these patients, combined with anaemia, leads to relative tissue hypoxia.  Indeed, it is 
recognised that tissue hypoxia is a potent stimulator of local and systemic inflammation 
(Wouters 2005; Zinkernagel, Johnson et al. 2007). If this were to be the case, it might be 
expected that systemic inflammation would be closely associated with pathological markers 
of tissue hypoxia such as tumour necrosis.  Further work is needed to define such 
relationships.  
The results from the present study have a number of implications.  The POSSUM scoring 
systems have already proven accurate in predicting post-operative mortality (Senagore, 
Warmuth et al. 2004; Ferjani, Griffin et al. 2007) and morbidity (Menon and Farouk 2002; 
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Valenti, Hernandez-Lizoain et al. 2009) after colorectal cancer surgery.  Clearly, a single 
scoring system that would allow assessment of post-operative outcomes and predict long-
term cancer survival would be advantageous.  Both the POSSUM score and mGPS have the 
potential to offer such an assessment. However, the POSSUM physiology score has eleven 
component variables, some of which may not be routinely recorded.  In contrast, the mGPS 
has only two components, is easier to construct and may therefore be less subject to 
interpretative error.  It remains to be determined which system will be most useful in 
predicting both short term and long outcome in patients undergoing surgery for colorectal 
cancer. 
These results also suggest that the pre-operative targeting of patient physiological and 
inflammatory status may represent a novel approach to improving outcomes in patients with 
cancer.  There is already some evidence that „host-related‟ targets may be of considerable 
importance. For example, the use of statins has recently been reported to improve survival 
from colorectal cancer, possibly by improvement in cardiovascular status (Siddiqui, Nazario 
et al. 2009).  The attenuation of the systemic inflammatory response and the improvement of 
oxygen delivery to the tissues represent other possibilities. 
In summary, patient physiology and the systemic inflammatory response are strongly 
associated. However, POSSUM physiology score and mGPS were independent predictors of 
cancer specific and overall survival in patients with primary operable colorectal cancer. 
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Number at risk Year 1 Year 2 Year 3 Year 4 Year 5 
Group 1 109 102 97 91  78 
Group 2 134 126 113 103 85 
Group 3 69 57 47 39 29 
Group 4 8 6 6 3 1 
 
 
 
Figure 3.1. The relationship between POSSUM physiology score and cancer-specific 
survival in patients undergoing potentially curative resection for colorectal cancer. Groups 1 
– 4 are shown top to bottom (p<0.001; log-rank test). 
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Number at risk Year 1 Year 2 Year 3 Year 4 Year 5 
Group 1 109 103 99 92 78 
Group 2 134 128 116 104 88 
Group 3 69 59 48 40 29 
Group 4 8 6 6 4 1 
 
 
Figure 3.2. The relationship between POSSUM physiology score overall survival in patients 
undergoing potentially curative resection for colorectal cancer. Groups 1 – 4 are shown top to 
bottom (p<0.001; log-rank test). 
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Figure 3.3. Graphic representation demonstrating the relationship between mGPS and 
individual POSSUM physiological variables.  
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Table 3.1. Physiological variables used in the construction of the POSSUM physiology 
score. (Age is excluded from the original physiology score and is analysed in the study as an 
independent variable). 
 
 
POSSUM physiology 
score 
1 2 4 8 
Cardiac normal Cardiac drugs 
Oedema 
Warfarin 
JVP 
Cardiomegaly 
Respiratory normal 
SOB exertion 
Mild COPD 
SOB stairs 
Mod COPD 
SOB rest 
Fibrosis 
E.C.G. normal - AF (60-90) Other abnormality 
Systolic B.P. 
(mmHg) 
110-130 
131-170 
100-109 
≥ 171 
90-99 
≤ 89 
Pulse 
(beats/min) 
50-80 
81-100 
40-49 
101-120 
≥ 120 
≤ 39 
Haemoglobin 
(g/dL) 
13-16 
11.5-12.9 
16.1-17 
10-11.4 
17.1-18 
≤ 9.9 
≥ 18.1 
White cell count 
(x10
12
/L) 
4-10 
10.1-20 
3.1-3.9 
≥ 20.1 
≤ 3 
- 
Sodium 
(mmol/L) 
≥ 136 131-135 126-130 ≤ 125 
Potassium 
(mmol/L) 
3.5-5 
3.2-3.4 
5.1-5.3 
2.9-3.1 
5.4-5.9 
≤ 2.8 
≥ 6 
Urea 
(mmol/L) 
≤ 7.5 7.6-10 10.1-15 ≥ 15.1 
G.C.S. 15 12-14 9-11 ≤ 8 
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Table 3.2. The relationship between clinico-pathological variables and survival in patients 
undergoing potentially curative resection for colorectal cancer; univariate survival analysis. 
 
 
Variable 320 (%) Cancer-specific survival Overall survival 
 Hazard ratio  
(95% C.I.) 
p-value 
 
Hazard ratio  
(95% C.I.) 
p-value 
 
Age 
 ≤64 111 (35)     
 65-74 102 (32)     
 ≥75 107 (33) 1.66 (1.26, 2.18) <0.001 1.80 (1.45, 2.23) <0.001 
Sex 
Male 170 (53)     
Female 150 (47) 1.30 (0.84, 2.01) 0.25 1.18 (0.84, 1.66) 0.34 
Deprivation  
1-2 12 (4)     
3-5 99 (31)     
6-7 209 (65) 1.11 (0.74, 1.65) 0.46 0.98 (0.72, 1.32) 0.77 
Smoking 
Never 135 (42)     
Current/previous 185 (58) 1.62 (1.02, 2.55) 0.04 1.67 (1.17, 2.39) 0.004 
Presentation 
Elective 307 (96)     
Emergency 13 (4) 3.93 (1.80, 8.56) <0.001 3.00 (1.53, 5.94) 0.001 
Tumour site 
Colon 197 (62)     
Rectum 123 (38) 0.84 (0.53, 1.32) 0.45 1.09 (0.77, 1.54) 0.62 
Differentiation 
Well/moderate 286 (89)     
Poor 34 (11) 1.26 (0.63, 2.52) 0.51 1.58 (0.96, 2.59) 0.07 
TNM stage 
Stage I 38 (12)     
Stage II 153 (48)     
Stage III 129 (40) 2.21 (1.51, 3.21) <0.001 1.60 (1.21, 2.10) 0.004 
Adjuvant therapy 
No 254 (79)     
Yes 66 (21) 1.00 (0.59, 1.69) 0.99 0.90 (0.59, 1.37) 0.61 
mGPS 
Low (0) 194 (61)     
Intermediate (1) 90 (28)     
High (2) 36 (11) 1.71 (1.29, 2.27) <0.001 1.60 (1.28, 2.01) <0.001 
POSSUM physiology score 
Group 1 (11-14) 109 (34)     
Group 2 (15-20) 134 (42)      
Group 3 (21-30) 69 (21)     
Group 4 (>30) 8 (3) 1.73 (1.33, 2.25) <0.001 1.59 (1.29, 1.96) <0.001 
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Table 3.3. The relationship between clinico-pathological variables and survival in patients 
undergoing potentially curative resection for colorectal cancer; multivariate survival analysis.  
 
Variable 
Cancer-specific survival Overall survival 
Hazard ratio  
(95% C.I.) 
p-value 
Hazard ratio 
 (95% C.I.) 
p-value 
Age 1.46 (1.10, 1.94) <0.01 1.64 (1.32, 2.05) <0.001 
Smoking 1.46 (0.92, 2.32) 0.10 1.52 (1.06, 2.18) 0.02 
Presentation 2.08 (0.91, 4.76) 0.08 1.70 (0.84, 3.45) 0.14 
TNM stage 2.39 (1.59, 3.59) <0.001 1.64 (1.22, 2.20) <0.001 
mGPS 1.78 (1.32, 2.41) <0.001 1.60 (1.26, 2.02) <0.001 
POSSUM physiology 
score 
1.38 (1.05, 1.82) 0.02 1.27 (1.02, 1.58) 0.03 
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Table 3.4. The relationships between POSSUM physiology score and clinico-pathological 
characteristics in patients undergoing potentially curative resection for colorectal cancer. 
 
 
 
Variable 
Group 1 
11 - 14 
(n=109) 
Group 2 
15 - 20 
(n=134) 
Group 3 
21 - 30 
(n=69) 
Group 4 
> 30 
(n=8) 
 
 
p-value 
 
 
POSSUM variables 
     
Cardiac (1/2/4/8) 82/27/0/0 66/60/8/0 6/40/20/3 0/1/5/2 <0.001 
Resp. (1/2/4/8) 86/23/0/0 80/39/13/2 32/15/19/3 2/2/3/1 <0.001 
E.C.G. (1/4/8) 109/0/0 125/3/6 26/12/31 2/1/5 <0.001 
S.B.P. (1/2/4/8) 59/50/0/0 43/75/15/1 26/35/7/1 0/4/4/0 <0.001 
Pulse (1/2/4/8) 83/26/0/0 80/46/8/0 37/27/5/0 4/3/1/0 0.01 
Hb. (1/2/4/8) 71/37/1/0 33/36/43/22 14/14/13/28 0/3/2/3 <0.001 
W.C.C. (1/2/4) 104/4/1 103/28/3 49/19/1 1/6/1 <0.001 
Sodium (1/2/4/8) 107/2/0/0 121/10/3/0 62/5/2/0 5/2/1/0 0.008 
Potassium (1/2/4/8) 106/3/0/0 123/7/4/0 64/4/1/0 6/1/1/0 0.11 
Urea (1/2/4/8) 107/2/0/0 114/16/4/0 62/6/1/0 2/1/4/1 <0.001 
G.C.S. (1/2/4/8) 109/0/0/0 134/0/0/0 69/0/0/0 8/0/0/0 N/A 
Age      
≤64/65-74/≥75 57/31/21 41/41/52 13/27/29 0/3/5 <0.001 
Sex      
Male/female 64/45 64/70 38/31 4/4 0.38 
Smoking      
Never/current or ex 54/55 55/79 25/44 1/7 0.09 
Presentation      
Elective/emergency 107/2 127/7 66/3 7/1 0.34 
Tumour site      
Colon/rectum 51/58 85/49 54/15 7/1 <0.001 
Deprivation      
1-2/3-5/6-7 5/42/62 5/39/93 2/19/48 0/2/6 0.47 
Differentiation      
Well or mod/poor 101/8 122/12 57/12 6/2 0.08 
TNM stage      
I/II/III 22/46/41 13/67/54 3/37/29 0/3/5 0.03 
mGPS 
0/1/2 80/22/7 77/44/13 34/21/14 3/3/2 0.006 
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4.0 THE ACCURACY OF SCORING SYSTEMS IN THE PREDICTION OF 
OPERATIVE MORTALITY FOLLOWING RESECTION OF COLORECTAL 
CANCER.  
4.1 Introduction 
The majority of patients with diagnosis of colorectal cancer undergo surgical resection and 
hospitals increasingly require robust and accurate systems for recording operative outcomes 
(Russell, Bruce et al. 2003).  Operative mortality is often used as an indirect measure of 
quality of care but population heterogeneity means comparing crude mortality rates can be 
misleading.  The use of standardised risk-adjustment models allows fair comparison of 
outcome by correcting for the confounding effects of case-mix (Sagar, Hartley et al. 1994; 
Jones and de Cossart 1999).  
Several different predictive models have been proposed for patients undergoing surgical 
resection of colorectal cancer. One of the earliest, the Physiologic and Operative Severity 
Score for the enUmeration of Mortality and morbidity (POSSUM) model (Copeland, Jones et 
al. 1991), was developed for use within general operative practice.  The original model, 
however, consistently over-predicted death in low risk patients, leading to the Portsmouth 
modification (P-POSSUM) (Whiteley, Prytherch et al. 1996; Prytherch, Whiteley et al. 1998).  
Recently, a specialty-specific model known as colorectal POSSUM (CR-POSSUM) has been 
developed for use within benign and malignant colorectal surgery (Tekkis, Prytherch et al. 
2004). 
Conflicting reports regarding the ability of P-POSSUM and CR-POSSUM to predict 
colorectal cancer outcome (Senagore, Warmuth et al. 2004; Slim, Panis et al. 2006; Leung, 
Ferjani et al. 2009), coupled with the complexity of their construction, has limited the use of 
either model in routine clinical practice.  In an effort to combat these shortcomings, a 
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simplified risk-adjustment model was developed by the Association of Coloproctology of 
Great Britain and Ireland (ACPGBI) (Tekkis, Poloniecki et al. 2003).  Dedicated to 
estimating operative mortality following colorectal cancer surgery, the model was designed 
for use in both clinical audit and preoperative counselling and required only five widely 
recorded variables; age, American Society of Anaesthesiology (ASA) grade, cancer stage, 
operative urgency and resection status.  In 2010, the online version of the ACPGBI model 
was revised to include age, ASA grade, cancer stage, operative urgency and operation type 
(minor/intermediate/major/complex) (http://www.riskprediction.ork.uk).  To our knowledge, 
the revised ACPGBI model has yet to be externally validated in a cohort of patients 
undergoing colorectal cancer resection at a single institution.   
The aim of the present study, therefore, was to compare the performance of the revised 
ACPGBI model, the original ACPGBI model, P-POSSUM and CR-POSSUM in the 
prediction of operative mortality following potentially curative resection of colorectal cancer. 
Specifically, we wanted to assess model performance in high risk subgroups, including 
emergency cases and patients with high ASA grades or evidence of an elevated systemic 
inflammatory response.  
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4.2 Materials and Methods 
Patients with colorectal cancer who were considered to have undergone potentially curative 
resection of colorectal cancer between January 1
st
 1997 and December 31
st
 2007 at Glasgow 
Royal Infirmary were identified from the same prospective database described in Chapter 3.   
Preoperative patient characteristics were recorded including age, sex, smoking status, mode 
of presentation, ASA grade and systemic inflammatory response as measured by the modified 
Glasgow Prognostic Score (mGPS).  Operative details included tumour site (colon or rectum) 
and operation type. The tumours were staged according to conventional AJCC/TNM 
classification (5
th
 Edition) (Fleming ID 1997). 
The risk-adjustment models were then constructed. Physiological, operative and pathological 
variables were recorded according to the P-POSSUM, CR-POSSUM, ACPGBI (original) and 
ACPGBI (revised) criteria (Table 4.1).  Variables required for the construction of the 
ACPGBI models were collected prospectively as part of the core data set within the 
colorectal cancer database.  Additional data required for the construction of the P-POSSUM 
and CR-POSSUM models was recorded retrospectively from health records.  Missing data, 
limited to „evidence of peritoneal soiling‟ in 20 cases (5%) and „blood loss‟ in 14 cases (3%), 
were allocated normal values and included in the analysis, in line with published 
recommendations (Senagore, Warmuth et al. 2004).  The predicted risk of mortality using 
each model was generated using an online calculator according to the equations shown in 
Table 4.1.  The study was approved by the West of Scotland Research Ethics Committee 
(WoSREC), Glasgow. 
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Statistics 
Observed operative mortality was defined as death within 30 days of operation.  Predicted 
mortality rates for each model are represented as the mean value with 95% confidence 
intervals (CI).  Observed and expected mortality rates were compared to generate observed to 
expected (O:E) ratios.  Model calibration (the ability of the model to assign the correct 
probabilities of outcome to individual patients) was assessed using the Hosmer-Lemeshow 
goodness-of-fit test. Model discrimination (the ability of the model to assign higher 
probabilities of outcome to patients who died than to those who did not) was assessed by 
measuring the area under the Receiver Operator Characteristic curve (AUC). Statistical 
analysis was performed using SPSS
®
 version 19.0 (IBM SPSS, Illinois, USA).  
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4.3 Results 
A total of 423 patients who underwent potentially curative resection of colorectal cancer were 
included. Baseline clinical, pathological and operative characteristics of the patients are 
shown in Table 4.2.  The majority of patients were younger than 75 years (65%) with a 
similar number of males and females.  Preoperative assessment recorded 43% of patients as 
having never smoked and 54% of patients as ASA grade I or II.  In terms of systemic 
inflammatory response 58% were mGPS 0, 27%  were mGPS 1 and 15% were mGPS 2.  The 
majority of operations (93%) were undertaken on an elective basis and all resections were 
performed via open surgery.  The site of the primary tumour was the colon in 62% and the 
rectum in 38%.  Ninety percent of operations involved an anastomosis with the remainder 
either a Hartmann`s procedure (3%) or an abdominoperineal resection of rectum (APR) (7%).  
Pathological reports classified the tumours as Stage 1 (12%), Stage II (44%) or Stage III 
(44%) (Table 4.2).   
In the postoperative period a total of seventeen patients died (30 day mortality = 4.0%).  The 
causes of death were cardiovascular complications in 8 patients, respiratory complications in 
5 patients, intra-abdominal sepsis in 3 patients and cerebrovascular accident (CVA) in 1 
patient.  The relationships between clinico-pathological variables and operative mortality are 
shown in Table 4.2.  The patient subgroups identified as at significantly increased risk of 
operative mortality were elderly patients (p<0.001) and those with high ASA grade 
(p=0.008). There was a trend between both emergency presentation (p=0.073) and increased 
mGPS (p=0.072) and increased rates of operative mortality although this did not reach 
statistical significance.  
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The summary analyses of model performance in the prediction of operative mortality are 
shown in Table 4.3.  In terms of numbers of deaths, the rate expected by the revised ACPGBI 
model was closest to the observed rate although there was no statistically significant 
difference in the rates predicted by the revised ACPGBI model and P-POSSUM.  In terms of 
mortality ratios, the calculated O:E ratio was closest to „1‟ using the revised ACPGBI model.  
In terms of discrimination, CR-POSSUM attained the largest AUC (0.84) but there was no 
significant difference between any of the models with overlapping confidence intervals in all 
cases.  In terms of calibration, the revised ACPGBI model attained the largest p-value (0.20) 
but all four models fitted the data adequately (p≥0.05, demonstrating no significant lack of 
fit) (Table 4.3). 
The analyses of model performance across high and low risk patient subgroups are shown in 
Table 4.4.  Considering the highest risk subgroups; in patients 75 years or older, the revised 
ACPGBI model predicted mortality most closely; in emergency presentation, the revised 
ACPGBI model and P-POSSUM predicted mortality equally well; in patients with high ASA 
grades, CR-POSSUM predicted mortality most closely and in patients with systemic 
inflammation the revised ACPGBI performed the most accurately. Considering the lowest 
risk subgroups; in patients 64 years or younger, in those presenting electively and in those 
with ASA grade I, the revised ACPGBI model again predicted mortality most closely (Table 
4.4).  
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4.4 Discussion 
The present study reports the revised ACPGBI risk-adjustment model to be a simple and 
accurate predictor of operative mortality in patients undergoing potentially curative resection 
of colorectal cancer.  Furthermore, the recent revision appears to have improved the 
performance of the model.   
The ability of risk-adjustment models to accurately predict outcome is often judged by their 
performance across low or high risk patient subgroups.  The present study confirmed 
operative mortality rates to be highest in elderly patients, those with high ASA grades and in 
those presenting as an emergency.  In addition, a novel finding of the present study was that 
patients with evidence of a preoperative systemic inflammatory response appear to be at 
increased risk of death in the postoperative period.  Although no single model performed 
consistently well across all these high risk subgroups, the revised ACPGBI model performed 
well in elderly patients, emergency cases and in those with systemic inflammation.  
Previously, it has been reported that the original ACPGBI model performed poorly in 
emergency colorectal cancer surgery (Metcalfe, Norwood et al. 2005; Ferjani, Griffin et al. 
2007); an observation confirmed in the present study.  The reasons behind an improved 
performance of the revised model in the emergency setting are not entirely clear. One 
explanation may be that all patients included in the present study underwent primary 
resection.  The revised ACPGBI model, which substitutes „resection status‟ for „operation 
type‟, may therefore have offered additional stratification to the emergency cases. 
The accurate prediction of mortality in low risk groups has also been a documented weakness 
of previous risk-adjustment models.  Indeed, the phenomenon of over-prediction of events in 
low risk groups was the original stimulus for the development of P-POSSUM (Whiteley, 
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Prytherch et al. 1996).  Although all four models examined in the present study over-
predicted death in the youngest patients and in those undergoing elective surgery, the revised 
ACPGBI model performed best in both instances.  The mortality rates following elective 
colorectal cancer surgery are often extremely low; possibly the result of sub-specialisation 
(Zorcolo, Covotta et al. 2003), high volume centres (Hillner, Smith et al. 2000) or 
improvements in perioperative management (de Leon, Pezzi et al. 2009). For a model to 
perform well in low risk patients, the lowest attainable score must reflect this level of risk and 
it appears the revised ACPGBI model achieves this. 
The present study suggests the revised ACPGBI model has more predictive value in 
colorectal cancer surgery than the specialty-specific model, CR-POSSUM.  A possible 
explanation for the poor performance of CR-POSSUM in the present cohort may be gained 
by examining the dataset on which the model was developed.  The CR-POSSUM model was 
based on the examination of surgical outcome following approximately 7000 colorectal 
operations which included a large proportion of minor and benign cases (Tekkis, Prytherch et 
al. 2004).  This population heterogeneity, albeit within a colorectal specialty, may 
compromise the models‟ accuracy when applied to major colorectal cancer resection.  The 
revised ACPGBI model, in contrast, was developed using data from over 7000 patients 
exclusively undergoing resection of colorectal cancer which may explain its enhanced 
performance in the present cohort. 
 
This study refers only to patients undergoing open colorectal cancer resection and these 
results may not be applicable to patients undergoing laparoscopic resection.  It may be 
surmised, however, that as none of the variables in the ACPGBI model are attributable to 
operative technique, the scores generated for individual patients would be unaltered.  If this 
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were so, the performance of the model would only be changed if laparoscopic resection 
impacted on operative mortality rates; current evidence suggests this not to be the case (Reza, 
Blasco et al. 2006).   Future studies should aim to assess the performance of the model in 
patients undergoing laparoscopic resection of colorectal cancer.  
The accuracy of all predictive models, however, must be interpreted with caution.  Although 
the reporting of O:E ratios is a simple method for comparing model performance, it must be 
remembered that disparate observed and expected rates may be a reflection of surgical under- 
or over-performance rather than model inaccuracy.  The present study attempted to counter 
this by supplying additional data on the discrimination and calibration of each model.  
Although such statistics can help quantify the ability of a model to assign the correct 
probabilities of outcome to each patient, it should be remembered that these models were 
designed to predict population rather than individual mortality risk. 
The development of an accurate scoring system for the prediction of operative mortality 
following colorectal cancer surgery is a major challenge.  An ideal system would be simple to 
construct, rely on readily available objective data and perform consistently across low and 
high risk patient subgroups.  The revised ACPGBI model fulfils many of these criteria and 
may have several important clinical applications.  First, consistent performance across low 
risk elective patients means the model could be an important audit tool for comparing 
individual surgeon or hospital performance.  An accurate estimation of mortality for high risk 
patients would not only facilitate the consent process but could play an active role in surgical 
decision-making.  Currently, clinicians often rely on subjective judgment in such cases, while 
patients often misinterpret the level of risk (Ravitch 1989).  The addition of a predictive 
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model would add an important objective element to this process, benefiting both patient and 
clinician.  
In summary, the present study reports the revised ACPGBI model to be the most simple and 
accurate predictor of operative mortality following potentially curative resection of colorectal 
cancer.  
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Table 4.1. The variables used in the construction of the P-POSSUM, CR-POSSUM and 
ACPGBI models including the equations used to calculate the risk (R) of mortality. 
.  
 
Model 
 
Physiological variables Operative variables 
P-POSSUM Age (years) Operation category 
 Cardiac failure Number. of procedures 
 Respiratory status Total blood loss (ml) 
 E.C.G. Peritoneal soiling 
 Systolic B.P. (mmHg) Cancer stage 
 Pulse (beats/min) Operative urgency 
 Haemoglobin (g/dL)  
 White cell count (x10
12
/L)  
 Sodium (mmol/L)  
 Potassium (mmol/L)  
 Urea (mmol/L)  
 Glasgow Coma Score  
Mortality equation:  Log [R/(1-R)] = -9.065 + (0.16 x physiological score) + (0.15 x operative score) 
 
CR-POSSUM Age (years) Operative severity 
 Cardiac failure Peritoneal soiling 
 Systolic B.P. (mmHg) Total blood loss (ml) 
 Pulse (beats/min) Operative urgency 
 Urea (mmol/L) Cancer stage 
 Haemoglobin (g/dL)  
Mortality equation:  Log [R/(1-R)] = -9.167 + (0.33 x physiological score) + (0.30 x operative score) 
 
ACPGBI (original) Age (years) Cancer stage 
 ASA grade Operative urgency 
  Cancer resection status 
Mortality equation:  Log [R/(1-R)] = (-4.859 + total score) 
 
ACPGBI (revised) Age (years) Cancer stage 
 ASA grade Operative urgency 
  Operative procedure 
Mortality equation:  Log [R/(1-R)] = (-4.859 + total score) 
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Table 4.2. The relationships between clinico-pathological characteristics and 30-day 
mortality in patients undergoing colorectal cancer surgery with curative intent. 
 
 
 
Variable 
 
Patient group 
 
423 (%) 
30 day mortality 
n (%) 
p-value 
 
Age (years) 
 
≤ 64 
 
140 (33) 0 (0)  
 65 – 74 135 (32) 4 (3)  
 ≥ 75 148 (35) 13 (9) <0.001 
Sex Male 230 (54) 12 (5)  
 Female 193 (46) 5 (3) 0.171 
Smoking Status Non-smoker 183 (43) 5 (3)  
 Ex-smoker 150 (36) 8 (5)  
 Current smoker 90 (21) 4 (4) 0.381 
Presentation Elective  395 (93) 14 (4)  
 Emergency 28 (7) 3 (10) 0.073 
ASA Grade ASA I 52 (12) 0 (0)  
 ASA II 178 (42) 5 (3)  
 ASA III 168 (40) 9 (5)  
 ASA IV 25 (6) 3 (12) 0.008 
Tumour Site Colon 264 (62) 11 (4)  
 Rectum 159 (38) 6 (4) 0.842 
Operation Right hemicolectomy 130 (31) 3 (2)  
 Sigmoid colectomy 79 (16) 3 (4)  
 Subtotal colectomy 13 (3) 1 (8)  
 Colonic unspecified 44 (10) 2 (7)  
 Hartmann‟s procedure 12 (3) 1 (8)  
 Anterior resection 126 (30) 3 (2)  
 APR 28 (7) 3 (11) 0.416 
TNM stage Stage I 51 (12) 5 (10)  
 Stage II 186 (44) 5 (3)  
 Stage III 186 (44) 7 (4) 0.211 
mGPS 0 246 (58) 8 (3)  
 1 114 (27) 3 (3)  
 2 63 (15) 6 (10) 0.072 
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Table 4.3. Comparison of P-POSSUM, CR-POSSUM and ACPGBI models in the prediction 
of 30-day operative mortality following colorectal cancer surgery with curative intent.   
 
 
Model 
Observed  
Mortality
a
 
Performance Indicators 
Exp. Mortality
b
 O:E ratio
c
 Discrimation
d
 Calibration
e
 
P-POSSUM 4.0 4.6 (3.79-5.34) 0.87 0.79 (0.71-0.88) 10.63, p = 0.06 
CR-POSSUM 4.0 6.3 (5.65-6.94) 0.63 0.84 (0.79-0.90) 15.84, p = 0.05 
ACPGBI (original) 4.0 6.9 (6.31-7.55) 0.58 0.76 (0.68-0.84) 14.23, p = 0.08 
ACPGBI (revised) 4.0 3.8 (3.43-4.27) 1.05 0.73 (0.63-0.82) 11.02, p = 0.20 
 
a 
Observed 30 day mortality rate 
b
 Expected 30 day mortality rate (95% confidence intervals) 
c
 O:E ratio represents the observed to expected mortality ratio. 
d
 Discrimination is measured by the area under the Receiver-Operator Characteristic curve (95% confidence 
intervals): higher values represent better model discrimination.
 
e
 Calibration is measured by the Hosmer-Lemeshow statistic: smaller values and larger p-values represent better 
model calibration. 
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Table 4.4. Comparison of the performance of P-POSSUM, CR-POSSUM and ACPGBI 
models in high risk patient subgroups. 
 
Patient 
subgroup 
Observed 
Mortality 
(%) 
P-POSSUM CR-POSSUM ACPGBI (original) ACPGBI (revised) 
Exp
a
 O:E ratio
b
 Exp
a
 O:E ratio
b
 Exp
a
 O:E ratio
b
 Exp
a
 O:E ratio
b
 
 
Age 
≤ 64 0 2.0 N/A 2.5 N/A 2.4 N/A 1.5 N/A 
65 – 74 3.0 5.3 0.57 5.0 0.60 6.9 0.43 3.3 0.91 
≥ 75 years 8.8 6.4 1.38 11.1 0.79 11.3 0.78 6.6 1.33 
 
Mode of Presentation 
Elective 3.5 4.1 0.85 5.9 0.59 6.2 0.56 3.3 1.06 
Emergency 10.7 11.8 0.91 12.2 0.88 17.1 0.63 11.8 0.91 
 
ASA Grade 
ASA 1  0 1.2 N/A 2.6 N/A 1.1 N/A 0.8 N/A 
ASA 2 2.8 2.2 1.27 5.3 0.53 3.7 0.68 2.0 1.15 
ASA 3 5.4 5.9 0.92 7.7 0.70 9.8 0.55 5.1 1.06 
ASA 4 12.0 19.6 0.61 11.6 1.03 23.0 0.52 14.5 0.83 
 
mGPS 
0 3.3 3.2 1.03 5.5 0.60 5.8 0.57 2.9 1.14 
1 2.6 5.1 0.51 6.8 0.38 7.4 0.35 4.0 0.65 
2 9.5 9.0 1.05 8.5 1.12 12.1 0.78 8.0 1.19 
 
All patients 
 
4.0 4.6 0.87 6.3 0.63 6.9 0.58 3.8 1.05 
 
a
Exp represent the expected mortality (mean value). 
b
O:E ratio represents the observed to expected mortality ratio. 
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5.0 THE RELATIONSHIPS BETWEEN BODY COMPOSITION AND THE 
SYSTEMIC INFLAMMATORY RESPONSE IN PATIENTS WITH PRIMARY 
OPERATIVE COLORECTAL CANCER.  
5.1  Introduction 
Approximately 1 in 3 people in the United Kingdom will develop cancer during their lifetime 
(Bosanquet and Sikora 2004).  Of these, almost half will experience a progressive involuntary 
weight loss with their disease, termed cancer cachexia.  The degree of weight loss varies by 
tumour type but gastrointestinal tumours have a particularly high prevalence (Dewys, Begg et 
al. 1980).  Indeed, it is estimated that up to half of patients with colorectal cancer have 
experienced weight loss by the time of presentation (Khalid, Spiro et al. 2007). 
Cachexia has long been recognised as a marker of poor prognosis in cancer patients; 
associated with an increased risk of surgical complications (Peng, van Vledder et al. 2011) , 
resistance to chemotherapy (Ross, Ashley et al. 2004; Prado, Baracos et al. 2007), reduced 
quality of life (Dewys, Begg et al. 1980)  and decreased survival (Andreyev, Norman et al. 
1998; O'Gorman, McMillan et al. 2000; van Vledder, Levolger et al. 2012).  The clear link 
between weight loss, reduced performance status, impaired response to treatment and poor 
prognosis in such patients may be due to the preferential loss of skeletal muscle.  It has been 
suggested that, although the loss of adipose tissue accounts for the majority of the weight 
loss, it is the loss of muscle which impacts upon morbidity and mortality (Kotler 2000; 
Morley, Thomas et al. 2006; Fearon, Strasser et al. 2011).  This has led some to describe the 
phenomenon of cancer-related weight loss as „sarcopenia‟; a term originally employed to 
describe the gradual loss of skeletal muscle seen with ageing.  The aetiological factors 
responsible for these changes in body composition are unclear but previous observations 
indicate there may be an association with inflammation.  Indeed, there is now evidence that 
the systemic inflammatory response, already recognized as a marker of poor prognosis in 
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patients with gastrointestinal cancer (Proctor, Morrison et al. 2011), is associated with the 
cardinal features of cachexia (Argiles, Busquets et al. 2005; McMillan 2009).  Previous work 
has demonstrated an association between systemic inflammation and a loss of lean tissue as 
measured using a total body potassium scanner (McMillan, Scott et al. 1998) although such 
equipment is not routinely available, is unlikely to be useful in clinical practice and has been 
superseded by the advent of cross-sectional imaging. 
The aim of the present study, therefore, was to examine the relationships between CT 
measured parameters of body composition and the systemic inflammatory response in 
patients with primary operable colorectal cancer. 
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5.2 Materials and Methods 
Patients with colorectal cancer who were considered to have undergone potentially curative 
resection for colorectal cancer between January 1
st
 2003 and December 31
st
 2010 at Glasgow 
Royal Infirmary were identified from the same prospective database described in Chapter 3.  
Of these, only patients with recorded height data and CT images taken preoperatively for 
diagnostic or staging purposes and stored in an electronic format suitable for image analysis 
were included in the study.   
Patient height and weight was recorded from preoperative assessment health records and 
included only if documented within 30 days of CT scan.  Patients were classified by body 
mass index (BMI) as underweight (BMI<18.5), normal weight (BMI 18.5-24.9), overweight 
(BMI 25.0-29.9) or obese (BMI>30) according to World Health Organisation (WHO) 
criteria. The tumours were staged according to conventional AJCC/TNM classification (5
th
 
Edition) (Fleming ID 1997).   
Preoperative systemic inflammatory response in the present study was assessed using three 
different measures (Chapter 1, Table 1.9). These were (1) serum white cell count (WCC) 
(Maltoni, Caraceni et al. 2005), (2) neutrophil to lymphocyte ratio (NLR) (Walsh, Cook et al. 
2005) and (3) the modified Glasgow Prognostic Score (mGPS) (McMillan 2008).  
The image analysis of CT scans was undertaken using medical imaging software.  To test the 
reliability of different software packages, one commercially available program (Slice-O-
Matic, version 4.3, Tomovision) and one governmental free-ware program (NIH ImageJ, 
version 1.44, http://rsbweb.nih.gov.ij/), were compared.  Two trained investigators (CSDR 
and MTM) analysed a random sample of 50 cases using each of the software packages with 
the following results. (1) CSDR versus MTM using Slice-O-Matic software, mean difference 
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of 4.51 cm
2
, limits of agreement -1.67 cm
2
 to 10.69 cm
2
, interclass correlation coefficient 
(ICC) = 0.977, (2) CSDR versus MTM using ImageJ software, mean difference of 1.52 cm
2
, 
limits of agreement -8.81 cm
2
 to 11.85 cm
2
, ICC = 0.987, (3) Slice-O-Matic versus ImageJ 
software, mean difference of 7.50 cm
2
, limits of agreement -13.63 cm
2
 to 28.64 cm
2
, ICC = 
0.953.  After establishing that both software packages provided reliable measurements, 
ImageJ was used for the entire cohort.  Figure 5.1 provides an example of CT image analysis 
using NIH ImageJ software.  
Total fat, subcutaneous fat, visceral fat and skeletal muscle cross-sectional areas (cm
2
) were 
measured at the level of L3 using standard Hounsfield unit ranges (adipose tissue: -190 to -
30; skeletal muscle: -29 to +150) (Mitsiopoulos, Baumgartner et al. 1998).  Each parameter 
was then normalized for patient stature, as is conventional for BMI, and designated as total 
fat index (cm
2
/m
2
), subcutaneous fat index (cm
2
/m
2
), visceral fat index (cm
2
/m
2
), skeletal 
muscle index (cm
2
/m
2
). To further test inter-observer agreement, each parameter was again 
measured independently by two investigators in a random sample of 50 cases (total fat index, 
ICC = 0.982; subcutaneous fat index, ICC = 0.992; visceral fat index, ICC = 0.955; skeletal 
muscle index, ICC = 0.987). The study was approved by the West of Scotland Research 
Ethics Committee (WoSREC), Glasgow. 
Statistics 
Body composition parameters are presented as mean values with standard deviation (SD) and 
are categorised into sex-specific tertiles (low/medium/high).  Grouping of other variables was 
carried out using standard or previously published thresholds.  Relationships between 
continuous and categorical variables were examined using X 
2 
linear-by-linear analysis, non-
parametric tests and Pearson correlation coefficients (r) as appropriate.  P values of less than 
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0.05 were considered statistically significant. Statistical analysis was performed using SPSS
®
 
version 19.0 (IBM SPSS, Illinois, USA).  
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5.3 Results 
A total of 548 patients underwent potentially curative resection of colorectal cancer during 
the study period.  Of these, 374 patients were excluded (314 patients did not have an 
electronic version of their CT scans available for image analysis and 60 patients did not have 
any height data recorded) and 174 patients were included.  Figure 5.2 summarises the study 
selection process.  Baseline clinico-pathological characteristics of the included cohort are 
shown in Table 5.1.  Approximately one third of patients were 75 years or older with a 
similar number of males and females.  The majority of patients had no evidence of a systemic 
inflammatory response prior to surgery.  According to WHO BMI classification, 3% of 
patients were underweight, 36% normal weight, 33% overweight and 28% obese.  The 
operations were carried out for colon cancer in 66% of cases and rectal cancer in 34%.  
Pathology reports classified 16% of the tumours as stage I, 44% as stage II and 40% as stage 
III (Table 5.1). 
The body composition parameters of the patients are shown in Table 5.2.  There were no sex 
differences in BMI.  Females had significantly more total fat (150.3cm
2
/m
2
 versus 124.1 
cm
2
/m
2
, p<0.001) and subcutaneous fat (104.4cm
2
/m
2
 versus 73.7cm
2
/m
2
, p<0.001) while 
males had significantly more skeletal muscle (46.2cm
2
/m
2
 versus 36.9cm
2
/m
2
, p<0.001).  
These differences justified the use sex-specific tertiles in the study i.e. data relating to body 
composition is thus corrected for sex (Table 5.2).  
The relationships between parameters of body composition and measures of the systemic 
inflammatory response in patients with primary operable cancer are shown in Table 5.3.  
There were no relationships between any parameter of body composition and serum WCC or 
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NLR.  However, there was a significant relationship between an elevated mGPS and a low 
skeletal muscle index (p=0.001) (Table 5.3). 
To further examine this relationship, absolute values of C-reactive protein and albumin were 
correlated with each parameter of body composition.  With regard to C-reactive protein, there 
were no relationships with total fat index, subcutaneous fat index or visceral fat index but 
there was a significant negative correlation with skeletal muscle index (r=-0.21, p=0.005).  
With regard to albumin, there were no relationships with total fat index or subcutaneous fat 
index but there were significant positive correlations with visceral fat index (r=0.18, p=0.02) 
and skeletal muscle index (r=0.31, p<0.001).  Scatterplots demonstrating these correlations 
are shown in Figure 5.3.  
The relationships between skeletal muscle index and clinicopathological characteristics of the 
patients are shown in Table 5.4.  There were significant associations between a low skeletal 
muscle index and increasing age (p<0.001) and presence of anaemia (p=0.029).  There were 
no associations between skeletal muscle index and any of the tumour-related variables (Table 
5.4).  
The relationships between BMI classification and skeletal muscle index are illustrated in 
Figure 5.4.  At least some patients from all the BMI categories fell within the lowest tertile of 
skeletal muscle index.  In females, this meant a total of 24 patients (30%) with a normal, 
overweight or obese BMI were within the lowest tertile of skeletal muscle index.  In males, 
31 patients (33%) with a normal, overweight or obese BMI were within the lowest tertile of 
skeletal muscle index (Figure 5.4).  
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5.4 Discussion 
The results of the present study demonstrate a strong association between low skeletal muscle 
mass and the presence of a systemic inflammatory response, as measured by mGPS, in 
patients with primary operable colorectal cancer.  Furthermore, there were no direct 
relationships between skeletal muscle mass and any tumour-related variables, including 
tumour stage or nodal status.  Taken together, these results would suggest that the loss of lean 
tissue in cancer cachexia may be driven by the host systemic inflammatory response.  
The negative impact of systemic inflammation on cancer outcome has been reported 
previously; associated with an increased risk of septic complications (Moyes, Leitch et al. 
2009), functional decline and decreased survival (Richards, Platt et al. 2011).  The present 
study confirms that, using a different methodological approach, systemic inflammation plays 
a role in the development of muscle wasting in patients with colorectal cancer.  This is 
supported by experimental models whereby pro-inflammatory cytokines, including 
interleukin-1 (IL-1), IL-6 and tumour necrosis factor-ά (TNF), have been reported as 
mediators of both anorexia and skeletal muscle proteolysis (Argiles, Busquets et al. 2005), 
the key components of weight loss in patients with cancer.  Furthermore, the present study 
points to such inflammatory mediators having an effect on the liver, key to the elaboration of 
the systemic inflammatory response (Gabay and Kushner 1999).  In addition to the hepatic 
production of acute phase proteins and their influence on skeletal muscle metabolism, there is 
also an increase in liver enzyme activity associated with an elevated mGPS (Brown, Milroy 
et al. 2007; Roxburgh, Wallace et al. 2010).  Overall, these results highlight the potential 
importance of a liver-derived systemic inflammatory response in the progressive nutritional 
and functional decline of patients with colorectal cancer.  It should be emphasised that these 
findings may also be applicable to benign disease.  Indeed, similar observations regarding the 
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depletion of skeletal muscle being associated with activation of the systemic inflammatory 
response have been made in non-cancer cohorts, including patients with renal failure and 
chronic obstructive airways disease (Kotler 2000; Morley, Thomas et al. 2006). 
Several previous studies investigating the clinical impact of cancer cachexia have focused 
specifically on the loss of lean tissue (Pichard, Kyle et al. 2004; Peng, van Vledder et al. 
2011).  However, in cancer patients, muscle wasting can occur with or without the loss of 
adipose tissue while in non-cancer patients there is evidence that obesity and visceral adipose 
tissue in particular are associated with a low grade inflammatory state (Saijo, Kiyota et al. 
2004; Trayhurn and Wood 2004).  In order to examine these relationships in detail we 
included measures of both adipose tissue and skeletal muscle and can now report that a 
systemic inflammatory response in patients with colorectal cancer is associated with a 
reduction in skeletal muscle as opposed to an increase in visceral adiposity.  
It is clear from the present study that a simple measure of BMI is insufficient to detect the 
changes in body composition associated with malignant disease.  This is particularly true in 
populations with an increasing prevalence of obesity; it is of interest that only 3% of patients 
in the present study were classified as underweight according to WHO classification.  Even 
the application of a cutoff value of <20, as suggested by Fearon and co-workers (Fearon, 
Strasser et al. 2011) as a more sensitive indicator of cachexia, increased this figure to only 
5%.  It is evident that traditional descriptors of body composition, such as BMI, do not have 
the capacity to adequately identify patients with reduced levels skeletal muscle (Thibault, 
Genton et al. 2012).  The present study, therefore, supports the use of cross-sectional imaging 
to assess the body composition of patients with malignant disease (Thibault and Pichard 
2012).  By comparing two widely-available software packages, we have demonstrated that 
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such analysis of CT scans is an objective and reproducible method of quantifying body 
composition.  
In the present study we chose to use sex-specific tertiles rather than specific cutoff values to 
define levels of adiposity and sarcopenia.  The most common current definition of sarcopenia 
is an appendicular skeletal muscle index more than two SDs below that of healthy adults 
(5.45 kg/m2 for females and 7.26 kg/m2 for males) (Baumgartner, Koehler et al. 1998).  
These values relate to dual-energy x-ray (DEXA) scanning and may not be readily applied to 
cross-sectional imaging.  Prado and co-workers, using CT image analysis, defined a skeletal 
muscle index of 52.4cm
2
/m
2
 in men and 38.5cm
2
/m
2
 in women as associated with mortality 
(Prado, Lieffers et al. 2008).  However, the population on which these cutoff values were 
developed was highly selective, consisting of 250 patients with an obese BMI (≥30) and a 
heterogeneous selection of respiratory tract and gastrointestinal cancers.  Application of these 
cutoff values to the present cohort would have resulted in over 70% of patients being 
classified as „sarcopenic‟; a figure which highlights the need for additional reference values 
for cross-sectional imaging modalities.  Indeed, an international consensus group on the 
diagnostic criteria for cancer cachexia concluded that definitive cutoffs for the diagnosis of 
sarcopenia still need to be determined from large contemporary datasets (Fearon, Strasser et 
al. 2011). 
This study has a number of limitations.  Height and weight data were primarily based on 
patient-reported values, although these have proven reliable in previous studies (Stunkard and 
Albaum 1981; Perry, Byers et al. 1995).  Electronic records of CT images were difficult to 
access prior to 2006 and only routinely available after 2008, meaning long term outcomes 
could not be assessed. In addition, although cancer-related weight loss is a continuous 
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process, this study only assessed body composition at a single point in time.  The changes in 
adipose tissue and skeletal muscle mass which occur over time and the relationships with 
cancer survival are of considerable interest and will be the subject of future work.  
The present study adds important objective evidence to what is often empirically accepted; 
that patients with cancer preferentially lose lean tissue during the cachectic process. In 
addition, these results highlight a direct relationship between low levels of skeletal muscle 
and the presence of a systemic inflammatory response in patients with primary operable 
colorectal cancer.   
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Figure 5.1. An example of CT image analysis using NIH ImageJ software.   (a) the original 
CT image in JPEG format, (b) the scale is set using a known distance (10cm) from the 
original CT image, (c) skeletal muscle thresholds (-29 to +150 HU) are applied, (d) the 
abdominal contents and L3 vertebrae are cropped and the skeletal muscle cross sectional area 
calculated in cm
2
.
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Figure 5.2. Flow chart representing the study selection process.  
*
 All patients undergoing potentially curative resection of colorectal cancer January 1
st
 2003 
and December 31
st
 2010. 
†
 No CT scan stored in an electronic format suitable for image analysis. 
All patients*  
(N = 548) 
 
 
No CT scan†  
(N = 314) 
Included 
(N = 174) 
 
Males = 95 (55) 
Females = 79 (45) 
Median age (range) = 70 years (36-90) 
Stage I = 27 (16) 
Stage II = 77 (44) 
Stage III = 70 (40) 
 
Excluded 
(N = 374) 
 
Males = 211 (56) 
Females = 163 (44) 
Median age (range) = 71 years (21-97) 
Stage I = 59 (16) 
Stage II = 170 (45) 
Stage III = 145 (39) 
 
No height data  
(N = 60) 
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Figure 5.3. Scatterplots of the associations between C-reactive protein, albumin and skeletal 
muscle index. Fit lines are shown for male (
 ____
) and female (-----) patients.  
r = Pearsons correlation coefficient for all patients. 
  
r = -0.21 
p = 0.005 
r = 0.31 
p < 0.001 
r = -0.46 
p < 0.001 
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Figure 5.4. The relationship between B.M.I. classification and skeletal muscle index in male 
(top panel) and female (bottom panel) patients with primary operable colorectal cancer.  
Dashed lines represent cutoff values of the sex-specific tertiles.  
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Table 5.1. Clinicopathological characteristics of patients with primary operable colorectal 
cancer.  
 
Variable  N = 174 (%) 
Clinical variables 
Age ≤ 64 51 (29) 
 65 – 74 63 (36) 
 ≥ 75 60 (35) 
Sex Female 79 (45) 
 Male  95 (55) 
ASA grade* 1 / 2 77 (44) 
 3 / 4 68 (39) 
Presentation Elective 165 (95) 
 Emergency 9 (5) 
Anaemia* None 93 (53) 
 Mild 50 (29) 
 Severe 30 (17) 
Smoking status* Never 74 (43) 
 Ex 64 (37) 
 Current 33 (19) 
Inflammatory variables 
White cell count (x109/L)* < 8.5 112 (64) 
 8.5 – 11 34 (20) 
 > 11 15 (9) 
Neutrophil:lymphocyte ratio* < 5 118 (68) 
 > 5 34 (20) 
mGPS 0 123 (71) 
 1 20 (12) 
 2 31 (18) 
Pathological variables 
Tumour site Colon 115 (66) 
 Rectum 59 (34) 
T stage T 1/2 33 (19) 
 T 3 94 (54) 
 T 4 47 (27) 
N Stage N 0 105 (60) 
 N 1 48 (28) 
 N 2 21 (12) 
TNM stage Stage I 27 (16) 
 Stage II 77 (44) 
 Stage III 70 (40) 
Venous invasion Absent 77 (44) 
 Present  97 (56) 
Differentiation  Well/mod 163 (94) 
 Poor 11 (6) 
Lymph nodes retrieved > 12 130 (75) 
 < 12 44 (25) 
 
 
* Missing values: ASA (n=29), anaemia (n=1), smoking (n=3), white cell count (n=13), 
neutrophil:lymphocyte ratio (n=22) 
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Table 5.2. Body composition parameters of patients with primary operable  
 colorectal cancer. 
 
 
 
Parameter 
Male Female 
p* 
value N (%) value N (%) 
 
Body mass index (kg/m2) 
    Mean (SD) 27.7 (6.8)  26.9 (6.2)  0.59 
    Range 18.5 – 64.5  14.5 – 47.6   
    Underweight < 18.5 1 (1) < 18.5 5 (6)  
    Normal weight 18.5 – 24.9 33 (35) 18.5 – 24.9 30 (38)  
    Overweight 25.0 – 29.9 37 (39) 25.0 – 29.9 20 (25)  
    Obese > 30 24 (25) > 30 24 (30)  
 
Total fat index (cm2/m2) 
    Mean (SD) 124.1 (52.2)  150.3 (58.6)  <0.001 
    Range 38.1 – 309.7  29.5 – 318.2   
    Sex-specific tertile “Low” 38.0 – 101.0 32 (34) 29.5 – 130.5 27 (34)  
    Sex-specific tertile “Medium” 101.0 – 134.5 32 (34) 130.5 – 177.5 27 (34)  
    Sex-specific tertile “High” 134.5 – 310.0 31 (32) 177.5 – 318.5 25 (32)  
 
Subcutaneous fat index (cm2/m2) 
    Mean (SD) 73.7 (37.5)  104.4 (44.6)  <0.001 
    Range 24.4 – 231.4  14.9 – 207.9   
    Sex-specific tertile “Low” 24.0 – 58.5 32 (34) 14.5 – 85.5 27 (34)  
    Sex-specific tertile “Medium” 58.5 – 73.5 32 (34) 85.5 – 129.5 27 (34)  
    Sex-specific tertile “High” 73.5 – 231.5 31 (32) 129.5 – 208.0 25 (32)  
 
Visceral fat index (cm2/m2) 
    Mean (SD) 50.4 (21.8)  45.9 (22.9)  0.13 
    Range 10.8 – 134.9  5.9 – 114.4   
    Sex-specific tertile “Low” 10.5 – 40.5 32 (34) 5.5 – 37.5 27 (34)  
    Sex-specific tertile “Medium” 40.5 – 55.5 32 (34) 37.5 – 50.5 27 (34)  
    Sex-specific tertile “High” 55.5 – 135.0 31 (32) 50.5 – 114.5 25 (32)  
 
Skeletal muscle index (cm2/m2) 
    Mean (SD) 46.2 (8.6)  36.9 (7.8)  <0.001 
    Range 26.9 – 68.8  24.8 – 72.2   
    Sex-specific tertile “Low” 26.5 – 42.0 32 (34) 24.5 – 32.5 27 (34)  
    Sex-specific tertile “Medium” 42.0 – 49.5 32 (34) 32.5 – 39.0 27 (34)  
    Sex-specific tertile “High” 49.5 – 69.0 31 (33) 39.0 – 72.5 25 (32)  
 
 
* Mann-Whitney U test. 
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 Table 5.3. The relationships between parameters of body composition and measures of the systemic inflammatory response in 
patients with primary operable colorectal cancer. 
 
Inflammatory 
response 
Body mass index 
(kg/m2) 
Total fat index 
(cm2/m2) 
Subcutaneous fat 
index (cm2/m2) 
Visceral fat index 
(cm2/m2) 
Skeletal muscle index 
(cm2/m2) 
under/norm/over/obese p* low/med/high p* low/med/high p* low/med/high p* low/med/high p* 
 
WCC 
< 8.5 4/43/39/26  39/39/34  41/35/36  38/44/30  39/37/36  
8.5 – 11 0/10/7/17  5/14/15  7/11/16  9/8/17  8/14/12  
> 11 0/5/6/4 0.08 6/4/5 0.34 3/8/4 0.18 4/6/5 0.15 7/6/2 0.51 
 
NLR 
< 5 3/38/42/35  34/44/40  36/41/41  38/38/42  40/38/40  
> 5 0/15/7/12 0.94 14/10/10 0.28 13/11/10 0.41 11/15/8 0.44 9/17/8 0.85 
 
mGPS 
0 3/41/46/33  41/46/36  39/45/39  39/47/37  35/41/47  
1 1/5/5/9  4/4/12  6/4/10  5/5/10  7/7/6  
2 2/17/6/6 0.09 14/9/8 0.76 14/9/8 0.40 15/7/9 0.50 17/11/3 0.001 
 
 
* X 2 linear-by-linear analysis 
WCC = white cell count 
NLR = neutrophil;lymphocyte ratio 
mGPS = modified Glasgow Prognostic Score 
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Table 5.4. The relationship between skeletal muscle index and clinico-pathological 
characteristics in patients with primary operable colorectal cancer.  
 
  
Variable  
Skeletal muscle index (cm2/m2) 
p * Low 
(n = 59) 
Medium 
(n = 59) 
High 
(n = 56) 
 
Age 
 
≤ 64 
 
8 (16) 
 
14 (27) 
 
29 (57) 
 
 65 – 74 22 (35) 24 (38) 17 (27)  
 ≥ 75 29 (48) 21 (35) 10 (17) <0.001 
 
ASA grade 1 / 2 
 
26 (34) 
 
26 (34) 
 
25 (32) 
 
 3 / 4 22 (32) 23 (34) 23 (34) 0.84 
 
Presentation Elective 
 
53 (32) 
 
58 (35) 
 
54 (33) 
 
 Emergency 6 (67) 1 (11) 2 (22) 0.11 
 
Anaemia 
 
None 
 
25 (27) 
 
30 (32) 
 
38 (41) 
 
 Mild 22 (44) 17 (34) 11 (22)  
 Severe 11 (37) 12 (40) 7 (23) 0.029 
 
Smoking status Never 
 
22 (30) 
 
30 (40) 
 
22 (30) 
 
 Ex 26 (41) 17 (27) 21 (33)  
 Current 9 (27) 11 (33) 13 (39) 0.64 
 
Tumour site Colon 
 
36 (31) 
 
40 (35) 
 
39 (34) 
 
 Rectum 23 (39) 19 (32) 17 (29) 0.33 
 
T stage 
 
T 1/2 
 
8 (24) 
 
9 (27) 
 
16 (49) 
 
 T 3 35 (37) 32 (34) 27 (29)  
 T 4 16 (34) 18 (38) 13 (28) 0.08 
 
N stage 
 
N 0  
 
35 (33) 
 
34 (32) 
 
36 (34) 
 
 N 1 18 (38) 17 (35) 13 (27)  
 N 2 6 (29) 8 (38) 7 (33) 0.85 
 
TNM stage Stage I 
 
6 (22) 
 
7 (26) 
 
14 (52) 
 
 Stage II 29 (38) 26 (34) 22 (29)  
 Stage III 24 (34) 26 (37) 20 (29) 0.14 
 
Venous invasion 
 
Absent 
 
24 (31) 
 
28 (36) 
 
25 (33) 
 
 Present  35 (36) 31 (32) 31 (32) 0.66 
 
Differentiation  
 
Well/mod 
 
55 (34) 
 
54 (33) 
 
54 (33) 
 
 Poor 4 (36) 5 (46) 2 (18) 0.49 
 
Lymph nodes retrieved 
 
> 12 
 
42 (32) 
 
47 (36) 
 
41 (32) 
 
 < 12 17 (39) 12 (27) 15 (34) 0.79 
 
* X 2 linear-by-linear analysis. 
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6.0 THE IMPACT OF PREOPERATIVE RISK FACTORS, TUMOUR 
PATHOLOGY AND POSTOPERATIVE COMPLICATIONS ON DISEASE 
RECURRENCE FOLLOWING POTENTIALLY CURATIVE RESECTION OF 
COLORECTAL CANCER.  
6.1 Introduction 
As described in Chapter 1, the identification of patients with colorectal cancer who are at risk 
of developing disease recurrence following potentially curative surgery is currently reliant on 
tumour stage or the presence of „high risk‟ pathological criteria such as vascular invasion, 
perineural invasion and resection margin status.   
Recently, there has been considerable interest in the impact of postoperative complications on 
colorectal cancer recurrence.  McArdle and coworkers  initially reported that, in a prospective 
cohort of 2,235 patients undergoing potentially curative resection, the presence of 
anastomotic leak was associated with poorer disease specific survival, independent of tumour 
stage (McArdle, McMillan et al. 2005).  This observation has been repeated by a number of 
studies reporting an association between surgical complications and increased risk of 
colorectal cancer recurrence (Bell, Walker et al. 2003; Walker, Bell et al. 2004).  
Although the impact of complications on postoperative mortality is intuitive, the mechanism 
by which they contribute to reduced long-term survival has not been defined.  One hypothesis 
is that pro-inflammatory cytokines released during major infective complications stimulate 
residual tumour growth and result in higher rates of disease recurrence (Balkwill and 
Mantovani 2001).  An alternative hypothesis is that postoperative complications are simply a 
surrogate marker for underlying preoperative patient-related risk factors, and it is these that 
are the true determinants of outcome.  Indeed, there is now evidence that an elevated 
preoperative systemic inflammatory response, a predictor of survival following colorectal 
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cancer resection (Chapter 1), is also associated with the development of postoperative 
infective complications (Moyes, Leitch et al. 2009).  Furthermore, altered preoperative 
patient physiology, itself a risk factor for surgical complications, appears to also predict long 
term survival following colorectal cancer surgery (Chapter 3).   
Despite the above evidence, few studies have assessed the relative importance of 
preoperative, pathological and postoperative variables in a single cohort.  The aim of the 
present study was, therefore, to examine the impact of preoperative risk factors, tumour 
pathology and postoperative complications on disease recurrence following potentially 
curative resection of colorectal cancer. 
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6.2 Materials and Methods 
Patients with histologically proven colorectal cancer who were considered to have undergone 
potentially curative resection for colorectal cancer between January 1
st
 1997 and December 
31
st
 2007 were identified from the same prospective database described in Chapter 3.  The 
tumours were staged according to conventional AJCC/TNM classification (5
th
 Edition) 
(Fleming ID 1997).  
Preoperative patient physiology was assessed according to the POSSUM criteria described in 
Chapter 3. Preoperative systemic inflammatory response was assessed using the modified 
Glasgow Prognostic Score (mGPS) (Chapter 3).  
Postoperative mortality and morbidity were recorded as in-hospital rates. All postoperative 
complications were recorded and categorised as infective or non-infective. Infective 
complications were classified as surgical site infections (SSI) or remote site infections (RSI) 
while non-infective complications were classified by system (cardiovascular, respiratory) as 
suggested by the Centers for Disease Control and Prevention (CDC) (Mangram, Horan et al. 
1999).   
Patients who survived to discharge were reviewed at one month postoperatively, at 6 month 
intervals for 2 years and then annually until five years post surgery.  The follow up regime 
included annual computed tomography of the chest, abdomen and pelvis and colonoscopic 
surveillance every 3 years.  Disease recurrence was defined as local (colon, pelvis or 
peritoneum) or systemic (hepatic, pulmonary or multi-organ) on the basis of clinical, 
endoscopic or radiological findings at the time of diagnosis.  
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All survival analysis was carried out after excluding postoperative deaths. Information on 
date and cause of death was cross-checked with that received by the cancer registration 
system and the Registrar General (Scotland).  Death records were complete until 31
st
 July 
2010, which served as the censor date.  Disease-free survival was measured from the date of 
surgery until the date of documented disease recurrence or death from colorectal cancer; 
overall survival from the date of surgery to the date of death from any cause.  The study was 
approved by the West of Scotland Research Ethics Committee (WoSREC), Glasgow. 
Statistics 
Grouping of variables was carried out using standard or previously published thresholds.  
Comparison of categorical variables was performed using binary logistic regression; variables 
significant on univariate analysis were entered into a multivariate model.  All survival 
analyses were performed using Cox proportional hazards regression; variables significant on 
univariate analysis were entered into a multivariate model, using a backward conditional 
method.  P values of less than 0.05 were considered statistically significant. Statistical 
analysis was performed using SPSS
®
 version 19.0 (IBM SPSS, Illinois, USA). 
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6.3 Results 
A total of 423 patients who underwent potentially curative surgery for colorectal cancer were 
included.  Baseline preoperative, pathological and postoperative characteristics of the patients 
are shown in Table 6.1.  The majority of patients were older than 65 years (67%) with a 
similar number of males and females.  More than half the patients (59%) lived in areas with 
the highest deprivation scores and were either ex or current smokers (57%).  The majority of 
operations were elective (93%) and all resections were performed via open surgery.  The 
operations were carried out for both colonic (62%) and rectal (38%) tumours and the overall 
rate of neo-adjuvant therapy was 5% (13% of rectal tumours).  The majority of patients had 
no evidence of preoperative systemic inflammation (mGPS) (58%) and had physiology 
scores between 11 and 20 (75%).  Pathological reports classified 12% of tumours as Stage I, 
44% as Stage II and 44% as Stage III.  The rates of vascular (intramural and extramural) and 
perineural invasion were 43% and 11% respectively.  The tumour extended to the surgical 
resection margins in 13% of cases (this included cases where tumour cells were present on 
the peritoneal surface of the resected specimen).  In the postoperative period, 17 patients died 
(in-hospital mortality rate = 4%) and a 142 patients developed at least one complication (in-
hospital morbidity rate = 34%).  A total of 20% of patients received adjuvant therapy and 
35% of patients developed disease recurrence in the follow up period (Table 6.1).  
The details and classification of postoperative complications are shown in Table 6.2.  The 
majority of complications were infective (74%) with surgical site infections (SSI) the most 
prevalent subtype (43%).  Remote site infections (RSI) were predominantly pneumonia 
(20%) and urinary tract infection (6%).  Approximately one third (32%) of complications 
were non-infective; the majority of which related to the cardiovascular (18%) and respiratory 
systems (5%) (Table 6.2).   
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The relationships between preoperative variables and the development of postoperative 
complications are shown in Table 6.3.  On univariate analysis, age (p<0.05), smoking status 
(p<0.01), emergency presentation (p<0.01), systemic inflammation (mGPS) (p<0.01) and 
POSSUM physiology score (p<0.001) were significantly associated with postoperative 
complications.  On multivariate analysis, smoking status (OR 1.38, 95% CI 1.06 – 1.82, 
p=0.019) and POSSUM physiology score (OR 1.66, 95% CI 1.17 – 2.27, p<0.001) remained 
independently associated with the development of postoperative complications (Table 6.3).  
When infective complications were considered alone; univariate analysis reported an 
association with deprivation (p<0.05), smoking status (p<0.01), emergency presentation 
(p<0.01), systemic inflammation (mGPS) (p<0.01) and POSSUM physiology score (p<0.05). 
On multivariate analysis, smoking status (OR 1.70, 95% CI 1.27 – 2.29, p<0.001) and 
emergency presentation (OR 3.27, 95% CI 1.45 – 7.36, p=0.004) remained independently 
associated with the development of infective complications. When non-infective 
complications were considered alone; univariate analysis reported an association with age 
(p<0.001), smoking status (p<0.05) and POSSUM physiology score.  On multivariate 
analysis, age (OR 2.42, 95% CI 1.51 – 3.90, p<0.001) and POSSUM physiology score (OR 
1.55, 95% CI 1.03 – 2.32, p=0.036) remained independently associated with the development 
of non-infective complications.   
The median follow up for survivors was 80 months (range 37 – 158).  During this period 142 
patients developed disease recurrence, 124 patients died from colorectal cancer and 72 
patients died from other causes.  The relationships between preoperative, pathological and 
postoperative variables and disease-free survival are shown in Table 6.4a.  On univariate 
analysis, age (p<0.05), deprivation (p<0.01), smoking (p<0.05), presentation (p<0.001), 
systemic inflammation (mGPS) (p<0.001), POSSUM physiology score (p<0.001), TNM 
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stage (p<0.001), vascular invasion (p<0.001), perineural invasion (p<0.001) and margin 
involvement (p<0.001) were significantly associated with disease-free survival.  On 
multivariate analysis, smoking status (HR 1.25, 95% CI 1.01 – 1.55, p=0.043), systemic 
inflammation (mGPS) (HR 1.31, 95% CI 1.04 – 1.65, p=0.021), POSSUM physiology score 
(HR 1.31, 95% CI 1.06 – 1.63, p=0.012), TNM stage (HR 1.87, 95% CI 1.37 – 2.55, 
p<0.001) and margin involvement (HR 4.72, 95% CI 3.20 – 6.96, p<0.001) were 
independently associated with disease-free survival (Table 6.4a).  
The relationships between preoperative, pathological and postoperative variables and overall 
survival are shown in Table 6.4b.  On univariate analysis, age (p<0.001), deprivation 
(p<0.01), smoking (p<0.01), presentation (p<0.01), systemic inflammation (mGPS) 
(p<0.001), POSSUM physiology score (p<0.001), TNM stage (p<0.001), vascular invasion 
(p<0.001), perineural invasion (p<0.001), margin involvement (p<0.001) and any 
postoperative complication (p<0.05) were significantly associated with overall survival.  On 
multivariate analysis, age (HR 1.48, 95% CI 1.23 – 1.79, p<0.001), smoking status (HR 1.33, 
95% CI 1.10 – 1.60, p=0.003), systemic inflammation (mGPS) (HR 1.28, 95% CI 1.05 – 
1.57, p=0.015), POSSUM physiology score (HR 1.24, 95% CI 1.03 – 1.49, p=0.025), TNM 
stage (HR 1.52, 95% CI 1.17 – 1.96, p=0.002) and margin involvement (HR 3.62, 95% CI 
2.50 – 5.25, p<0.001) were independently associated with overall survival (Table 6.4b).  
The site of recurrence was classified as local in 36 patients (25%), including metastases to the 
colon (n=17), pelvis (n=9) or peritoneum (n=10).  Recurrence was classified as systemic in 
101 patients (71%), including metastases to the liver (n=55), lung (n=13) or multiple organs 
(n=33). In the remaining 5 patients (4%), disease recurrence was diagnosed clinically with no 
imaging to confirm the site.  
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The relationships between site of disease recurrence and the variables associated with 
reduced disease-free survival are shown in Table 6.5.  On univariate analysis, smoking status 
(p<0.05) and vascular invasion (p<0.05) were significantly associated with systemic, rather 
than local, disease recurrence.  No other variables were associated with recurrence to a 
particular site.  
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6.4 Discussion 
The results of the present study show that smoking status, patient physiology and systemic 
inflammation are associated with early disease recurrence, independent of tumour stage, 
following potentially curative resection of colorectal cancer.  Furthermore, these same 
preoperative variables are associated with the development of postoperative complications. 
Taken together, these results suggest that preoperative patient-related factors are important 
determinants of both short and long term outcome following colorectal cancer resection.   
In Chapter 3, patient physiology was shown to be an independent predictor of survival 
following potentially curative resection of colorectal cancer.  These results now demonstrate 
that altered physiology is a risk factor for both postoperative complications and early disease 
recurrence.  In addition, despite considerable evidence that the systemic inflammatory 
response is associated with poor outcome from a range of solid organ tumours (Chapter 1), 
the present study confirms, for the first time, an association between systemic inflammation 
and early recurrence following colorectal cancer resection.   
With reference to smoking, our results are in line with previous reports.  There is now 
consistent evidence that cigarette smoking increases the risk of postoperative complications 
following a range of surgical procedures, including colorectal cancer resection (Sorensen, 
Jorgensen et al. 1999; Nickelsen, Jorgensen et al. 2005).  There is also evidence that smoking 
shortens survival following curative resection of colorectal cancer (Munro, Bentley et al. 
2006; Carsin, Sharp et al. 2008). The present study suggests the mechanism behind this 
association may be an increased risk of early systemic metastases. 
Previous studies have reported that postoperative complications are associated with poorer 
long term survival after major surgery (Khuri, Henderson et al. 2005).  In the present study, 
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the development of a postoperative complication was not independently associated with 
reduced disease-free or overall survival after colorectal cancer resection.  Several possibilities 
may be considered to explain these apparent differences.  The study by Khuri and co-
workers, one of the largest to date, reported only overall survival while the present study 
investigated disease specific outcome. Indeed, the present results did initially suggest an 
association between complications and overall survival; this only became non-significant 
after correction for preoperative risk factors.  Importantly, the number of patients in the 
current study precluded meaningful sub-analysis of individual complications and it remains a 
possibility that only major infective complications, such as anastomotic leak, have an adverse 
influence on long term outcomes.  
Results from the present study have implications for our understanding of how morbidity 
following cancer surgery may influence survival.  Previous hypotheses relating postoperative 
complications to poorer survival were based on the paradigm that infective complications 
initiated an inflammatory cascade, including the release of pro-inflammatory cytokines and 
vascular growth factors, which promoted tumour growth and dissemination (Abramovitch, 
Marikovsky et al. 1999).  In the event of an anastomotic leak, it has been suggested that 
malignant cells may „spill‟ into the pelvis with subsequent implantation and local recurrence 
(O'Dwyer and Martin 1989).  The present results suggest that, rather than being the cause of 
disease recurrence, surgical complications are a consequence of poor patient physiology 
coupled with a  pro-inflammatory state; the true determinants of long term outcome.  
The mechanisms underlying the relationship between smoking, patient physiology, the 
systemic inflammatory response and disease recurrence are likely to be complex.  There is 
now considerable evidence that a strong inflammatory cell infiltrate within and around the 
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tumour has a protective effect on disease progression in colorectal cancer (Chapter 1).  One 
hypothesis, therefore, is that physiological dysfunction or a systemic inflammatory response 
impairs the ability of the host to mount an effective local immune response.   Further work is 
needed to clarify the relationships between physiological function, the systemic inflammatory 
response and immune response within the tumour microenvironment.  
The reported impact of preoperative factors on disease recurrence may also have implications 
for staging and pre-surgical optimization of patients about to undergo potentially curative 
resection of colorectal cancer.  With reference to staging, there is now evidence that the 
combination of positron emission tomography and computed tomography (PET/CT) can 
increase the detection rate of colorectal metastases prior to surgery (Orlacchio, Schillaci et al. 
2009).  It may be that patients with a pronounced inflammatory response represent those who 
already have tumour dissemination, undetectable with current imaging modalities.  Patients 
with an elevated mGPS prior to surgery thus represent a cohort who may benefit from such 
additional staging modalities.   
With regard to improving preoperative physiological function, more emphasis should be 
placed on „multimodal‟ approach; utilizing medication review, exercise programmes, 
smoking cessation and a period of intensive inpatient cardiovascular optimization for those at 
highest risk (Khoo, Vickery et al. 2007).   
From the present and previous studies there is now consistent evidence that preoperative risk 
factors predict short and long term outcome after colorectal cancer surgery.  Despite this, few 
studies have been undertaken to test whether manipulation of such factors is associated with 
improved outcome.  There is some evidence that smoking cessation (Kenfield, Stampfer et al. 
2008), exercise programmes (Meyerhardt, Giovannucci et al. 2009) or the routine 
166 
 
administration of anti-inflammatory medication (Chan, Ogino et al. 2009) has a positive 
impact on colorectal cancer survival but further prospective studies, specifically targeting the 
risk factors highlighted in the current study, are warranted.  
In summary, the present study reports that preoperative risk factors, including smoking status, 
patient physiology and systemic inflammation, are associated with the both the development 
of postoperative complications and early disease recurrence following potentially curative 
resection of colorectal cancer. 
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Table 6.1. Preoperative, pathological and postoperative characteristics of 423 patients 
undergoing potentially curative resection of colorectal cancer.  
 
 
Variable 
 
Patient group 423 (%) 
 
Preoperative variables 
Age ≤ 64 140 (33) 
 65 – 74 135 (32) 
 ≥ 75 148 (35) 
Sex Male 230 (54) 
 Female 193 (46) 
Deprivation score 1 - 2 20 (5) 
 3 - 5 150 (36) 
 6 - 7 241 (59) 
Smoking status Non smoker 183 (43) 
 Ex smoker 150 (36) 
 Current smoker 90 (21) 
Presentation Elective  395 (93) 
 Emergency 28 (7) 
Tumour site Colon 254 (62) 
 Rectum 159 (38) 
Neo-adjuvant therapy Yes 21 (5) 
 No 402 (95) 
Systemic inflammation mGPS = 0 246 (58) 
 mGPS = 1 114 (27) 
 mGPS = 2 63 (15) 
POSSUM physiology score  11 – 14  143 (33) 
 15 – 20 177 (42) 
 21 – 30  92 (22) 
 > 30 11 (3) 
 
Pathological criteria 
TNM stage Stage I 51 (12) 
 Stage II 186 (44) 
 Stage III 186 (44) 
Vascular invasion Yes 181 (43) 
 No 242 (57) 
Perineural invasion Yes 48 (11) 
 No 371 (88) 
Margin involvement Yes 54 (13) 
 No 366 (87) 
 
Postoperative outcome 
In-hospital mortality Yes 17 (4) 
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 No 406 (96) 
In-hospital morbidity  Yes 142 (34) 
 No 281 (66) 
Adjuvant therapy Yes 86 (20) 
 No 337 (80) 
Disease recurrence Yes 142 (35) 
 No 264 (65) 
Status at censor date Alive 210 (52) 
 Colorectal cancer death 124 (30) 
 Non-cancer death 72  (18) 
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Table 6.2. Classification of postoperative complications recorded in 423 patients following 
potentially curative resection of colorectal cancer.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Classification of complication 
 
 
142 (%) 
 
Infective  
 
 
105 (74)* 
    
   Surgical site infection  
 
 
61 (43) 
      -  Anastomotic leak 18 (13) 
      -  Intra-abdominal abcess 33 (23) 
      -  Wound 31 (22) 
    
   Remote site infection 
 
 
46  (32) 
     -  Pneumonia 29 (20) 
     -  UTI 8 (6) 
     -  GI tract 7 (5) 
     -  Other 5  (4) 
 
Non-infective 
 
 
45 (32)* 
    
   Cardiovascular 
  
 
25 (18) 
     - Atrial fibrillation 11 (8) 
     - Acute Coronary Syndrome 10 (7) 
     - Other 4 (3) 
   
   Respiratory 
  
 
7 (5) 
     - Pulmonary Embolus 3 (2) 
     - Pulmonary Oedema 3 (2) 
     - Pleural Effusion 1 (1) 
    
   Miscellaneous  
 
 
13 (9) 
 
* Values do not equal 100% as several patients had more than one complication 
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Table 6.3. The relationships between preoperative variables and the development of 
postoperative complications. 
 
 
Variable Patient 
Group 
Patients 
with  
complication 
 n (%) 
Univariate 
 
Multivariate 
 
OR (95% C.I.) p  OR (95% C.I.) p 
 
Age 
 
< 65  
 
38 (27)     
 65 – 74  44 (33)     
 ≥ 75  60 (40) 1.36 (1.06, 1.74) 0.016  0.127 
 
Sex 
 
Male 
 
84 (36)    
 
 Female 58 (30) 1.34 (0.89, 2.01) 0.161   
 
Deprivation 
score 1 – 2 5 (25)     
 3 – 5 45 (30)     
 6 - 7 86 (36) 1.29 (0.90, 1.85) 0.162   
 
Smoking status 
 
Non  
 
50 (27)    
 
 Ex  52 (35)     
 Current   40 (44) 1.45 (1.12, 1.89) 0.005 1.38 (1.06, 1.82) 0.019 
 
Presentation 
 
Elective  
 
126 (32)    
 
 Emergency 16 (57) 2.85 (1.31, 6.20) 0.008  0.097 
 
Tumour site Colon 88 (33)    
 
 Rectum 54 (35) 1.13 (0.75, 1.70) 0.581   
 
Neo-adjuvant Rx Yes 6 (29)    
 
 No 99 (25) 1.23 (0.50, 3.04) 0.653   
 
Systemic 
inflammation 
 
mGPS = 0 
 
70 (28)    
 
 mGPS = 1 44 (39)     
 mGPS = 2 28 (44) 1.45 (1.11, 1.90) 0.007  0.192 
 
POSSUM 
physiology score 
 
11 – 14  
 
33 (23)    
 
 15 – 20  61 (35)     
 21 – 30 41 (45)     
 > 30 7 (64) 1.68 (1.30, 2.16) <0.001 1.66 (1.17, 2.27) <0.001 
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Table 6.4a. The relationships between preoperative, pathological and postoperative variables 
and disease-free survival; cox regression analysis (In-hospital mortality has been excluded). 
 
 
 
 
Variable Univariate Multivariate 
HR (95% C.I.) p  HR (95% C.I.) p  
Preoperative variables 
Age 1.25 (1.03, 1.52) 0.028  0.660 
Sex 1.30 (0.94, 1.80) 0.116   
Deprivation 1.56 (1.15, 2.13) 0.004  0.183 
Smoking status 1.25 (1.02, 1.53) 0.035 1.25 (1.01, 1.55) 0.043 
Presentation 2.60 (1.52, 4.43) <0.001  0.422 
Tumour site 0.77 (0.55, 1.08) 0.134 
 
 
 
Neo-adjuvant therapy 1.39 (0.73, 2.65) 0.313   
mGPS 1.42 (1.15, 1.74) <0.001 1.31 (1.04, 1.65) 0.021 
POSSUM physiology score 1.46 (1.20, 1.79) <0.001 1.31 (1.06, 1.63) 0.012 
Pathological criteria 
TNM stage 2.16 (1.63, 2.85) <0.001 1.87 (1.37, 2.55) <0.001 
Vascular invasion 2.49 (1.79, 3.46) <0.001  0.117 
Perineural invasion 2.52 (1.67, 3.79) <0.001  0.525 
Margin involvement 5.56 (3.85, 8.03) <0.001 4.72 (3.20, 6.96) <0.001 
Postoperative variables 
Any complication 1.25 (0.89, 1.77) 0.197   
Infective complication 1.06 (0.72, 1.56) 0.762   
Non-infective complication 1.28 (0.75, 2.18) 0.371   
Adjuvant therapy 1.14 (0.77, 1.67) 0.517   
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Table 6.4b. The relationships between preoperative, pathological and postoperative variables 
and overall survival; cox regression analysis (In-hospital mortality has been excluded). 
 
 
 
 
Variable Univariate Multivariate 
HR (95% C.I.) p  HR (95% C.I.) p  
Preoperative variables 
Age 1.55 (1.30, 1.85) <0.001 1.48 (1.23, 1.79) <0.001 
Sex 1.22 (0.92, 1.61) 0.171   
Deprivation 1.44 (1.10, 1.87) 0.007  0.242 
Smoking status 1.30 (1.09, 1.55) 0.004 1.33 (1.10, 1.60) 0.003 
Presentation 2.34 (1.42, 3.86) 0.001  0.370 
Tumour site 1.02 (0.77, 1.36) 0.883 
 
 
 
Neo-adjuvant therapy 0.96 (0.51, 1.82) 0.902   
mGPS 1.39 (1.16, 1.67) <0.001 1.28 (1.05, 1.57) 0.015 
POSSUM physiology score 1.47 (1.23, 1.75) <0.001 1.24 (1.03, 1.49) 0.025 
Pathological criteria 
TNM stage 1.73 (1.38, 2.18) <0.001 1.52 (1.17, 1.96) 0.002 
Vascular invasion 1.99 (1.50, 2.64) <0.001  0.337 
Perineural invasion 2.13 (1.44, 3.14) <0.001  0.295 
Margin involvement 4.62 (3.27, 6.53) <0.001 3.62 (2.50, 5.25) <0.001 
Postoperative variables 
Any complication 1.36 (1.01, 1.82) 0.044  0.788 
Infective complication 1.26 (0.91, 1.74) 0.163   
Non-infective complication 1.18 (0.73, 1.92) 0.499   
Adjuvant therapy 0.86 (0.61, 1.23) 0.420   
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Table 6.5.  The relationships between variables significantly associated with reduced disease-
free survival and site of disease recurrence; linear-by-linear association. 
 
 
  
Variable Patient group Local 
recurrence 
36 (%) 
Systemic recurrence 
101 (%) 
 
p 
 
Age 
 
< 65  
 
11 (24) 
 
34 (76) 
 
 65 – 74  10 (23) 34 (77)  
 ≥ 75  15 (31) 33 (69) 0.451 
 
Deprivation 1 – 2 
 
0 (0) 
 
3 (100) 
 
 3 – 5 14 (33) 28 (67)  
 6 - 7 21 (24) 67 (76) 0.609 
 
Smoking Non  
 
19 (37) 
 
33 (63) 
 
 Ex  11 (22) 40 (78)  
 Current   6 (18) 28 (82) 0.041 
 
Presentation 
 
Elective  
 
30 (25) 
 
92 (75) 
 
 Emergency 6 (40) 9 (60) 0.202 
 
Systemic inflammation mGPS = 0 
 
22 (30) 
 
51 (70) 
 
 mGPS = 1 9 (23) 30 (77)  
 mGPS = 2 5 (20) 20 (80) 0.270 
 
POSSUM physiology score 
 
11 – 14  
 
12 (32) 
 
26 (68) 
 
 15 – 20  9 (16) 48 (84)  
 21 – 30 14 (40) 21 (60)  
 > 30 1 (14) 6 (86) 0.802 
 
TNM stage 
 
Stage I 
 
1 (14) 
 
6 (86) 
 
 Stage II 13 (29) 32 (71)  
 Stage III 22 (26) 63 (74) 0.869 
 
Vascular invasion 
 
No 
 
20 (35) 
 
37 (65) 
 
 Yes 16 (20) 64 (80) 0.048 
 
Perineural invasion 
 
No 
 
29 (27) 
 
79 (73) 
 
 Yes 7 (25) 21 (75) 0.844 
 
Margin involvement 
 
No 
 
26 (26) 
 
72 (74) 
 
 Yes 10 (26) 29 (74) 0.915 
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7.0 THE RELATIONSHIPS BETWEEN TUMOUR NECROSIS AND HOST 
INFLAMMATORY RESPONSES IN PRIMARY OPERABLE COLORECTAL 
CANCER.  
7.1 Introduction 
It is now recognized that colorectal cancer outcome is dependent on interactions between 
tumour and host related factors.  The host inflammatory response plays a key role in disease 
progression and has the capacity to either promote or inhibit tumour growth. There is now 
good evidence that an elevated systemic inflammatory response is detrimental to survival 
while a pronounced inflammatory cell infiltrate at a local level has been consistently 
associated with improved clinical outcome (Chapter 1). The evidence to date suggests that 
these host responses are acting independently and as yet there has been no documented link 
between local and systemic inflammation.  
Tumour necrosis has recently been proposed as a prognostic marker in colorectal cancer 
(Pollheimer, Kornprat et al. 2010).  This follows a number of similar studies reporting 
necrosis as a marker of poor prognosis in renal, breast and lung carcinoma (Fisher, Palekar et 
al. 1978; Frank, Blute et al. 2002; Swinson, Jones et al. 2002).  The mechanisms 
underpinning the relationship between necrosis and cancer survival, however, are unclear. 
One plausible hypothesis is that tumour necrosis may impact on colorectal cancer survival by 
influencing the host inflammatory responses.  Indeed, there is evidence from other cancer 
types that tumour necrosis is associated with markers of systemic inflammation, such as 
serum white cell count and erythrocyte sedimentation rate (ESR) (Sengupta, Lohse et al. 
2005), as well as alterations in the local recruitment of inflammatory cells (Carlomagno, 
Perrone et al. 1995).   The aim of the present study was to investigate the prognostic value of 
tumour necrosis in colorectal cancer and to examine its relationships with the host systemic 
and local inflammatory responses. 
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7.2 Materials and Methods 
Patients with colorectal cancer who were considered to have undergone potentially curative 
resection of colorectal cancer between January 1997 and December 2007 were identified 
from the same prospective database described in Chapter 3.   
The tumours were staged according to conventional AJCC/TNM classification (5
th
 Edition) 
(Fleming ID 1997). Additional high risk pathological features were recorded from reports 
issued at the time.  The Petersen Index (PI) was constructed from scores allocated to four 
selected pathological variables present in the tumour specimen. Intra or extramural vascular 
invasion, peritoneal involvement and margin involvement were allocated a score of 1 and 
tumour perforation was allocated a score of 2. The cumulative total is calculated and the PI 
considered low risk (score 0 – 1) or high risk (score 2 – 5) (Petersen, Baxter et al. 2002). 
Preoperative systemic inflammatory response was assessed using the modified Glasgow 
Prognostic Score (mGPS) as described in Chapter 1. Routine laboratory measurements of 
haemoglobin (Hb), white cell count (WCC), albumin and C-reactive protein (CRP) were 
recorded prior to surgery.  Using local reference ranges, anaemia was defined as a Hb 
concentration <13.0g/dl in males and <11.5g/dl in females.  Severe anaemia was defined as a 
Hb measurement <11.0g/dl in males and <10.0g/dl in females (Hamilton, Lancashire et al. 
2008).  
Assessment of both the local inflammatory cell infiltrate and tumour necrosis was undertaken 
on the same original haematoxylin and eosin (H&E) sections. The sections were selected 
from areas of the central tumour felt to represent the maximum depth of tumour invasion. A 
median of 3 sections (range 2 – 5) were examined per patient.  The local inflammatory cell 
infiltrate had been previously assessed in the cohort according to the Klintrup-Makinen (K-
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M) criteria (Roxburgh, Salmond et al. 2009).  Briefly, the invasive margin of each tumour 
was scored according to a 4 point scale.  A score of 0 indicated there was no increase in 
inflammatory cells; score 1 denoted a mild or patchy increase; score 2 denoted a prominent 
inflammatory reaction and score 3 denoted a florid „cup-like‟ inflammatory infiltrate.  The 
inflammatory cell infiltrate was subsequently classified as low grade (score 0 - 1) or high 
grade (score 2 - 3).  The inter-observer intra-class correlation coefficient (ICC) for the 
assessment of the inflammatory cell infiltrate was 0.81. 
Assessment of tumour necrosis was undertaken according to the methodology of Pollheimer 
and coworkers (Pollheimer, Kornprat et al. 2010).  The sections were examined at low 
magnification (x40) for evidence of tumour necrosis.  The extent of necrosis was 
semiquantitatively assessed and, using published thresholds, graded as „absent‟ (none), 
„focal‟ (< 10% of tumour area), „moderate‟ (10 - 30% of tumour area) or „extensive‟ (> 30% 
of tumour area) in each section before an assessment was made of the overall extent of 
necrosis.    To test consistency of scoring, 50 cases were examined independently by two 
observers (CHR and CSDR) blinded to clinical outcome. The ICC for the assessment of 
tumour necrosis was 0.86.  CHR then scored all cases and these data were used in the 
analysis. Figure 7.1 provides examples of the four necrosis categories. 
Information on date and cause of death was cross-checked with that received by the cancer 
registration system and the Registrar General (Scotland).  Death records were complete until 
1
st
 December 2010, which served as the censor date.  Cancer specific survival was measured 
from the date of surgery until the date of death from colorectal cancer.  The study was 
approved by the West of Scotland Research Ethics Committee (WoSREC), Glasgow. 
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Statistics 
Grouping of variables was carried out using standard or previously published thresholds.  
Associations between categorical variables were examined using chi square tests for linear 
trend.  Survival analyses were performed using Cox proportional hazards regression to 
calculate hazard ratios (HR). All variables significant on univariate analysis were entered into 
a multivariate model using a backwards conditional method.  P values of less than 0.05 were 
considered statistically significant. Statistical analyses were performed using SPSS
®
 version 
19.0 (IBM SPSS, Illinois, USA). 
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7.3 Results 
A total of 343 patients who underwent potentially curative resection of colorectal cancer were 
included.  Summary characteristics of the cohort are shown in Table 7.1.  The majority of 
patients were 65 years or older (65%) with a similar number of males and females.  The 
majority of operations were carried out electively (94%) and all were performed by open 
surgery.  The resections were carried out for both colonic (69%) and rectal (31%) cancer and 
pathological reports classified the tumours as Stage I (7%), Stage II (49%) or Stage III (44%).  
The Petersen Index classified 81% of the tumours as low risk and 19% as high risk.  There 
was no evidence of a systemic inflammatory response in the majority of patients (56%) while 
the local inflammatory cell infiltrate was classified as low grade in 65% of cases and high 
grade in 35% (Table 7.1).    
Tumour necrosis was graded as „absent‟ in 32 cases (9%), „focal‟ in 166 cases (48%) , 
„moderate‟ in 101 cases (29%) and „extensive‟ in 44 cases (13%).  The relationships between 
tumour necrosis and clinico-pathological variables in all patients are shown in Table 7.1.  
There were significant relationships between tumour necrosis and both systemic 
inflammatory response (p<0.001) and local inflammatory cell infiltrate (p=0.004). To 
examine whether these associations were independent of tumour stage, the analyses were 
repeated in patients with node negative disease (Table 7.2).   
The median follow up for the survivors was 96 months (range 45 – 167 months).  During this 
period, 103 patients died from colorectal cancer and 78 patients died from other causes.  The 
Kaplan-Meier survival curve, demonstrating a significant association between tumour 
necrosis and reduced cancer specific survival, is shown in Figure 7.2.   
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The multivariable survival analyses for all patients are shown in Table 7.3.  When all 
variables were considered (Model 1), age (HR 1.29, p=0.050), systemic inflammatory 
response (HR 1.74, p=0.001), low grade local inflammatory cell infiltrate (HR 2.65, 
p=0.001), TNM stage (HR 1.55, p=0.041) and high risk Petersen Index (HR 3.50, p<0.001) 
were independently associated with reduced cancer specific survival.  When the systemic and 
local inflammatory responses were removed from the model (Model 2), age (HR 1.28, 
p=0.062), TNM stage (HR 1.62, p=0.020), high risk Petersen Index (HR 3.43, p<0.001) and 
tumour necrosis (HR 1.35, p=0.027) were independently associated with cancer specific 
survival (Table 7.3).   
These analyses were then repeated in patients with node negative disease (Table 7.4).  When 
all variables were considered (Model 1), age (HR 1.78, p=0.005), systemic inflammatory 
response (HR 1.71, p=0.019), low grade local inflammatory cell infiltrate (HR 3.33, p=0.002) 
and high risk Petersen Index (HR 4.67, p<0.001) were independently associated with reduced 
cancer specific survival.  When the systemic and local inflammatory responses were removed 
from the model (Model 2), age (HR 1.84, p=0.004) and high risk Petersen Index (HR 4.07, 
p<0.001) were independently associated with cancer specific survival (Table 7.4).  
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7.4 Discussion 
The present study confirms tumour necrosis as a marker of poor prognosis, independent of 
pathological stage, in patients with primary operable colorectal cancer.  Necrosis is directly 
associated with both an elevation of the systemic inflammatory response and an attenuation 
of the local inflammatory cell infiltrate.  This suggests that the impact of tumour necrosis on 
colorectal cancer survival may be explained by close relationships with the host inflammatory 
responses. 
Previously, tumour necrosis has shown prognostic value in a variety of solid organ tumours 
including renal (Frank, Blute et al. 2002), breast (Fisher, Palekar et al. 1978), lung (Swinson, 
Jones et al. 2002) and colorectal malignancy (Gao, Arbman et al. 2005; Pollheimer, Kornprat 
et al. 2010). It is clear from these studies that necrosis is not an isolated pathological feature 
but is strongly related to aggressive tumour characteristics including size, grade and 
pathological stage.  The present study now confirms that tumour necrosis is associated 
specific pathological characteristics pertinent to colorectal cancer progression, namely 
vascular invasion, peritoneal involvement, margin involvement and tumour perforation. The 
relationship with these pathological variables, however, cannot adequately explain the 
influence of tumour necrosis on colorectal cancer outcome.  Indeed, the present results 
confirm necrosis as a marker of poor prognosis, independent of tumour stage.  We therefore 
hypothesized that the mechanisms underpinning the relationships between necrosis and 
survival may instead involve interactions with patient related variables, in particular those 
relating to the inflammatory response.   
The impact of inflammation on cancer outcome has received significant attention in recent 
years.  Studies now indicate that a preoperative systemic inflammatory response is one of the 
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most important factors in determining both short and long term outcomes in patients 
undergoing surgery for colorectal cancer.  In contrast, a pronounced inflammatory response at 
a local level has been consistently associated with improved clinical outcome in patients with 
colorectal cancer (Chapter 1).  For example, there is evidence that a pronounced 
inflammatory cell infiltrate is associated with an absence of vascular and lymphatic emboli; 
the earliest signs of tumour invasion and dissemination (Pages, Berger et al. 2005).  Despite 
these established findings, the initial stimulus for the development of an inflammatory 
response in patients with colorectal cancer has not been clear.  The present results suggest 
that the presence of tumour necrosis, itself associated with a weak local inflammatory 
reaction, may represent a trigger for the host to initiate a systemic inflammatory response.  
The relationships between tumour necrosis and the inflammatory response might be further 
explained by how malignant cells respond to hypoxic stress.  Indeed, it has been postulated 
that the combination of inflammation and necrosis provide an environment in which the 
epigenetic regulation of genes, cell death, cell proliferation and mutagenesis occurs (Vakkila 
and Lotze 2004).  At sites of chronic inflammation, cells are continuously dying as a 
consequence of hypoxic stress; an event in turn promoting growth and proliferation of the 
local epithelium.  Cells that die due to hypoxic stress have limited ways of initiating the 
apoptotic cascade because important pathways are blocked by endogenous inhibitors.  The 
apoptotic to necrotic conversion that is associated with unscheduled cell death and the 
subsequent release of necrotic mediators is recognized not to be a “clean” death but instead 
further stimulates inflammatory pathways.  These inflammatory pathways are now 
recognized to be important for angiogenesis, stromagenesis and the promotion of epithelial 
proliferation, all of which are required for tumour growth (Colotta, Allavena et al. 2009).  
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With regard to other patient variables, the present study reports an association between 
tumour necrosis and the presence of preoperative anaemia, supporting similar observations in 
both renal cell carcinoma (Sengupta, Lohse et al. 2005) and malignant mesothelioma 
(Edwards, Swinson et al. 2003).  Necrosis is generally attributed to rapid tumour growth 
resulting in vascular insufficiency and tissue hypoxia.  It is evident, however, that necrosis 
can occur even in small tumours, suggesting that impaired oxygen delivery to the tissues may 
be a contributory factor in the development of necrosis.  Alternatively, the reduced 
haemoglobin concentrations observed in such patients may simply be a consequence of 
cancer-associated inflammation (Spivak 2005). 
To further our understanding of the relationships between tumour necrosis and inflammation, 
future studies should include a detailed examination of the associations between tumour 
necrosis and cell signalling pathways, genetic changes and markers of tumour cell growth.  In 
addition, a detailed investigation of the individual immune cell types most strongly associated 
with necrosis is needed.  
The present study has a number of limitations.  First, despite much of the data, including the 
blood tests used in the calculation of the systemic inflammatory response, being collected 
prospectively, the analysis of tumour necrosis was undertaken in a retrospective fashion.  In 
addition, the grading of both the inflammatory cell infiltrate and tumour necrosis was 
undertaken using a semiquantitative technique, introducing the possibility of sampling bias. 
To minimize this risk, two independent observers examined between two and five sections 
per case before assigning each patient an overall score. Indeed, the high level of inter-
observer agreement in the grading of both the inflammatory cell infiltrate and tumour 
necrosis suggests these techniques to be simple and reproducible. Finally, the distribution of 
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inflammatory cells and necrotic areas is variable and analysing only a small number of 
pathological sections may not be representative of the whole tumour.   
In summary, the present study confirms tumour necrosis as a stage independent prognostic 
marker in colorectal cancer.  Furthermore, these results indicate that the impact of tumour 
necrosis on colorectal cancer survival may be explained by close relationships with the host 
inflammatory responses.  
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Figure 7.1. Examples of the four grades of histological tumour necrosis in H&E sections; 
Panel A = „absent‟ (none) necrosis, Panel B = „focal‟ (< 10%) necrosis, Panel C = „moderate‟ 
(10 - 30%) necrosis, Panel D = „extensive‟ (> 30%) necrosis.  
A B 
C D 
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Number at risk Year 1 Year 2 Year 3 Year 4 Year 5 
Absent  32 31 31 30 30 
Focal  166 163 158 148 144 
Moderate  101 99 93 90 87 
Extensive  44 42 37 33 28 
 
Figure 7.2. The relationship between tumour necrosis and cancer specific survival in all 
patients (n=343); necrosis groups „absent‟, „focal‟, „moderate‟ and „extensive‟ are shown top 
to bottom (Kaplan-Meier; p<0.001, log-rank test). 
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Table 7.1.  The relationships between tumour necrosis and clinico-pathological variables in 
all patients (n = 343). 
 
 
 
Variable  
Tumour necrosis 
p
†
 Absent 
(n=32) 
Focal 
(n=166) 
Moderate 
(n=101) 
Extensive 
(n=44) 
Patient related variables 
Age ≤ 64 11 (9) 62 (52) 34 (29) 12 (10)  
 65 – 74 15 (14) 49 (44) 29 (26) 18 (16)  
 ≥ 75 6 (5) 55 (49) 38 (34) 14 (12) 0.214 
Sex Female 13 (8) 75 (48) 45 (29) 23 (15)  
 Male 19 (10) 91 (49) 56 (30) 21 (11) 0.390 
Presentation Elective 29 (9) 158 (49) 95 (30) 39 (89)  
 Emergency 3 (14) 8 (36) 6 (27) 5 (23) 0.438 
Tumour site Colon 24 (10) 109 (46) 71 (30) 33 (14)  
 Rectum 8 (8) 57 (54) 30 (28) 11 (10) 0.526 
Anaemia
*
 None 15 (10) 82 (57) 35 (24) 13 (9)  
 Mild 6 (8) 28 (39) 27 (38) 11 (15)  
 Severe 8 (11) 29 (40) 23 (32) 13 (18) 0.022 
White cell count 
**
 < 8.5 (x10
9
/L) 22 (12) 90 (50) 54 (30) 15 (8)  
 8.5-11 (x10
9
/L) 4 (6) 33 (49) 19 (28) 12 (18)  
 > 11(x10
9
/L) 5 (9) 20 (37) 17 (32) 12 (22) 0.006 
Systemic inflammatory 
response  mGPS 0 22 (11) 106 (55) 51 (26) 15 (8) 
 
 mGPS 1 7 (6) 48 (43) 35 (31) 22 (20)  
 mGPS 2 3 (8) 12 (32) 15 (41) 7 (19) <0.001 
Local  inflammatory 
cell infiltrate  (K-M)  Low grade 15 (7) 108 (48) 62 (28) 38 (17) 
 
 High grade 17 (14) 58 (48) 39 (33) 6 (5) 0.004 
Tumour related variables 
T stage T1 2 (25) 5 (63) 0 (0) 1 (13)  
 T2 7 (25) 18 (64) 2 (7) 1 (4)  
 T3 18 (9) 99 (50) 63 (32) 20 (10)  
 T4 5 (5) 44 (41) 36 (34) 22 (21) <0.001 
N stage N0 23 (12) 94 (49) 50 (26) 26 (14)  
 N1 7 (6) 54 (48) 37 (33) 15 (13)  
 N2 2 (5) 18 (49) 14 (38) 3 (8) 0.322 
TNM stage Stage I 6 (23) 17 (65) 2 (8) 1 (4)  
 Stage II 17 (10) 77 (46) 48 (29) 25 (15)  
 Stage III 9 (6) 72 (48) 51 (34) 18 (12) 0.015 
Petersen Index Low risk 30 (11) 140 (50) 78 (28) 31 (11)  
 High risk 2 (3) 26 (41) 23 (36) 13 (20) 0.003 
† 
chi square linear by linear association 
*
 available in 290/343 patients,  
**
 available in 303/343 patients 
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Table 7.2. The relationships between tumour necrosis and clinico-pathological variables in 
patients with node negative disease (n = 193). 
 
 
Variable  
Tumour necrosis 
p† Absent 
(n=23) 
Focal 
  (n=94) 
Moderat
e 
 (n=50) 
Extensiv
e 
(n=26) 
Patient related variables 
Anaemia* None 11 (15) 42 (58) 15 (21) 5 (7)  
 Mild 6 (13) 20 (44) 13 (28) 7 (15)  
 Severe 6 (14) 16 (36) 13 (30) 9 (21) 0.020 
White cell count ** < 8.5 (x109/L) 15 (14) 53 (51) 29 (28) 7 (7)  
 
8.5-11 
(x109/L) 
3 (8) 19 (53) 8 (22) 6 (17)  
 > 11(x109/L) 5 (16) 10 (31) 8 (25) 9 (28) 0.022 
Systemic inflammatory 
response  mGPS 0 15 (14) 62 (56) 23 (21) 10 (9) 
 
 mGPS 1 6 (10) 23 (38) 18 (30) 13 (22)  
 mGPS 2 2 (9) 9 (39) 9 (39) 3 (13) 0.014 
Local  inflammatory cell 
infiltrate  (K-M)  Low grade 11 (10) 55 (49) 24 (21) 22 (20) 
 
 High grade 12 (15) 39 (48) 26 (26) 4 (14) 0.061 
Tumour related variables 
T stage T1 2 (40) 3 (60) 0 (0) 0 (0)  
 T2 4 (19) 14 (67) 2 (10) 1 (5)  
 T3 12 (10) 60 (48) 38 (31) 14 (11)  
 T4 5 (12) 17 (40) 10 (23) 11 (26) 0.001 
Petersen Index Low risk 21 (12) 86 (50) 46 (27) 20 (12)  
 High risk 2 (10) 8 (40) 4 (20) 6 (30) 0.114 
 
† chi square linear by linear association 
* available in 163/193 patients,  ** available in 172/193 patients  
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Table 7.3. The relationships between clinico-pathological variables and cancer specific 
survival in all patients (n = 343).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable 
Multivariable anlaysis 
HR (95% C.I.) p  
Model 1 (all variables) 
Age 
(≤64/65-74/≥75) 
1.29 (1.00, 1.66) 0.050 
Systemic inflammatory response  
(mGPS 0/1/2) 
1.74 (1.27, 2.39) 0.001 
Local inflammatory cell  infiltrate  
(K-M low grade/high grade) 
2.65 (1.52, 4.63) 0.001 
TNM stage 
(I/II/III) 
1.55 (1.02, 2.35) 0.041 
Petersen Index 
(low risk/high risk) 
3.50 (2.21, 5.55) <0.001 
Model 2 (without inflammatory variables) 
Age 
(≤64/65-74/≥75) 
1.28 (0.99, 1.66) 0.062 
TNM stage 
(I/II/III) 
1.62 (1.08, 2.43) 0.020 
Petersen Index 
(low risk/high risk) 
3.43 (2.16, 5.45) <0.001 
Tumour necrosis 
(absent/focal/moderate/extensive) 
1.35 (1.04, 1.77) 0.027 
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Table 7.4. The relationships between clinico-pathological variables and cancer specific 
survival in patients with node negative disease (n = 193). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Variable 
Multivariable analysis 
HR (95% C.I.) p  
Model 1 (all variables) 
Age 
(≤64/65-74/≥75) 
1.78 (1.19, 2.65) 0.005 
Systemic inflammatory response  
(mGPS 0/1/2) 
1.71 (1.09, 2.66) 0.019 
Local inflammatory cell  infiltrate  
(K-M low grade/high grade) 
3.33 (1.55, 7.13) 0.002 
Petersen Index 
(low risk/high risk) 
4.67 (2.23, 9.77) <0.001 
Model 2 (without inflammatory variables) 
Age 
(≤64/65-74/≥75) 
1.84 (1.22, 2.77) 0.004 
Petersen Index 
(low risk/high risk) 
4.07 (1.94, 8.57) <0.001 
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8.0 THE RELATIONSHIP BETWEEN CELLULAR COMPONENTS OF THE 
PERITUMOURAL INFLAMMATORY RESPONSE, CLINICOPATHOLOGICAL 
CHARACTERISTICS AND SURVIVAL IN PRIMARY OPERABLE COLORECTAL 
CANCER.  
8.1 Introduction 
Local infiltration of inflammatory cells in the tumour microenvironment is associated with 
improved survival in patients with colorectal cancer (Chapter 1).  However, despite extensive 
investigation over a 40 year period, a reliable measure of the local inflammatory cell infiltrate 
has yet to be incorporated into clinical practice.  In order to establish routine clinical utility 
there is therefore a need to standardize the assessment of the local inflammatory cell response 
in colorectal tumours.   
A logical starting point would be to compare the prognostic value and clinicopathological 
associations of individual immune cells with a more generalised assessment of local 
inflammation.  Indeed, a global assessment of peritumoural inflammatory cell infiltrate, using 
routinely stained sections, has been proposed by Klintrup and Makinen (K-M grade) 
(Klintrup, Makinen et al. 2005) and independently validated (Roxburgh, Salmond et al. 
2009).   
The aim of the present study, therefore, was to examine the relationships between individual 
inflammatory cells, overall K-M grade and survival in patients with primary operable 
colorectal cancer.   
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8.2 Materials and Methods 
Patients with colorectal cancer who were considered to have undergone potentially curative 
resection of colorectal cancer between January 1997 and December 2006 were identified 
from the same prospective database described in Chapter 3.   
The tumours were staged according to conventional AJCC/TNM classification (5
th
 Edition) 
(Fleming ID 1997). Additional pathological data were taken from reports issued at the time of 
resection.  With regard to venous invasion, cases in the present study which pre-dated the 
introduction of routine elastica staining at Glasgow Royal Infirmary in 2003 were stained and 
reported retrospectively.  Tumour necrosis was assessed as described in Chapter 7.   
The systemic inflammatory response was assessed using the modified Glasgow Prognostic 
Score, as described in Chapter 1.  The peritumoural inflammatory cell infiltrate was assessed 
according to the K-M criteria, as described in Chapter 7.    
The following method was then used to identify individual inflammatory cells. The original 
sections used for the K-M grading were retrieved from pathology archives and a single 
representative slide chosen for more detailed analysis.  This section was converted to 
electronic format using a high resolution digital scanner (Slidepath Digital Image Hub v3) 
before five distinct areas (560μm x 250μm) were selected at intervals along the invasive 
margin.  Gridlines (42μm x 42μm) were digitally superimposed and individual cells counted 
in ten random boxes within each of these areas. This resulted in a total of 50 boxes 
(approximately 0.09mm
2
)
 
being analysed per patient.  For the purposes of deciding if a cell 
which straddled a gridline was within a box or not, two perpendicular lines were considered 
„inclusion‟ lines and only cells touching these lines were included.  Cellular identification put 
each cell into one of six categories: lymphocyte, plasma cell, neutrophil, macrophage 
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(including mast cells), eosinophil or „other‟ which included neoplastic, stromal, endothelial, 
necrosed or unidentifiable cells. The cells were counted using image analysis software 
(ImageJ available at http://rsbweb.nih.gov/ij/).  A total of 20 cases were scored independently 
by two observers to confirm consistency of scoring.  The inter-observer intraclass correlation 
coefficients for each cell type were: lymphocytes 0.92, plasma cells 0.80, neutrophils 0.65, 
macrophages 0.40, eosinophils 0.92. Figure 8.1 shows an example of how five distinct areas 
were chosen from along the length of the invasive margin. 
Patients were followed up for five years after surgery.  Information on date and cause of 
death was cross-checked with that received by the cancer registration system and the 
Registrar General (Scotland).  Death records were complete until 1st December 2010, which 
served as the censor date.  Cancer-specific survival was measured from the date of surgery 
until the date of death from colorectal cancer.  The study was approved by the West of 
Scotland Research Ethics Committee (WoSREC), Glasgow. 
Statistical analysis 
The inflammatory cell types were divided into two equal groups termed „low‟ and „high‟ 
based on the median cell count.  Grouping of other variables was carried out using standard 
or previously published thresholds.  Associations between categorical and continuous 
variables were examined using chi-squared tests for linear trend and non-parametric tests 
respectively.  Survival analyses were performed using the Kaplan-Meier method and Cox 
proportional hazards regression.  Variables significant on univariate analysis were entered 
into a multivariate model using a backwards conditional method.  P<0.050 was considered 
statistically significant. Statistical analyses were performed using SPSS
®
 version 19.0 (IBM 
SPSS, Illinois, USA).  
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8.3 Results 
A total of 130 patients who underwent potentially curative resection of colorectal cancer were 
included.  The majority of patients were 65 years or older (68%) with a similar number of 
males (52%) and females (48%).  Most operations were elective (94%) and were carried out 
for both colon (68%) and rectal cancer (32%).  The preoperative systemic inflammatory 
response was graded as mGPS 0 in 68 patients (52%), mGPS 1 in 47 (36%) and mGPS 2 in 
15 (12%).  Original pathological reports classified 8% of the tumours as Stage I, 49% as 
Stage II and 43% as Stage III.  Using elastin staining, there was evidence of intra- or 
extramural venous invasion in 43 of the tumours (33%). In the postoperative period, a total of 
38 patients (29%) received adjuvant chemotherapy.  
Application of the K-M criteria graded the peritumoural inflammatory cell response as „low 
grade‟ in 63 patients (48%) and „high grade‟ in 67 patients (52%).  The distribution of 
individual inflammatory cell types in the invasive margin are summarised in Table 8.1.  The 
cells identified were primarily macrophages, lymphocytes and neutrophils with relatively few 
plasma cells or eosinophils (Table 8.1).  
The relationships between overall K-M grade and individual inflammatory cell types are 
shown in Figure 8.2.  There were significant relationships between high K-M grade and 
increased numbers of lymphocytes (p<0.001), plasma cells (<0.001), neutrophils (p<0.01) 
and eosinophils (p<0.01).  There was no relationship between K-M grade and macrophage 
count (Figure 8.2).  
The median follow-up for the survivors was 105 months (range 55 - 163).  During this period, 
37 patients died from colorectal cancer and 34 patients died from other causes.  The survival 
analyses for K-M grade and individual inflammatory cell types are shown in Table 8.2.  On 
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univariate analysis, K-M grade (p<0.01), lymphocyte infiltration (p<0.05) and plasma cell 
infiltration (p<0.01) were significantly associated with cancer-specific survival.  The Kaplan-
Meier survival curves demonstrating these relationships are shown in Figure 8.3.   
K-M grade, lymphocyte infiltration and plasma cell infiltration were then entered into a 
multivariate survival model with standard clinical and pathological variables (Table 8.3).  
This demonstrated that systemic inflammatory response (mGPS) (HR 2.27, p<0.01), TNM 
stage (HR 1.97, p<0.05), venous invasion (HR 2.03, p<0.05), tumour necrosis (HR 1.54, 
p<0.05) and K-M grade (HR 2.38, p<0.05) were independently associated with cancer-
specific survival (Table 3).  When patients with node-negative disease were considered alone, 
only systemic inflammatory response (mGPS) (HR 2.46, p<0.05) and K-M grade (HR 3.67, 
p<0.05) were independently associated with cancer-specific survival (data not shown).  
The relationships between K-M grade, individual inflammatory cell types and patient-related 
variables are shown in Table 8.4.  No relationships were observed between either K-M grade 
or lymphocyte infiltration and any of the patient-related variables studied, including markers 
of the systemic inflammatory response. There was a significant association between plasma 
cell infiltration and serum neutrophil count (p<0.05) (Table 8.4).  
The relationships between K-M grade, individual inflammatory cell types and tumour-related 
variables are shown in Table 8.5.  There were significant relationships between K-M grade 
and T stage (p<0.01), N stage (p<0.05), TNM stage (p<0.05), venous invasion (P<0.05), 
tumour necrosis (p<0.05) and margin characteristics (p<0.001). For individual cell types, 
there were significant relationships between lymphocyte infiltration, venous invasion 
(p<0.05) and margin characteristics (p<0.01).  Similarly, there were significant relationships 
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between plasma cell infiltration and N stage (p<0.05), TNM stage (p<0.05), venous invasion 
(p<0.01), tumour necrosis (p<0.05) and margin characteristics (p<0.05) (Table 8.5). 
196 
 
8.4 Discussion 
Results from the present study demonstrate that a strong infiltration of inflammatory cells in 
the invasive margin of colorectal tumours confers a distinct survival advantage for patients 
with primary operable colorectal cancer.  Furthermore, although a strong overall 
inflammatory cell infiltrate is a superior predictor of prognosis than the analysis of individual 
cell types, lymphocytes and plasma cells appear particularly important and are associated 
with a number of favourable pathological characteristics.  Taken together, these results 
indicate a prominent role for a coordinated adaptive immune response in the prevention of 
tumour progression in colorectal cancer.  
A large number of previous studies, published over 40 year period, have examined the 
prognostic value of inflammatory cell infiltration in colorectal cancer (Roxburgh and 
McMillan 2011). Despite this volume of work, there is still no standardised method for the 
assessment of the local inflammatory response in colorectal tumours.  This lack of consensus 
may be partly explained by the fact that many previous studies have concentrated on single 
cell types (Naito, Saito et al. 1998; Forssell, Oberg et al. 2007), have relied on tissue 
microarrays (TMA‟s) (Galon, Costes et al. 2006; Salama, Phillips et al. 2009) or have 
employed immunohistochemical techniques (Menon, Janssen-van Rhijn et al. 2004; Sandel, 
Dadabayev et al. 2005).  Importantly, few previous studies have directly compared different 
methods for assessing the local inflammatory response on full sections.   
If such assessments are to move from experimental research into clinical practice, the 
technique employed must be simple, reproducible and easy to incorporate into existing 
pathological staging systems.  The present study suggests that a simplified overall assessment 
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of peritumoural inflammation, using the K-M grade, fulfils these criteria and is a superior 
predictor of prognosis than an assessment of individual inflammatory cells. 
In addition to comparing the prognostic value of the above methods, the present study also 
included a detailed examination of the cellular composition of the invasive margin of 
colorectal tumours.  When all patients were considered, macrophages were the most prevalent 
cell type, followed closely by lymphocytes and neutrophils.  When the cellular composition 
was re-examined in patients with a high grade peritumoural inflammatory response, the 
relative proportion of lymphocytes increased while the proportions of neutrophils and 
macrophages fell.  These findings suggests that such patients are mounting a coordinated 
inflammatory response mediated primarily though lymphocytes.  
The mechanisms by which a strong local adaptive immune response improves prognosis in 
patients with colorectal cancer are not clear.  The present study found no association between 
an infiltration of inflammatory cells and any of the patient-related variables examined.  In 
particular, there were no direct relationships between local inflammation and serum white 
cell count or systemic inflammatory response.  These findings, therefore, suggest a model 
whereby the initial stimulus for the development of a local inflammatory cell response is 
evoked by events within the tumour and its microenvironment (Whiteside 2008). In the case 
of a non-specific immune cell reaction, this may include local tissue damage caused directly 
by tumour invasion with subsequent hypoxia, cellular necrosis and the release of pro-
inflammatory cytokines (Chapter 7).  Alternatively, a beneficial adaptive immune cell 
response may be triggered by altered antigenicity of the tumour cells themselves 
(Goedegebuure and Eberlein 1995).  Indeed, the presence of lymphocytes in the present study 
was associated with a number of favourable tumour characteristics including an expanding 
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rather than infiltrative growth pattern, a feature previously reported as an independent 
prognostic factor in colorectal cancer (Cianchi, Messerini et al. 1997). An association 
between intra-tumoural lymphocytes and lower levels of venous invasion has been reported 
previously (Pages, Berger et al. 2005) and the present results suggest this relationship also 
exists with lymphocytes in the invasive margin.  That this finding has not been reported 
previously may be explained by the use of elastica staining in the present study to aid the 
detection of venous emboli; a technique resulting in a higher prevalence of venous invasion 
than seen in many previous studies (Roxburgh and Foulis 2011). 
In contrast to cells associated with the adaptive immune response, an abundance of 
neutrophils or macrophages at the tumour border did not influence survival in the present 
cohort.  Evidence regarding the prognostic value of these cell types, intimately associated 
with the innate immune response, has been conflicting.  Although a number of studies have 
suggested that a strong infiltration of neutrophils (Baeten, Castermans et al. 2006) and 
macrophages (Forssell, Oberg et al. 2007) is beneficial to patients with colorectal cancer, 
others have reported no relationship with survival (Nagtegaal, Marijnen et al. 2001; 
Nagorsen, Voigt et al. 2007).  Indeed, in certain situations tumours may exploit these innate 
inflammatory cells to promote tumour proliferation and invasion (Pollard 2004).  Rather than 
reflecting a protective host response, the presence of these cell types in the tumour 
microenvironment then favours tumour growth and dissemination (Liotta and Kohn 2001; 
Whiteside 2008).  However, using H&E stained slides it is difficult to identify and assess the 
degree of macrophage infiltration.  Further work using immunohistochemistry may be 
required to examine the prognostic value of tumour associated macrophages (TAM‟s) 
although there should be careful consideration of the markers to be used since some, such as 
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CD68, may be expressed by other non myeloid tissues in cancer specimens (Gottfried, Kunz-
Schughart et al. 2008). 
The present study has a number of limitations.  The identification and classification of 
individual cell types on H&E stained sections is a time consuming process, limiting patient 
numbers and restricting potential clinical application.  However, this level of detail was 
required to compare the two methods and we can now confirm that a laborious examination 
of individual cells offers no additional prognostic information compared to a simplified 
global assessment of inflammation.  The present study focused only on the invasive margin 
and did not assess inflammatory cells within the tumour itself.  The primary reason for this 
approach was that the tumour border is felt to represent a critical interface between pro- and 
anti-tumour factors (Zlobec and Lugli 2009).  Furthermore, inflammatory cells within the 
tumour itself are difficult to identify on H&E-stained sections and there is currently no global 
assessment of intra-tumoural inflammation against which to make a comparison.  
Nevertheless, an examination of the prognostic value of intra-tumoural inflammatory cells, 
using immunohistochemical techniques, is of considerable interest and will be the subject of 
future work.  
In summary, the present study confirms that a simple assessment of peritumoural 
inflammation, using the K-M grade, has independent prognostic value in patients with 
primary operable colorectal cancer.  Examination of individual cell types does not improve 
prediction of outcome but does suggest a prominent role for lymphocytes in the prevention of 
tumour progression in these patients.  Taken together these findings give additional support to 
the prognostic significance of the local inflammatory response in colorectal cancer and to the 
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idea that a simple overall assessment of peritumoral inflammation could be applied in clinical 
practice.  
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Figure 8.1. Example of how 5 distinct areas (560μm x 250μm) were chosen from the 
invasive margin (black line) of each H&E stained section. The inflammatory cells in each of 
these areas were then categorised and counted.  
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Figure 8.2. Boxplot representation of the relationships between individual inflammatory cell 
types and K-M grade; lymphocytes (p<0.001, Mann-Whitney U test), plasma cells (p<0.001), 
neutrophils (p=0.002), macrophages (p=0.21), eosinophils (p=0.001). 
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Figure 8.3. Kaplan-Meier survival curves demonstrating the relationships between K-M 
grade (p=0.001, log-rank test), lymphocyte infiltration (p=0.041, log-rank test), plasma cell 
infiltration (p=0.001, log-rank test) and cancer-specific survival.
Number at 
risk 
Year 1 Year 2 Year 3 Year 4 Year 5 
K-M high 
grade 
67 63 62 58 53 
K-M low 
grade 
63 56 47 43 36 
Number at 
risk 
Year 1 Year 2 Year 3 Year 4 Year 5 
Lymphocytes 
(high) 
65 61 56 53 48 
Lymphocytes 
(Low) 
65 59 51 49 41 
Number at 
risk 
Year 1 Year 2 Year 3 Year 4 Year 5 
Plasma cells 
(high) 
65 63 59 57 53 
Plasma cells 
(low) 
65 57 48 44 37 
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Table 8.1. Distribution of individual inflammatory cell types in the invasive margin of 
colorectal tumours. 
 
 
 
 
 
Cell type N 
Cell count* % of all cells 
Median (range) Mean (95% C.I.) 
Macrophages 130 19 (6 - 49) 22 (21 - 23) 
Lymphocytes 130 17 (2 - 86) 21 (20 - 23) 
Neutrophils 130 15 (1 - 78) 18 (16 - 20) 
Plasma Cells 130 9 (1 - 41) 11 (10 - 12) 
Eosinophils 130 1 (0 - 14) 2 (1 - 2) 
Others† 130 19 (5 - 55) 22 (20 - 24) 
 
* Cell count/ 0.018mm2 
† Including neoplastic cells, stromal cells and endothelial cells. 
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Table 8.2. The relationships between K-M grade, individual inflammatory cell types and 
cancer-specific survival (univariate survival analysis).  
 
 
 
 
 
Variable 
Univariate 
HR (95% C.I.) p 
Peritumoural  
inflammation 
K-M low grade 3.13 (1.53, 6.38) 0.002 
 K-M high grade  1.00  
Lymphocytes Low 1.98 (1.02, 3.86) 0.045 
 High 1.00  
Plasma cells Low 2.99 (1.49, 5.99) 0.002 
 High  1.00  
Neutrophils Low 1.45 (0.75, 2.81) 0.27 
 High 1.00  
Macrophages Low 1.38 (0.71, 2.68) 0.34 
 High  1.00  
Eosinophils Low 1.72 (0.89, 3.35) 0.11 
 High 1.00  
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Table 8.3. The relationships between clinico-pathological characteristics and cancer-specific 
survival (multivariate survival analysis).  
 
 
 
 
 
Variable 
Univariate Multivariate 
HR (95% C.I.) p  HR (95% C.I.) p  
Sex 
(female/male) 
1.15 (0.60, 2.19) 0.68   
Age 
(≤64/65-74/≥75) 
1.30 (0.87, 1.96) 0.20   
Presentation 
(elective/emergency) 
1.79 (0.55, 5.87) 0.34   
Smoking 
(never/ex/current) 
1.19 (0.73, 1.95) 0.49   
Anaemia 
(none/mild/severe) 
0.97 (0.60, 1.57) 0.91   
Systemic inflammatory response  
(mGPS 0/1/2) 
2.40 (1.55, 3.73) <0.001 2.27 (1.36, 3.80) 0.002 
Tumour site 
(colon/rectum) 
0.72 (0.34, 1.53) 0.39   
TNM stage 
(I/II/III) 
2.25 (1.24, 4.05) 0.007 1.97 (1.01, 3.82) 0.046 
Differentiation 
(well or mod/poor) 
2.47 (1.12, 5.43) 0.024  0.12 
Venous invasion 
(no/yes) 
2.38 (1.24, 4.54) 0.009 2.03 (1.02, 4.06) 0.044 
Tumour necrosis 
(absent/focal/moderate/extensive) 
2.02 (1.36, 2.99) <0.001 1.54 (1.02, 2.33) 0.038 
Character or margin 
(expanding/infiltrating) 
2.25 (1.16, 4.34) 0.016  0.29 
Peritumoural inflammation 
(K-M high grade/low grade) 
3.13 (1.53, 6.38) 0.002 2.38 (1.08, 5.22) 0.031 
Lymphocytes 
(high/low) 
1.98 (1.02, 3.86) 0.045  0.36 
Plasma cells 
(high/low) 
2.99 (1.49, 5.99) 0.002  0.54 
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Table 8.4. The relationships between K-M grade, lymphocyte infiltration, plasma cell 
infiltration and patient-related variables. 
 
 
 
Variable 
K-M grade 
(low/high) 
p 
Lymphocytes 
(low/high) 
p 
Plasma cells 
(low/high) 
p 
Sex  0.71  1.00  0.48 
    Male 34/34  34/34  32/36  
    Female 29/33  31/31  33/29  
Age  0.92  0.91  0.59 
    ≤ 64 19/22  17/24  19/22  
    65 - 74 25/22  30/17  23/24  
    > 75 19/23  18/24  23/19  
Presentation  0.17  1.00  0.47 
    Elective 61/61  61/61  60/62  
    Emergency 2/6  4/4  5/3  
Smoking status  0.28  0.13  0.37 
    Never 21/30  21/30  24/27  
    Ex 18/15  20/13  14/19  
    Current 11/10  12/9  13/8  
Anaemia  0.56  0.41  0.41 
    Mild 25/31  27/29  30/26  
    Moderate 8/15  14/9  8/15  
    Severe 15/13  10/18  13/15  
Serum leukocytes*       
    White cell count 9.3/8.9 0.63 9.3/8.8 0.50 9.7/8.4 0.11 
    Neutrophils 6.8/5.9 0.12 6.8/5.8 0.10 6.9/5.7 0.037 
    Lymphocytes 1.5/1.6 0.21 1.5/1.6 0.64 1.6/1.5 0.24 
Systemic 
inflammatory 
response 
 0.50  0.70  0.16 
    mGPS = 0 30/38  35/33  30/38  
    mGPS = 1 26/21  23/24  26/21  
    mGPS = 2 7/8  7/8  9/6  
 
*x109/l 
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Table 8.5. The relationships between K-M grade, lymphocyte infiltration, plasma cell 
infiltration and tumour-related variables. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Variable 
K-M grade 
(low/high) 
p 
Lymphocytes 
(low/high) 
p 
Plasma 
cells 
(low/high) 
p 
Tumour site  0.67  0.09  0.85 
    Colon 42/47  40/49  44/45  
    Rectum 21/20  25/16  21/20  
T stage  0.001  0.41  0.06 
    T1/2 1/14  6/9  4/11  
    T3/4 62/53  59/56  61/54  
N stage  0.039  0.72  0.03 
    N0 30/44  38/36  31/43  
    N1/2 33/23  27/29  34/22  
TNM stage  0.006  0.78  0.024 
    I 1/9  5/5  3/7  
    II 29/35  33/31  28/36  
    III 33/23  27/29  34/22  
Differentiation  0.72  0.48  0.83 
    Well/moderate 53/57  54/56  55/55  
    Poor 10/9  11/8  9/10  
Venous invasion  0.008  0.016  0.005 
    No 35/52  37/50  36/51  
    Yes 28/15  28/15  29/14  
Tumour necrosis  0.018  0.11  0.010 
    Absent 3/7  6/4  2/8  
    Focal 26/33  26/33  27/32  
    Moderate 20/22  19/23  23/19  
    Extensive 13/4  14/3  12/5  
Character or margin  
<0.00
1 
 0.009  0.016 
    Expanding 25/53  32/46  32/46  
    Infiltrating 37/14  33/18  32/19  
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9.0 THE CLINICAL UTILITY OF THE LOCAL INFLAMMATORY RESPONSE 
IN PRIMARY OPERABLE COLORECTAL CANCER. 
9.1 Introduction 
It is now recognized that the host immune response is an important determinant of outcome 
in human cancers (Hanahan and Weinberg 2011).  A number of studies have demonstrated 
that infiltration of inflammatory cells in colorectal tumours is associated with improved 
survival, regardless of pathological stage (Roxburgh and McMillan 2011).  It is generally 
assumed that the presence of these cells is a manifestation of an effective immune response 
although it is unclear whether this reflects distinct tumour biology or particular host 
characteristics.  
Despite the potential to improve risk stratification for patients with colorectal cancer, a 
reliable measure of the local inflammatory response has yet to be incorporated into clinical 
practice.  The reasons for this are likely to include the multitude of individual cell types or 
„immune scores‟ that have been proposed as prognostic as well as the inherent complexities 
of immunohistochemistry (Galon, Pages et al. 2012).  In particular, there is a need to clarify 
whether lymphocyte subtyping adds additional prognostic information beyond the evaluation 
of inflammatory cells on routinely stained sections (Huh, Lee et al. 2012). 
The aims of the present study, therefore, were to evaluate the type, density and location of 
tumour infiltrating lymphocytes (TIL‟s) in patients with primary operable colorectal cancer 
and to examine relationships with both tumour and host characteristics.  Furthermore, we 
sought to compare the prognostic value of individual T-cell subtypes, an 
immunohistochemistry-based score and a simple histopathological assessment of 
inflammatory cell infiltrate.  
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9.2 Materials and Methods 
Patients with colorectal cancer who were considered to have undergone potentially curative 
resection of colorectal cancer between January 1997 and December 2006 were identified 
from the same prospective database described in Chapter 3.   
Prospectively collected data included patient demographics, pathological characteristics and 
laboratory measurements; haemoglobin (Hb), white cell count (WCC), albumin, C-reactive 
protein (CRP), urea and electrolytes.  Medical records were reviewed retrospectively to 
record deprivation index, American Society of Anesthesiologists (ASA) grade, smoking 
status and POSSUM physiology scores, as described in Chapter 3.  Preoperative systemic 
inflammatory response was assessed using three validated measures; (1) serum white cell 
count (WCC) (Maltoni, Caraceni et al. 2005), (2) neutrophil to lymphocyte ratio (NLR) 
(Walsh, Cook et al. 2005) and (3) the modified Glasgow Prognostic Score (mGPS) 
(McMillan 2008).  
Histopathology and immunohistochemistry 
Tumours were staged according to the 5
th
 edition of the AJCC/TNM staging system (Fleming 
ID 1997).  Additional pathological features, including tumour differentiation and venous 
invasion, were taken from contemporary reports.  Tumour necrosis was graded 
semiquantitatively as „absent‟ (none), „focal‟ (< 10% of tumour area), „moderate‟ (10–30%) 
or „extensive‟ (>30%), as described in Chapter 7. 
Archived paraffin embedded blocks of the central tumour were then retrieved to perform 
immunohistochemistry.  One block, representative of the point of deepest tumour invasion, 
was chosen per case.  Consecutive blank 4μm sections were cut and mounted on silanized 
slides before being dewaxed in xylene and rehydrated using graded alcohol washes.  Heat-
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induced antigen retrieval was performed by microwaving under pressure using a citrate or 
Tris/EDTA buffer before endogenous peroxidase activity was blocked (5% normal goat 
serum in TRIS buffered saline (TBS)) and the following primary antibodies applied; CD3
+
 
(Vector Labs, code VP-RM01, 1/100 dilution), CD8
+
 (DakoCytomation, code M7103, 1/100 
dilution), CD45R0
+
 (DakoCytomation, code M0742, 1/150 dilution) and FOXP3
+
 (Abcam, 
code 20034, 1/200 dilution).  Sections were washed with TBS, incubated with Dako 
Envision, washed again and had 3‟3‟ diaminobenzidine (DAB) applied. Finally, sections 
were washed with water, counterstained with haemotoxylin, dehydrated and mounted 
(Appendix 1 – 4 describe the full immunohistochemistry protocols)  
Evaluation of T-cell density was carried out by investigators blinded to clinicopathologic 
information.  Density was graded semi-quantitatively as absent, weak, moderate or strong in 
three separate tumour compartments; (1) invasive margin (IM), (2) tumour stroma (ST) and 
(3) cancer cell nests (CCN).  Figure 9.1 shows examples of different patterns of T-cell 
infiltration in the tumour microenvironment.  To confirm consistency of grading, 100 cases 
were scored independently by two investigators. 
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Immune Scores 
In addition to assessing individual T-cell subtypes, two previously proposed „immune scores‟ 
for the assessment of the local inflammatory response in colorectal cancer were applied; (1) 
The Galon Immune Score, a composite immunohistochemistry-based score which grades 
CD45R0
+
 and CD8
+
 infiltration in the invasive margin and central tumour (Mlecnik, Tosolini 
et al. 2011) and (2) the Klintrup-Makinen (K-M) grade, a global assessment of inflammatory 
cell infiltration at the invasive margin using haematoxylin and eosin (H&E) stained sections 
(Klintrup, Makinen et al. 2005).  
Statistical analysis 
All variables were grouped according to standard or previously published thresholds.  
Associations were examined using Chi-square tests for linear trend and Mann Whitney tests.  
Death records were complete until 1
st
 December 2011, which served as the censor date.  
Univariate survival analyses were performed using Kaplan–Meier survival curves with log-
rank tests.  Multivariate analyses were performed using Cox proportional hazards regression 
with a backwards conditional method.  p<0.05 was considered statistically significant. 
Statistical analyses were performed using SPSS
®
 version 19.0 (IBM SPSS, Chicago, Illinois, 
USA).  
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9.3 Results 
A total of 365 patients who underwent potentially curative resection of colorectal cancer in 
the study period were included.  Clinical data was unavailable in a number of cases; 
deprivation index (2%), ASA grade (22%), smoking status (17%), POSSUM physiology 
score (27%), WCC (14%), NLR (23%) and anaemia (16%).  Immunohistochemistry and/or 
pathological data was missing in 12% (staining errors, broken slides and inability to clearly 
identify the invasive margin).  
Table 9.1 summarizes the clinical and pathological characteristics of the cohort.  The 
majority of patients were 65 years or older (67%) with a similar number of males (55%) and 
females (45%).  Approximately two thirds of operations were for colon cancer and one third 
for rectal cancer.  Conventional staging confirmed that 208/365 patients (57%) had 
undergone surgery for node-negative disease (Table 9.1).  
The type, density and location of T-cells in the tumour microenvironment are shown in Table 
9.2.  The distribution of T-cells in each tumour compartment varied between cellular subtype; 
there was a strong infiltration of CD3
+
, CD45R0
+
 and CD8
+
 cells at the invasive margin (IM) 
in approximately 10-15% of cases and within the cancer cell nests (CCN) in approximately 
10% of cases.  The distribution of T-cells within the tumour stroma varied considerably.  Of 
note, the densities of FOXP3
+
 infiltration were lower than other T-cell subtypes in all tumour 
compartments and were rarely found within the cancer cell nests (Table 9.2). The inter-
observer agreements for each T-cell subtype are also shown in Table 9.2.  There was 
excellent agreement (ICC>0.80) in the grading of all T-cell subtypes except FOXP3
+ 
cells. It 
should be noted that the ICC (0.81) of the K-M grade has been reported previously in this 
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cohort (Roxburgh, Salmond et al. 2009) while the Galon Immune Score is a combination of 
T-cell subtypes with individual inter-observer agreements (Table 9.2). 
The inter-relationships between T-cell subtypes in the tumour compartments are shown in 
Table 9.3.  Despite individual variations in patterns of infiltration, there were highly 
significant positive relationships between infiltration of all T-cell subtypes in all tumour 
compartments (all p<0.001, chi-square tests for linear trend).  Similarly, the K-M grade and 
Galon Immune Score were significantly related to all T-cell subtypes in all tumour 
compartments (all p<0.001,chi-square tests for linear trend) (Table 9.3).  
The median follow-up for the survivors in the study was 115 months (range 59 - 179).  
During this period, 137 patients died from colorectal cancer and 71 patients died from inter-
current disease. Table 9.4 shows the relationships between T-cell infiltration and cancer-
specific survival.  On univariate analysis there were significant relationships between 
infiltration of all T-cell subtypes and cancer-specific survival (all p<0.01).  To examine 
which subtype had the strongest prognostic value in each tumour compartment the invasive 
margin, tumour stroma and cancer cell nests were then considered separately.  On 
multivariate analysis, CD3
+
 (HR 0.49, 95% CI 0.38-0.63, p<0.001) was the strongest 
predictor of survival at the invasive margin, CD 3
+
 (HR 0.58, 95% CI 0.46-0.75, p<0.001) the 
strongest in the tumour stroma and CD8
+
 (HR 0.68, 95% CI 0.50-0.90, p=0.008) the strongest 
within the cancer cell nests (Table 9.4).  
Having established the prognostic value of CD3
+ 
IM and CD8
+ 
CCN in particular, their 
relationships with host characteristics and tumour biology were examined.  There were no 
significant relationships between CD3
+
 IM or CD8
+ 
CCN infiltration and patient 
demographics, markers of physiological health or any assessment of the systemic 
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inflammatory response (Table 9.5a).  In terms of tumour biology, significant associations 
were observed between CD3
+ 
IM and T stage (p<0.001), N stage (p=0.026), TNM stage 
(p=0.008), venous invasion (p=0.038) and growth pattern (p=0.001).  Similarly, CD8
+ 
CCN 
was significantly associated with T stage (p=0.014), N stage (<0.001), TNM stage (p=0.001), 
venous invasion (p=0.002) and growth pattern (p=0.003) (Table 9.5b). 
Comparison was then made between the prognostic value of individual T-cell subtypes 
(CD3
+ 
IM, CD3
+ 
ST and CD8
+ 
CCN), a composite immune score (Galon Immune Score) and 
a histopathological assessment of inflammatory cell infiltrate (K-M grade) (Table 9.6).  Four 
models were constructed to compare prognostic value in the following patient subsets; (1) 
stage I-III colorectal cancer, (2) stage I-II colorectal cancer, (3) colon cancer and (4) rectal 
cancer. On univariate analysis, significant survival relationships for CD3
+
 IM (all p<0.001), 
CD3
+
 ST (all p<0.001), CD8
+
 CCN (all p<0.01), K-M grade (all p<0.01) and Galon Immune 
Score (all p<0.01) were observed across all patient subsets.  On multivariate analysis, 
CD3
+
IM (HR 0.72, 95% CI 0.52-0.99, p=0.045) and CD8
+
CCN (HR 0.58, 95% CI 0.44-0.77, 
p<0.001) were independently associated with cancer specific survival in stage I-III colorectal 
cancer; CD3
+
ST (HR 0.61, 95% CI 0.39-0.93, p=0.020) and CD8
+
CCN (HR 0.56, 95% CI 
0.36-0.86, p=0.009) were independently associated with cancer specific survival in node-
negative colorectal cancer; CD3
+
 IM (HR 0.61, 95% CI 0.39-0.96, p=0.031) and CD8
+
 CCN 
(HR 0.55, 95% CI 0.39-0.79, p=0.001) were independently associated with cancer specific 
survival in colon cancer; CD3
+
 ST (HR 0.57, 95% CI 0.35-0.94, p=0.027) and CD8
+
 CCN 
(HR 0.45, 95% CI 0.26-0.78, p=0.005) were independently associated with cancer specific 
survival in rectal cancer (Table 9.6).   
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Kaplan-Meier curves demonstrating cancer specific survival according to the different 
methods of assessing the local inflammatory response in colorectal cancer are demonstrated 
in Figure 9.2; CD3
+ 
IM (p<0.001, log-rank test), CD8
+
 CCN (p<0.001, log-rank test), K-M 
grade (p<0.001, log-rank test) and Galon Immune Score (p<0.001, log-rank test). 
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9.4 Discussion 
The results of the present study confirm and extend our previous study of the prognostic 
value of inflammatory cells at the invasive margin of colorectal tumours, using H&E analysis 
(Chapter 8).  In particular, by using immunohistochemistry in a larger cohort we have 
identified that increased T-cell infiltrate, whether in the invasive margin, tumour stroma or 
cancer cell nests is consistently associated with improved cancer specific survival 
independent of nodal status or tumour site.  Taken together with previous work (Nielsen, 
Hansen et al. 1999; Roxburgh and McMillan 2011), these results suggest that the type and 
location of inflammatory cells are subordinate to the density of infiltration.  Indeed, a dense 
infiltrate of T-cells, indicative of a coordinated adaptive immune response, appears to be one 
of the most important factors in predicting outcome in patients undergoing potentially 
curative resection for colorectal cancer.  With a view to developing a standardised assessment 
of tumour inflammatory cell infiltrate which can be used in clinical practice, the observation 
that density is paramount provides a solid basis on which to base future methodological 
approaches. 
A large number of previous studies have examined the prognostic value of inflammatory cell 
infiltration in colorectal cancer (Roxburgh and McMillan 2011). However, despite 
accumulating evidence that effector/cytotoxic (CD3
+
/CD8
+
)(Naito, Saito et al. 1998; Galon, 
Costes et al. 2006), memory (CD45R0
+
) (Pages, Berger et al. 2005) and regulatory (FOXP3
+
) 
(Salama, Phillips et al. 2009) T-cells are important components of an anti-tumour response, 
there is no agreement as to which individual cell type(s) are most important.  This is likely to 
be due to many studies only reporting the prognostic value of certain cell subtypes or selected 
cell groups in a variety of locations; often failing to differentiate between different tumour 
compartments (Naito, Saito et al. 1998; Nagtegaal, Marijnen et al. 2001; Diederichsen, 
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Hjelmborg et al. 2003).  In addition, many studies have relied on tissue microarrays (TMA‟s) 
(Pages, Berger et al. 2005; Galon, Costes et al. 2006; Salama, Phillips et al. 2009) that, given 
the heterogenous patterns of inflammatory cell infiltration observed in the present study, may 
not be representative of full sections.  It is clear that for individual studies to be compared 
objectively results must include a precise description of the type, density and location of 
individual inflammatory cells; we sought to achieve this by examining a panel of T-cell 
markers and describing infiltration separately within the invasive margin, tumour stroma and 
cancer cell nests.  Interestingly, our results suggest that strong inter-relationships exist 
between all T-cell subtypes in all tumour compartments, perhaps explaining why each 
subtype has been reported as having individual prognostic value.  
The mechanisms by which a strong local immune response improves prognosis in patients 
with colorectal cancer are not clear.  The present study found no association between the 
strength of the local inflammatory response and surrogate markers of global health such as 
age, deprivation score or physiological function.  Similarly, there were no relationships 
between T-cell infiltration and serum leukocyte count or levels of circulating cytokines. 
These findings therefore support a model whereby a beneficial local inflammatory response is 
not solely reliant on a patients‟ inherent immunity but may rather be evoked by events within 
the tumour and its microenvironment (Nagtegaal, Marijnen et al. 2001).  If host 
characteristics cannot explain the presence or absence of a local immune response, our 
examination of relationships with pathological features offers some insight into the 
mechanisms by which survival is improved.  It has been shown that the microscopic 
characteristics of the invasive margin have prognostic significance in colorectal cancer(Jass, 
Love et al. 1987; Hase, Shatney et al. 1993; Kanazawa, Mitomi et al. 2008) and in the present 
study we observed that low levels of CD3
+ 
IM were associated with a more aggressive 
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infiltrative growth pattern.  A strong tumour inflammatory cell infiltrate in the mesenchyme 
may therefore protect against direct tumour growth and extension; a hypothesis supported by 
the strong association with T stage.  
In contrast, a strong infiltration of intra-tumoural T-cells was more closely associated with 
lymph node status, an indicator of metastatic spread rather than direct tumour growth.  This 
raises the possibility that the mechanisms by which TIL‟s improve outcome may vary 
depending on their location within the microenvironment.  Indeed, the present study found 
that a strong infiltration of CD8+ cells within the cancer cell nests was associated with a 
number of favourable pathological characteristics, including significantly lower levels of 
venous invasion.  This supports the work of Pages and colleagues (Pages, Berger et al. 2005) 
and suggests that intra-tumoural lymphocytes may confer a survival advantage through the 
prevention of vascular emboli, the earliest sign of metastatic invasion.  Further work is 
required to confirm such associations and investigate their biological relevance. 
Considering the importance of the host immune response in the control of tumour 
progression, it is now essential to incorporate a measure of this in the classification and 
prognostic stratification of colorectal cancer.  Not only does infiltration of inflammatory cells 
predict outcome in node negative disease, thereby having the potential to identify patients 
who may benefit from adjuvant chemotherapy, it has the advantage of representing a possible 
target for novel therapies.  A major barrier to inclusion in therapeutic trials or clinical 
practice, however, is the fact that no standardised methodology exists.  Indeed, Galon and 
colleagues (Galon, Pages et al. 2012) have identified the „harmonization‟ of methods to 
assess the local inflammatory response as essential in improving clinical decision-making for 
patients with colorectal cancer.  To our knowledge, this is the first study to directly compare 
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the prognostic value of individual T-cell subtypes, a composite immune score and a 
histopathological assessment on the same cohort of patients.  We have deliberately tried to 
avoid concluding that one method is better than another; instead recognizing that, in addition 
to predictive ability, factors such as simplicity, variability and ease of incorporation into 
existing staging systems must be taken into account when developing a standardized method 
of grading the local inflammatory response.  
The present study has a number of limitations.  Data relating to several clinical variables was 
collected retrospectively and was incomplete in a number of cases.  Despite this, the study 
included a detailed examination of relationships with patient-related characteristics, including 
markers of physiological health and the systemic inflammatory response.  We also chose to 
grade T-cell infiltrate semi-quantitatively rather that utilize automated cell counting software, 
introducing the possibility of observer variability.  However, inter-observer agreement was 
generally good and the technique permits a broader examination of full sections, allowing 
tumour compartments to be identified accurately and necrotic areas to be avoided.  Given the 
heterogeneity of T-cell density within single sections the authors believe this technique may 
be more representative than automated TMA analysis.  Finally, data on molecular features 
such as microsatellite instability (MSI) and genetic mutations were not available in the 
present study.  Although an association between lymphocyte infiltration and MSI has been 
shown in colorectal tumours (Jenkins, Hayashi et al. 2007), a well-powered study by Ogino 
and coworkers recently demonstrated that the survival benefit of T-cell infiltration was 
independent of any molecular or genetic features including MSI status and KRAS mutations 
(Ogino, Nosho et al. 2009).  
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In summary, the present study has shown that increased T-cell infiltrate in either the invasive 
margin, tumour stroma or cancer cell nests is consistently associated with improved  survival, 
independent of nodal status or tumour site, in patients with primary operable colorectal 
cancer.  These results provide a solid foundation on which to develop a standardised method 
for the routine assessment of tumour inflammatory cell infiltrate. 
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Table 9.1.  Clinico-pathological characteristics of the 365 patients with primary operable 
colorectal cancer. 
 
 
Variable  365 (%) 
Age ≤ 64 119 (33) 
 65 – 74 124 (34) 
 ≥ 75 122 (33) 
Sex Male 201 (55) 
 Female 164 (45) 
Presentation Elective  339 (93) 
 Emergency 26 (7) 
Deprivation score 1 - 2 17 (5) 
 3 - 5 148 (41) 
 6 - 7 193 (54) 
POSSUM physiology score  11 – 14  47 (18) 
 15 – 20 113 (43) 
 21 – 30  93 (35) 
 > 30 13 (5) 
ASA grade 1 – 2 175 (61) 
 3 – 4  110 (39) 
Smoking status Non smoker 125 (41) 
 Ex smoker 108 (36) 
 Current smoker 71 (23) 
Anaemia None 157 (51) 
 Mild 74 (24) 
 Severe 75 (25) 
White cell count  < 8.5 (x10
9
/L) 192 (61) 
 8.5-11 (x10
9
/L) 73 (23) 
 > 11(x10
9
/L) 50 (16) 
NLR < 5:1 216 (77) 
 ≥ 5:1 64 (23) 
mGPS 0 212 (58) 
 1 103 (28) 
 2 50 (14) 
Tumour site Colon 236 (65) 
 Rectum 129 (35) 
T stage T 1 10 (3) 
 T 2 26 (7) 
 T 3 219 (60) 
 T 4 110 (30) 
N Stage N 0 208 (57) 
 N 1 114 (31) 
 N 2 43 (12) 
TNM stage Stage I 26 (7) 
 Stage II 182 (50) 
 Stage III 157 (43) 
Venous invasion No 243 (67) 
 Yes 122 (33) 
Differentiation Well / Moderate 320 (88) 
 Poor 45 (12) 
Growth pattern Expanding 189 (54) 
 Infiltrative 163 (46) 
Tumour necrosis Absent 29 (9) 
 Focal 162 (49) 
 Moderate 95 (29) 
 Extensive 41 (13) 
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Table 9.2.  Type, location and density of inflammatory cell infiltration in the 
microenvironment of colorectal tumours with inter-observer variability testing. 
Cell type Location 
Density 
ICC p
*
 Absent  
N (%) 
Weak  
N (%) 
Moderate  
N (%) 
Strong  
N (%) 
CD3
+
 Margin 39 (12) 148 (47) 95 (30) 35 (11) 0.828 <0.001 
 Stroma 23 (7) 137 (42) 116 (35) 53 (16) 0.879 <0.001 
 CC nests 82 (25) 134 (41) 67 (20) 46 (14) 0.865 <0.001 
CD45R0
+
 Margin 36 (11) 141 (44) 94 (30) 48 (15) 0.883 <0.001 
 Stroma 8 (2) 142 (43) 116 (35) 64 (19) 0.898 <0.001 
 CC nests 85 (26) 145 (44) 69 (21) 31 (9) 0.872 <0.001 
CD8
+
 Margin 61 (20) 134 (43) 90 (29) 27 (9) 0.833 <0.001 
 Stroma 85 (26) 160 (49) 61 (19) 21 (6) 0.867 <0.001 
 CC nests 107 (33) 123 (38) 60 (18) 37 (11) 0.873 <0.001 
FOXP3
+
 Margin 63 (20) 122 (39) 126 (41) 0 (0) 0.823 <0.001 
 Stroma 71 (22) 122 (38) 130 (40) 0 (0) 0.727 <0.005 
 CC nests 166 (51) 157 (49) 0 (0) 0 (0) 0.422 0.134 
 
K-M grade
†
 Margin 72 (21) 160 (46) 86 (25) 28 (8) 0.81 <0.001 
Galon Immune 
Score
††
 
All 91 (25) 106 (29) 53 (15) 58 (16) N/A N/A 
 
 
†
 Includes all inflammatory cell types 
††
Composite score of CD45R0
+
 and CD8
+
 infiltration  in the invasive margin and central tumour and  
graded as (0)-Hi, (1-2)-Hi, (3)-Hi and (4)-Hi 
ICC=Inter-observer intraclass correlation coefficient 
*
 p value of the F-test  corresponding to the ICC 
 224 
 
Table 9.3.  Contingency table analysis demonstrating the inter-relationships between T-cell subtypes, K-M grade and the Galon 
Immune Score in colorectal tumours. 
 
 
 
CD3
+
 CD45R0
+
 CD8
+
 FOXP3
+
 
Margin Stroma CC nests Margin Stroma CC nests Margin Stroma CC nests Margin Stroma CC nests 
CD3
+
 Margin             
 Stroma <0.001            
 CC nests <0.001 <0.001           
CD45R0
+
 Margin <0.001 <0.001 <0.001          
 Stroma <0.001 <0.001 <0.001 <0.001         
 CC nests <0.001 <0.001 <0.001 <0.001 <0.001        
CD8
+
 Margin <0.001 <0.001 <0.001 <0.001 <0.001 <0.001       
 Stroma <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001      
 CC nests <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001     
FOXP3
+
 Margin <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001    
 Stroma <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001   
 CC nests <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 0.001 <0.001 <0.001 <0.001  
  
K-M grade <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
Galon Immune Score <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 
 
 
p values represent chi square tests for linear trend with all relationships positive unless stated 
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Table 9.4.  The relationships between T-cell infiltration and cancer specific survival in patients 
with primary operable colorectal cancer (Model 1; TIL‟s in the invasive margin, Model 2; TIL‟s 
in the tumour stroma, Model 3; TIL‟s in the cancer cell nests).  
 
   Univariate Multivariate 
Location Type Density HR 95% CI p
*
  HR 95% CI p
*
   
  
 Invasive margin 
Margin CD3
+
 Absent/weak/mod/strong 0.51 (0.40, 0.64) <0.001 0.49 (0.38, 0.63) <0.001 
Margin CD45R0+ Absent/weak/mod/strong 0.62 (0.50, 0.77) <0.001   0.45 
Margin CD8+ Absent/weak/mod/strong 0.53 (0.42, 0.66) <0.001   0.61 
Margin FOXP3
+
 Absent/weak/mod/strong 0.66 (0.51, 0.84) 0.001   0.18 
 
 Tumour stroma 
Stroma CD3
+
 Absent/weak/mod/strong 0.54 (0.43, 0.67) <0.001 0.58 (0.46, 0.75) <0.001 
Stroma CD45R0+ Absent/weak/mod/strong 0.64 (0.51, 0.82) <0.001   0.94 
Stroma CD8+ Absent/weak/mod/strong 0.70 (0.55, 0.88) 0.002   0.79 
Stroma FOXP3
+
 Absent/weak/mod 0.67 (0.53, 0.84) 0.001   0.06 
 
Cancer cell nests 
CC nests CD3
+
 Absent/weak/mod/strong 0.54 (0.44, 0.67) <0.001 0.73 (0.55, 0.97) 0.030 
CC nests CD45R0+ Absent/weak/mod/strong 0.64 (0.51, 0.79) <0.001   0.61 
CC nests CD8+ Absent/weak/mod/strong 0.53 (0.42, 0.66) <0.001 0.68 (0.50, 0.90) 0.008 
CC nests FOXP3
+
 Absent/weak 0.52 (0.36, 0.75) 0.001   0.08 
 
*
 Cox proportional hazards regression 
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Table 9.5a. The relationships between CD3
+
 IM, CD8
+
 CCN and host characteristics in patients with primary operable colorectal 
cancer.  
 
CD3
+
 IM 
p
*
 
CD8
+
 CCN 
p
*
  
Absent Weak Moderate Strong Absent Weak Moderate Strong 
Age 
(≤64/65-74/≥75) 
12/10/17 
(31/26/44) 
44/48/56 
(30/32/38) 
32/36/27 
(34/38/28) 
8/14/13 
(23/40/37) 
0.58 
38/30/39 
(36/28/36) 
34/46/43 
(28/37/35) 
23/20/17 
(38/33/28) 
9/13/15 
(24/35/41) 
0.77 
Sex 
(male/female) 
20/19 
(51/49) 
85/63 
(57/43) 
51/44 
(54/46) 
17/18 
(49/51) 
0.61 
59/48 
(55/45) 
65/58 
(53/47) 
32/28 
(53/47) 
22/15 
(60/40) 
0.79 
Presentation 
(elective/emergency 
33/6 
(85/15) 
139/9 
(94/6) 
91/4 
(96/4) 
33/2 
(94/6) 
0.10 
97/10 
(91/9) 
119/4 
(97/3) 
53/7 
(88/12) 
35/2 
(95/5) 
0.84 
Deprivation score 
(1-2/3-5/6-7) 
2/14/23 
(5/36/59) 
7/55/82 
(5/38/57) 
5/46/42 
(5/50/45) 
1/15/19 
(3/43/54) 
0.35 
7/49/49 
(7/47/47) 
4/48/49 
(3/40/57) 
1/25/33 
(2/42/56) 
3/12/21 
(8/33/58) 
0.20 
POSSUM physiology score  
(11-14/15-20/21-30/>30) 
5/16/9/2 
(16/50/28/6) 
16/42/39/5 
(16/41/38/5) 
10/31/28/4 
(14/43/38/5) 
6/9/8/1 
(25/38/33/4) 
0.90 
15/35/22/6 
(19/45/28/8) 
14/42/33/2 
(15/46/36/2) 
8/17/15/3 
(19/40/35/7) 
3/10/13/1 
(11/37/48/4) 
0.29 
ASA grade 
(1-2/3-4) 
16/16 
(50/50) 
63/50 
(56/44) 
52/24 
(68/32) 
18/9 
(67/33) 
0.05 
48/32 
(60/40) 
57/40 
(59/41) 
32/18 
(64/36) 
21/9 
(70/30) 
0.32 
Smoking status 
(non/ex/current) 
13/11/8 
(41/34/25) 
44/45/33 
(36/37/27) 
42/26/14 
(51/32/17) 
13/11/5 
(45/38/17) 
0.10 
41/22/23 
(48/26/27) 
38/37/24 
(38/37/24) 
23/24/7 
(43/44/13) 
14/12/8 
(41/35/24) 
0.82 
Anaemia 
(none/mild/severe) 
19/6/10 
(54/17/29) 
56/31/29 
(48/27/25) 
43/16/23 
(52/20/28) 
14/11/5 
(47/37/17) 
0.83 
44/23/19 
(51/27/22) 
55/21/28 
(53/20/27) 
29/11/12 
(56/21/23) 
10/13/9 
(31/41/28) 
0.31 
White cell count  
(<8.5/8.5-11/>11) 
21/9/8 
(55/24/21) 
75/27/20 
(62/22/16) 
47/22/13 
(57/27/16) 
22/5/3 
(73/17/10) 
0.23 
55/18/16 
(62/20/18) 
65/28/16 
(60/26/15) 
31/13/9 
(59/25/17) 
19/9/5 
(58/27/15) 
0.87 
NLR 
(<5:1/≥5:1) 
24/8 
(75/25) 
83/26 
(76/24) 
59/19 
(76/24) 
22/8 
(73/27) 
0.86 
59/17 
(78/22) 
78/25 
(76/24) 
40/8 
(83/17) 
21/12 
(64/36) 
0.38 
mGPS 
(0/1/2) 
18/14/7 
(46/36/18) 
82/46/20 
(55/31/14) 
61/23/11 
(64/24/12) 
20/10/5 
(57/29/14) 
0.19 
54/35/18 
(51/33/17) 
70/37/16 
(57/30/13) 
40/13/7 
(67/22/12) 
18/13/6 
(49/35/16) 
0.45 
 
 
* 
Chi square test for linear trend 
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Table 9.5b. The relationships between CD3
+
 IM, CD8
+
 CCN and tumour biology in patients with primary operable colorectal cancer.  
 
CD3
+
 IM 
p
*
 
CD8
+
 CCN 
p
*
 
Absent Weak Moderate Strong Absent Weak Moderate Strong 
Tumour site 
(colon/rectum) 
24/15 
(62/39) 
93/55 
(63/37) 
62/33 
(64/34) 
27/8 
(77/23) 
0.16 
64/43 
(60/40) 
81/42 
(66/34) 
37/23 
(62/38) 
30/7 
(81/19) 
0.07 
T stage 
(1/2/3/4) 
1/1/22/15 
(3/3/56/39) 
1/8/94/45 
(1/5/64/30) 
3/9/59/24 
(3/10/62/25) 
3/5/21/6 
(9/14/60/17) 
0.001 
0/6/64/37 
(0/6/60/34) 
3/10/76/34 
(2/8/62/28) 
4/5/36/15 
(7/8/60/25) 
2/4/21/10 
(5/11/57/27) 
0.014 
N Stage 
(0/1/2) 
16/18/5 
(41/46/13) 
81/50/17 
(55/34/12) 
57/28/10 
(60/30/10) 
24/9/2 
(69/26/6) 
0.026 
47/39/21 
(44/36/20) 
75/38/10 
(61/31/8) 
37/18/5 
(62/30/8) 
27/10/0 
(73/27/0) 
<0.001 
TNM stage 
(I/II/III) 
2/14/23 
(5/36/59) 
7/74/67 
(5/50/45) 
8/49/38 
(8/52/40) 
4/20/11 
(11/57/31) 
0.008 
5/42/60 
(5/39/56) 
9/66/48 
(7/54/39) 
5/32/23 
(8/53/38) 
5/22/10 
(13/60/27) 
0.001 
Differentiation 
(well or mod/poor) 
33/6 
(85/15) 
129/19 
(87/13) 
87/8 
(92/8) 
28/7 
(80/20) 
0.98 
91/16 
(85/15) 
113/10 
(92/8) 
54/6 
(90/10) 
28/9 
(76/24) 
0.43 
Venous invasion 
(no/yes) 
25/14 
(64/36) 
94/54 
(64/37) 
67/28 
(71/29) 
29/6 
(83/17) 
0.038 
64/43 
(60/40) 
81/42 
(66/34) 
46/14 
(77/23) 
31/6 
(84/16) 
0.002 
Growth pattern 
(expanding/infiltrative) 
10/28 
(26/74) 
73/66 
(53/47) 
59/35 
(63/37) 
22/13 
(63/37) 
0.001 
39/64 
(38/62) 
70/50 
(58/42) 
39/18 
(68/32) 
20/16 
(56/44) 
0.003 
Tumour necrosis 
(absent/focal/mod/ext) 
1/23/9/3 
(3/64/25/8) 
14/54/42/24 
(10/40/31/18) 
7/51/23/7 
(8/58/26/8) 
2/24/8/1 
(6/69/23/3) 
0.07 
6/53/30/11 
(6/53/30/11) 
9/59/30/17 
(8/51/26/15) 
8/26/13/6 
(15/49/25/11) 
2/16/14/2 
(6/47/41/6) 
0.65 
 
 
* 
Chi square test for linear trend 
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Table 9.6. Comparison of the prognostic value of different methods of assessing the local 
inflammatory response in patients with primary operable colorectal cancer (Model 1; stage I-
III colorectal cancer, Model 2; stage I-II colorectal cancer, Model 3; colon cancer, Model 4; 
rectal cancer).  
 
 Univariate Multivariate 
Immune Score HR 95% CI p
*
 HR 95% CI p
*
 
 
Colorectal cancer (stage I-III) 
CD3
+
 IM 0.51 (0.40, 0.64) <0.001 0.72 (0.52, 0.99) 0.045 
CD3
+
 ST 0.54 (0.43, 0.67) <0.001   0.07 
CD8
+
 CCN 0.53 (0.42, 0.66) <0.001 0.58 (0.44, 0.77) <0.001 
K-M grade 0.54 (0.43, 0.68) <0.001   0.20 
Galon Immune Score 0.72 (0.63, 0.82) <0.001   0.18 
 
Colorectal cancer (stage I-II) 
CD3
+
 IM 0.52 (0.35, 0.77) 0.001   0.35 
CD3
+
 ST 0.44 (0.30, 0.63) <0.001 0.61 (0.39, 0.93) 0.020 
CD8
+
 CCN 0.49 (0.38, 0.70) <0.001 0.56 (0.36, 0.86) 0.009 
K-M grade 0.56 (0.39, 0.79) 0.001   0.41 
Galon Immune Score 0.74 (0.60, 0.90) 0.003   0.45 
 
Colon cancer 
CD3
+
 IM 0.56 (0.41, 0.74) <0.001 0.61 (0.39, 0.96) 0.031 
CD3
+
 ST 0.57 (0.43, 0.76) <0.001   0.07 
CD8
+
 CCN 0.53 (0.41, 0.70) <0.001 0.55 (0.39, 0.79) 0.001 
K-M grade 0.58 (0.42, 0.74) <0.001   0.15 
Galon Immune Score 0.75 (0.64, 0.88) <0.001   0.08 
 
Rectal cancer 
CD3
+
 IM 0.43 (0.28, 0.64) <0.001   0.22 
CD3
+
 ST 0.45 (0.30, 0.67) <0.001 0.57 (0.35, 0.94) 0.027 
CD8
+
 CCN 0.51 (0.35, 0.76) 0.001 0.45 (0.26, 0.78) 0.005 
K-M grade 0.52 (0.35, 0.76) 0.001   0.49 
Galon Immune Score 0.68 (0.54, 0.85) 0.001   0.40 
 
*
Cox proportional hazards regression 
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Figure 9.1. Examples of stained sections demonstrating different patterns of T-cell 
infiltration in the microenvironment of colorectal tumours. Absence of T-cell infiltration 
(Panel A); Strong infiltration of CD3
+
 cells at the invasive margin (Panel B); Strong 
infiltration of CD3
+
 cells in the tumour stroma with relative „sparing‟ of the cancer cell nests 
(Panel C); and strong infiltration of CD8
+
 cells in the cancer cell nests (Panel D). 
  
A 
B 
C 
D 
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Number at risk Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Year 7 Year 8 
Absent 39 34 25 20 16 14 13 6 
Weak 148 130 115 100 85 80 71 60 
Moderate 95 90 86 82 72 69 62 55 
Strong 35 34 34 33 31 29 27 24 
 
 
Figure 9.2. Kaplan-Meier survival curves demonstrating the relationship between cancer-
specific survival in patients with colorectal cancer according to the application of different 
measures of the local inflammatory response. Shown on this panel; CD3
+
 IM (p<0.001, log-
rank test) 
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Number at risk Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Year 7 Year 8 
Absent 107 92 78 65 54 47 41 34 
Weak 123 112 99 87 65 72 65 57 
Moderate 60 57 55 53 48 46 41 37 
Strong 37 36 34 34 32 30 29 27 
 
Figure 9.2 (cont). Kaplan-Meier survival curves demonstrating the relationship between 
cancer-specific survival in patients with colorectal cancer according to the application of 
different measures of the local inflammatory response. Shown on this panel; CD8
+
 CCN 
(p<0.001, log-rank test) 
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Number at risk Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Year 7 Year 8 
Absent 72 65 54 43 37 32 27 23 
Weak 160 149 132 118 100 94 85 71 
Moderate 86 80 75 68 62 59 55 50 
Strong 28 28 28 27 27 26 23 22 
 
Figure 9.2 (cont). Kaplan-Meier survival curves demonstrating the relationship between 
cancer-specific survival in patients with colorectal cancer according to the application of 
different measures of the local inflammatory response. Shown on this panel; K-M grade 
(p<0.001, log-rank test) 
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Number at risk Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Year 7 Year 8 
0 Hi 91 79 64 52 46 42 35 31 
1 or 2 Hi 106 94 88 76 63 59 52 45 
3 Hi 53 50 46 43 39 38 35 32 
4 Hi 58 57 56 55 50 48 45 39 
 
 
 
Figure 9.2 (cont). Kaplan-Meier survival curves demonstrating the relationship between 
cancer-specific survival in patients with colorectal cancer according to the application of 
different measures of the local inflammatory response. Shown on this panel; Galon Immune 
Score (p<0.001, log-rank test) 
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10.0 CONCLUSIONS 
At the beginning of this period of research it was clear that a significant proportion of patients 
with colorectal cancer, despite undergoing potentially curative surgery, were nevertheless 
dying prematurely from their disease. It was recognized that disease progression in these 
patients was dependent not only on pathological stage but on complex interactions between 
tumour- and host-related factors. A substantial body of evidence already existed confirming 
an elevated systemic inflammatory response, as measured by the mGPS, as a reliable 
indicator of poor prognosis in these patients. Similarly, data assembled over a 40 year period 
concluded that a strong infiltration of inflammatory cells in the tumour microenvironment 
was associated with favourable outcomes in patients with colorectal cancer (Chapter 1.0). 
Despite this knowledge, at the outset of this thesis, several key questions remained 
unanswered. First, the underlying basis of the systemic inflammatory response in patients 
with colorectal cancer was unclear. Similarly, the factors associated with an effective local 
immune cell reaction remained undetermined. Many studies in this field had concentrated 
almost exclusively on tumour biology and few had investigated the potential role of host 
factors. It was also unclear whether the local and systemic inflammatory responses were in 
some way linked and a detailed investigation of these relationships was lacking. Finally, 
although the benefits of an effective anti-tumour response in these patients were not in doubt, 
no study had ever compared the prognostic value of different methods of assessing the local 
inflammatory response in a single cohort.  
This thesis started with an attempt to gain insight into the patient factors associated with 
systemic inflammation in patients with colorectal cancer (Chapter 3.0). The results 
demonstrated, for the first time, that abnormal patient physiology, in particular the presence 
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of anaemia and cardiac disease, was strongly associated with a systemic inflammatory 
response. These relationships raised the possibility that systemic inflammation in these 
patients was a result of relative tissue hypoxia, perhaps initiated by rapid tumour growth and 
aggravated by impaired oxygen delivery; a hypothesis that was to be investigated 
subsequently. When the long term outcomes of patients with impaired physiology were 
considered, it was apparent that they were dying prematurely from their disease. However, 
both physiology scores and mGPS were independently associated with cancer specific 
survival, suggesting that poor physiology alone could not fully explain the relationship 
between inflammation and cancer outcomes. Nonetheless, the results of this study did suggest 
that targeting patient physiology in the pre-operative period may be a novel way to improve 
outcomes in patients with colorectal cancer. In relation to future work, it would be of 
considerable interest to investigate whether improving these physiological parameters, for 
example through a period of intensive cardiovascular optimization, would lead to better 
outcomes via an attenuation of the systemic inflammatory response.  
Chapter 5.0 examined the influence of systemic inflammation on the body composition of 
patients with malignant disease. The results demonstrated a strong association between low 
skeletal muscle mass and the presence of a systemic inflammatory response in patients with 
primary operable colorectal cancer.  Many of these patients had a BMI in the normal range, 
promoting the view that the analysis of cross-sectional imaging is a more accurate way to 
quantify body composition in patients with cancer. It was of particular interest that advanced 
tumour stage was not directly related to significantly lower skeletal muscle mass; a result 
which suggests the loss of lean tissue in cancer cachexia is driven not by tumour biology but 
rather through the host systemic inflammatory response. The negative clinical impact of 
cancer-related weight loss has been well documented and these results not only offer insight 
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into the underlying basis of cancer cachexia, they identify the attenuation of the systemic 
inflammatory response as a potential therapeutic target. Future work in this area should focus 
on whether early changes in body composition, detectable from staging CT scans, can predict 
long term outcomes.  
Chapter 6.0 examined the question of whether surgical complications were truly responsible 
for reduced survival in patients with colorectal cancer or whether these associations could be 
explained by pre-existing patient-related factors.  The results demonstrated that smoking, 
impaired physiology and systemic inflammation were associated not only with the 
development of septic complications but also with reduced long term survival. Rather than 
being the cause of disease recurrence, surgical complications appeared to be a consequence of 
poor physiology or a pro-inflammatory state; the true determinants of long term outcome. 
These results support a concept whereby a patients‟ pre-operative status is of paramount 
importance. Attention should be directed towards identifying these high risk patients early 
and intervening where possible. Such interventions should include smoking cessation in all 
patients with colorectal cancer and, as far as possible, the correction of physiological 
parameters in the pre-operative period. Targeting the systemic inflammatory response 
through the administration of aspirin, statins or non-steroidal anti-inflammatory drugs offers 
another potential therapeutic strategy.  
The relationships between the systemic inflammatory response and local immune cell 
infiltrates were explored in Chapter 7.0.  We chose to examine these relationships with 
specific reference to tumour necrosis because this histological feature, recently reported as 
prognostic in colorectal cancer, has also been associated with serum markers of inflammation 
in other tumour types. The study validated a semi-quantative analysis of tumour necrosis as 
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an independent prognostic marker in patients with primary operable colorectal cancer. 
Furthermore, necrosis was directly associated with both an elevation of the systemic 
inflammatory response and an attenuation of the local immune cell infiltrate.  This represents 
the first documented link between local and systemic inflammation in patients with colorectal 
cancer. One hypothesis is that failure of local anti-tumour control leads to rapid tumour 
growth, tissue hypoxia and cellular necrosis. The presence of necrosis may then act as a 
trigger for the host to initiate a systemic inflammatory response. Indeed, it was evident that a 
strong linear relationship existed between the degree of tumour necrosis and circulating levels 
of serum CRP. To further our understanding of the relationships between necrosis and 
inflammation, future work should be directed towards a detailed examination of the 
associations between tumour necrosis and cell signalling pathways, genetic mutations, 
including microsatellite status and molecular markers of tumour cell proliferation.   
Previous work had established that a global assessment of peritumoural inflammation, using 
the K-M grade, was an independent prognostic marker in patients with primary operable 
colorectal cancer. As a logical starting point for developing a clinically relevant method of 
assessing the local inflammatory response, Chapter 8.0 sought to investigate which cellular 
components of the peritumoural infiltrate were most relevant to prognosis. The study 
demonstrated that individual immune cells could be reliably identified and categorized on 
H&E stained sections and suggested that a strong K-M reaction was primarily the result of 
lymphocyte infiltration. Although examination of individual cell types did not improve 
prediction of outcome compared to overall K-M grade, those tumours with a strong 
lymphocytic infiltrate were noted to have distinctly favourable pathological characteristics. 
This indicated a prominent role for the adaptive immune response in the prevention of tumour 
progression in colorectal cancer and allowed a subsequent analysis to focus on specifically on 
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lymphocytes.  Advances in the digital image analysis of pathological sections also mean that 
there is scope to develop an automated assessment of K-M grade on either full sections or 
tissue microarrays; a development with the potential to further standardise research practice.  
Chapter 9.0 sought to build on this knowledge by examining the clinical utility of the local 
inflammatory response in colorectal cancer. This was the first study to directly compare 
different methodologies for assessing the local inflammatory cell infiltrate and confirmed that 
all three measures were able to predict outcome in primary operable colorectal cancer. 
Indeed, strong inter-relationships existed between individual inflammatory cells, leading to 
the conclusion that the density of cellular infiltrate is the critical component of the local 
inflammatory response. Future work in this area should continue on two fronts. First, efforts 
must be made to achieve consensus on the measurement of the local inflammatory response 
in patients with colorectal cancer. The fact that the K-M grade offers a simple and 
reproducible way to grade inflammatory cell density on routinely stained sections promotes 
its use in all future research. Additional consideration must also be given to the underlying 
factors responsible for producing an effective immune cell response in the tumour 
microenvironment. One possibility is that CD8
+
 lymphocytes are responding to specific 
antigens and a detailed examination of tumour cell HLA expression is warranted.   
In summary, it is apparent that cancer-associated alterations in patient immune and 
inflammatory responses are complex (Figure 10).  Disease progression in these patients is not 
a tumour-cell autonomous process but is rather the result of a multitude of molecular 
interactions between tumour and host. In patients with primary operable colorectal cancer 
both the local and systemic inflammatory responses are important predictors of outcome. The 
aim of this thesis was to investigate the factors responsible for activating and maintaining 
 239 
 
these responses and, with this in mind, several conclusions may now be drawn. It seems 
likely that key events within the tumour microenvironment initially dictate whether a 
colorectal tumour develops or is successfully eliminated by the host. The work presented 
above clearly demonstrates that the local infiltration of immune cells is effective in 
preventing tumour growth and metastases. A strong local response, coordinated primarily 
through lymphocytes, is associated with favourable pathological characteristics, including 
lower levels of venous invasion, and translates into a lower incidence of disease recurrence 
and improved patient survival. In the alternative scenario, should malignant cells successfully 
evade host immunity, the microenvironment becomes dominated instead by molecular 
processes which promote tumour growth. In this situation, rather than being protective, the 
inflammatory response becomes destructive, facilitating angiogenesis and stimulating cellular 
proliferation. The resultant rapid growth results in tissue hypoxia and areas of necrosis 
develop within the central tumour. Results from this thesis suggest that the presence of 
tumour necrosis is one mechanism through which the host is stimulated to mount a systemic 
inflammatory response. However, it may be that this is only one of many ways through which 
an uncontrolled acute phase response is generated. Recently, there has been increased interest 
in the role of the stroma in influencing the growth and spread of malignant tumours. In 
particular, the presence of increased numbers of myofibroblasts has been associated with 
shorter disease-free survival in patients with colorectal cancer, leading to the hypothesis that 
the stroma itself is a key determinant of growth, invasion and metastases. The relationships 
between the tumour stroma and the inflammatory cells that surround and infiltrate have yet to 
be investigated but represent an intriguing avenue of research.  
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Figure 10. Cancer immunity and inflammation; a schematic representation of the complex 
interactions between the tumour and host.  
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Regardless of the initial stimulus, this thesis supports the idea that systemic inflammation in 
the context of malignancy represents an ultimate failure of homeostasis. This is evidenced by 
its association with a diverse range of patient-related factors, including deranged physiology, 
cardiovascular comorbidity, anaemia and a loss of skeletal muscle mass.  The presence of a 
systemic inflammatory response in patients with colorectal cancer is thus a useful and 
universal indicator of poor prognosis; associated with early disease recurrence, distant 
metastases and reduced survival.  
This thesis suggests that inflammation affects nearly every facet of tumour development. 
Ultimately, an increased understanding of the factors which govern the local and systemic 
inflammatory responses is fundamental to improving outcomes in patients with colorectal 
cancer.  
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APPENDIX 1 
Immunohistochemistry protocol using CD3 (Vector Labs, code VP-RM01) 
Performed in Beatson Oncology laboratory, Glasgow 
 
       
Time 
 Place sections in Xylene                                                        
 
5 minutes 
 Place sections in Ethanol                                                           
 
1 minute 
 Place sections in Ethanol                                                           
 
1 minute 
 Place sections in 70% Ethanol                                                   
 
1 minute 
 Wash sections in running tap water 
     Heat Induced Epitope retrieval – pH 6 Na Citrate buffer 
    2 minutes at full pressure in 800W microwave * 
     Leave sections in buffer to cool                                                
 
20 minutes 
Wash sections in 10mM Tris buffered Tween (TbT) pH7.5     
  
5 minutes(x2) 
Block endogenous Peroxidase (Dako EnVision)                       
 
5 minutes 
 Wash sections in TbT                                                                
 
5 minutes(x2) 
Apply Vector Labs CD 3 (1/100 @ room temperature)      
  
45 minutes 
Wash sections in TbT                                                                
 
5 minutes(x2) 
Apply secondary antibody (Dako EnVision)                             
 
40 minutes 
Wash sections in TbT                                                                
 
5 minutes(x2) 
Apply 3,3‟-Diaminobenzidine tetrahydrochloride                     
 
10 minutes 
Terminate reaction with deionised water 
   
1 minute 
 Gills haematoxylin                                                                      
 
5 minutes 
 Wash sections in deionised water 
    
30 seconds 
1% Acid alcohol                                                                         
 
2 dips 
 Wash sections in deionised water 
    
30 seconds 
Scotts tap water substitute                                                          
 
1 minute 
 Wash sections in deionised water 
   
30 seconds 
Dehydrate, clear and mount 
      
         Materials Used 
       Reagent 
  
Company Code 
    
         
CD 3 Rabbit Monoclonal Vector Labs 
VP-
RM01 
    Primary antibody diluent  Dako S2022 
    Retrieval buffer 10mM ph 6            Lab vision S2369 
    EnVision Rabbit Kit 
 
Dako K4011 
    Tris buffered tween (TbT)                        
- S3306 Dako S3306 
    
         *Other heat retrieval methods such as water baths, automated retrieval  
  (retrieval temperature should be set at 98 ºC) modules are also suitable but should be optimised   
For the technique before proceeding. 
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APPENDIX 2 
 
Immunohistochemistry protocol using CD8 (DakoCytomation, code M7103) 
Performed in Western Infirmary laboratory, Glasgow 
Dewax and Rehydrate 
 Dewax in Xylene    2 x 3 mins 
 Rehydrate in 100% alcohol 2 x 2 mins 
 90% alcohol 2 mins 
 70% alcohol 2 mins 
 Rinse in water 
 
Antigen Retrieval 
 Make Tris EDTA buffer pH8 
- 0.55g sodium EDTA 
- 0.825g Tris 
- Dissolve in 1.5 litres of dH20 in pressure cooker  
 Microwave on full power 13.5 minutes 
 Add slides and lid and microwave for 2 mins to bring up pressure 
 Microwave for 5mins under pressure 
 Leave to cool for 40mins 
 
Staining 
 Treat with 3% H2O2 (40mls H2O2 + 360mls dH2O) for 10 mins on a stirrer 
 Rinse in running water 
 Ring sections with Dako pen to create a barrier 
 Incubate in blocking solution: 5% Horse serum 50ul/ml TBS for 20mins at 25
0
C 
 Blot serum from sections 
 Incubate in primary antibody o/n at 40C (1:100) 
 Wash 2 x TBS for 5mins 
 Incubate in Envision for 30mins at room temperature 
 Wash 2 x TBS for 5mins 
 Incubate in DAB substrate until colour develops 2-10mins 
 Wash in running water for 10 minutes 
 
Counterstain 
 Haematoxylin for 45 secs 
 Rinse in running water 
 Blue with Scotts tap water substitute 45 secs 
 Rinse in running water 
 
Dehydrate and mount 
 70% alcohol  1 min 
 90% alcohol 1 min 
 100% alcohol 2 x 1 min 
 Xylene  2 x 1 min 
 Mount in DPX  
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APPENDIX 3 
 
Immunohistochemistry protocol using CD45 (Dako, code M0724) 
Performed in Beatson Oncology laboratory, Glasgow 
 
  
       
Time 
 Place sections in Xylene                                                        
 
5 minutes 
 Place sections in Ethanol                                                           
 
1 minute 
 Place sections in Ethanol                                                           
 
1 minute 
 Place sections in 70% Ethanol                                                   
 
1 minute 
 Wash sections in running tap water 
     Heat Induced Epitope retrieval – pH 6 Na Citrate buffer 
    2 minutes at full pressure in 800W microwave * 
     Leave sections in buffer to cool                                                
 
20 minutes 
Wash sections in 10mM Tris buffered Tween (TbT) pH7.5     
  
5 minutes(x2) 
Block endogenous Peroxidase (Dako EnVision)                       
 
5 minutes 
 Wash sections in TbT                                                                
 
5 minutes(x2) 
Apply Vector Labs CD 3 (1/100 @ room temperature)      
  
45 minutes 
Wash sections in TbT                                                                
 
5 minutes(x2) 
Apply secondary antibody (Dako EnVision)                             
 
40 minutes 
Wash sections in TbT                                                                
 
5 minutes(x2) 
Apply 3,3‟-Diaminobenzidine tetrahydrochloride                     
 
10 minutes 
Terminate reaction with deionised water 
   
1 minute 
 Gills haematoxylin                                                                      
 
5 minutes 
 Wash sections in deionised water 
    
30 seconds 
1% Acid alcohol                                                                         
 
2 dips 
 Wash sections in deionised water 
    
30 seconds 
Scotts tap water substitute                                                          
 
1 minute 
 Wash sections in deionised water 
    
30 seconds 
Dehydrate, clear and mount 
      
         Materials Used 
       Reagent 
  
Company Code 
    
         CD45 Mouse Monoclonal Dako M0724 
    Primary antibody diluent  Dako S2022 
    Retrieval buffer 10mM ph 6            Thermo S2369 
    EnVision Rabbit Kit 
 
Dako K4011 
    Tris buffered tween (TbT)                         Dako S3306 
    
         *Other heat retrieval methods such as water baths, automated retrieval  
  (retrieval temperature should be set at 98 ºC) modules are also suitable but should be optimised   
for the technique before proceeding. 
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APPENDIX 4 
 
Immunohistochemistry protocol using FOXP3
+
 (Abcam, code 20034) 
Performed in Western Infirmary Laboratory, Glasgow 
Dewax and Rehydrate 
 Dewax in Xylene    2 x 3 mins 
 Rehydrate in 100% alcohol 2 x 2 mins 
 90% alcohol 2 mins 
 70% alcohol 2 mins 
 Rinse in water 
 
Antigen Retrieval 
 Make Tris EDTA buffer pH8 
- 0.55g sodium EDTA 
- 0.825g Tris 
- Dissolve in 1.5 litres of dH20 in pressure cooker  
 Microwave on full power 13.5 minutes 
 Add slides and lid and microwave for 2 mins to bring up pressure 
 Microwave for 5mins under pressure 
 Leave to cool for 40mins 
 
Staining 
 Treat with 3% H2O2 (40mls H2O2 + 360mls dH2O) for 10 mins on a stirrer 
 Rinse in running water 
 Ring sections with Dako pen to create a barrier 
 Incubate in blocking solution: 5% Horse serum 50ul/ml TBS for 20mins at 25
0
C 
 Blot serum from sections 
 Incubate in primary antibody o/n at 40C (1:200) 
 Wash 2 x TBS for 5mins 
 Incubate in Envision for 30mins at room temperature 
 Wash 2 x TBS for 5mins 
 Incubate in DAB substrate until colour develops 2-10mins 
 Wash in running water for 10 minutes 
 
Counterstain 
 Haematoxylin for 45 secs 
 Rinse in running water 
 Blue with Scotts tap water substitute 45 secs 
 Rinse in running water 
 
Dehydrate and mount 
 70% alcohol  1 min 
 90% alcohol 1 min 
 100% alcohol 2 x 1 min 
 Xylene  2 x 1 min 
 Mount in DPX 
